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ABSTRACT 
Substantial evidence has accumulated for the involvement of peripheral N-methyl-D-aspartate 
(NMDA) receptors in visceral/chronic pain. Notably, poorly brain-penetrating glycineB NMDA 
antagonists were particularly potent in in vivo models of inflammatory visceral pain. The aim of 
this thesis was to further investigate the pharmacology of peripheral, compared to central, 
NMDA receptors. 
Although evaluation of possible inflammation-mediated blood-brain barrier dysfunctions in an 
in vitro blood-brain barrier (BBB) model could not exclude negative effects on BBB integrity, 
microdialysis experiments in vivo indicated that brain access of a poorly penetrant NMDA 
antagonist was unchanged under inflammatory conditions similar to those used in models of 
visceral pain. These data therefore indicate a peripheral site of action of the antagonists 
previously used in models of visceral pain. 
In dorsal root ganglion (DRG) neurons, RT-PCR, immunoblotting and immuno-histochemistry 
were used to investigate NMDA receptor subunit expression patterns. These experiments 
indicated the presence of all known NR1 subunit splice variants, some of them possibly 
glycosylated, plus NR2A, NR2B and NR3A subunits. 
For functional characterization of peripheral vs. central NMDA receptors, patch-clamp 
recordings from freshly cultured DRG and hippocampal neurons, and from a NR1/NR2A 
transfected BEK293 cell line were performed with various glycineB site modulators. Agonists 
(e. g. glycine) showed a -10-fold lower affinity for NMDA receptors in DRG neurons and 
transfected BEK293 cells compared to hippocampal neurons. GlycineB antagonists were 
correspondingly more potent in DRGs and BEK293 cells. Considering the excellent correlation 
between the pharmacology of DRGs and NR1/N2A expressing HEK293 cells, a predominant 
expression of NR1/NR2A receptors in DRG neurons is postulated, in contrast to literature 
claiming NR2B to be the major peripheral NR2 subunit. 
These results identify the pharmacological characteristics of functional NMDA receptors in 
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CHAPTER I 
1 GENERAL INTRODUCTION 
The involvement of N-methyl-D- aspartate (NMDA) receptors in nociceptive 
transmission in spinal cord neurons induced by repetitive C-fibre stimulation was reported in the 
late 1980s (Davies & Lodge, 1987), but the idea that peripheral NMDA receptors could also be 
involved was first postulated almost ten years later by Carlton et al. (1995) and Zhou et al., 
(1996); where glutamate receptor agonist injection in the skin was shown to produce mechanical 
allodynia and hyperalgesia. 
In addition to this, the primary trigger for the present studies was the finding that NMDA 
receptor antagonists binding at the glycine co-agonist site were much more potent in an acute 
model of visceral pain (Olivar & Laird, 1999) than would have been expected from maximal 
electroshock (MES) in vivo experiments targeting the central nervous system (CNS). This 
unexpected higher potency led to the hypotheses (a) that peripheral NMDA receptors are 
involved and (b) that there is a different pharmacology for such receptors. 
1.1 Excitatory amino acid (EAA) receptors 
The major excitatory neurotransmitter in the CNS is the amino acid L-glutamate (Kew & 
Kemp, 2005) and it has become clear in recent years that it is also very important in the 
peripheral nervous system (PNS). Glutamate is involved not only in fast synaptic transmission 
but also in synaptic plasticity, such as chronification of chronic pain states, as well as in higher 
cognitive functions. The high diversity of glutamate receptors and their role in numerous 
physiological and pathological functions renders this neurotransmitter system a very high level 
of complexity and makes it a challenging but promising pharmaceutical target for the treatment 
of numerous diseases. 
Glutamate receptors are grouped into the ionotropic and metabotropic receptor families 
(Kew & Kemp, 2005). Metabotropic glutamate receptors are G-protein coupled receptors 
modulating the second messenger system phospholipase C (PLC), in the case of group I 
metabotropic receptors, or adenylate cyclase (AC) for group I1/1II mGluRs (Pin & Duvoisin, 
1995). Within these three groups eight different subtypes have been identified so far (e. g. Pin et 
al., 2003). 
The thesis focuses on ionotropic glutamate receptors and, in particular, on NMDA 
receptors, therefore further details on metabotropic glutamate receptors (mGluR) are not 
discussed, although mGluR activation clearly interacts with NMDA receptor function (e. g. 
Krieger et al., 2000). 
1.2 Ionotropic glutamate receptors (structure/function) 
In contrast to the metabotropic glutamate receptors, receptor activation of ionotropic 
glutamate receptors is directly linked to ion currents (Na' and Ca2) through the channel pore. 
Within this receptor family three pharmacologically different classes exist. AMPA (a- 
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), kainate and NMDA receptors are 
named after their selective agonists (Dingledine et al., 1999). Initially, a pentameric 
composition of ionotropic receptors was postulated (Brose et al., 1993), but now a hetero- 
tetrameric assembly, containing more than one type of subunit, is well accepted (Laube et al., 
1998). 
Each subunit has four hydrophobic regions, although only 3 form transmembrane 
spanning domains (TM I, TM III and TM IV). TM II makes a hairpin bend within the 
membrane and forms the channel pore. The extracellular region prior to TM I and the 
extracellular TM III-TM IV loop form a ligand-binding pocket (Dingledine et al., 1999). 
So called non-NMDA receptors are represented by the AMPA subunits G1uR1, GluR2, 
G1uR3 and G1uR4 and in the case of kainate receptors by the subunits GluR5, G1uR6, G1uR7, 
KA-1, and KA-2. All are involved in fast synaptic neurotransmission. 
1.2.1 The NMDA receptor 
In contrast to the non-NMDA receptors, which are, in most cases, only permeant to the 
monovalent cations (Na', K+), NMDA receptors are also highly Ca2+ permeant and show slower 
gating kinetics. Likewise, somewhat unusually amongst neurotransmitter receptors, in addition 
to the neurotransmitter glutamate, NMDA receptors require glycine as an additional (essential) 
co-agonist for activation of the channel. Responses to NMDA cannot be obtained in the 
complete absence of glycine or D-serine. This glycine modulatory binding site has been termed 
glycineB site, to distinguish it from the regular inhibitory, strychnine sensitive glycine(A) site 
(Danysz & Parsons, 1998). 
The NMDA receptor, originally identified in the spinal cord of the frog by Evans et al. 
(1979), is blocked by extracellular Mg2+ at resting membrane potentials (Nowak et al., 1984; 
Mayer et al., 1984). This voltage-dependent channel block is only relieved by simultaneous 
membrane depolarization and agonist binding (see figure 1.1; Parsons et al., 1998). These 
unique characteristics therefore distinguish NMDA receptors from most other ligand-gated ion 
channels. As a result, NMDA receptor activation underlies not only neuronal plasticity, but also 
glutamate neurotoxicity (Danysz et al., 2000). 
2 
The NMDA Receptor 
NR1_-c Alternative splicing 0 Glycosylation sites 
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Fig. 1.1: The NMDA receptor. The figure shows the tetrameric heteromeric subunit composition of 
the receptor channel and its multiple binding sites for ligands and modulators. Functional 
NMDA receptors contain 2 NRI and 2 NR2 subunits. The NRI subunits can be alternatively 
spliced (the corresponding exons are indicated) to generate eight different isoforms. The NR2 
subfamily consists of four subtypes, NR2A - NR2D. The glutamate (and NMDA) 
recognition site is located at the NR2 subunits whereas the obligatory glycine (D-serine) co- 
agonist site is associated with NR1. Other modulatory sites are situated at extracellular 
regions, and phosphorylation sites on the intracellular regions of each protein. The figure is 
modified from Parsons et al. (1998) with the permission of the authors. 
Seven protein subunits are so far known for the NMDA receptor family: NRI, NR2A-D 
and NR3A-B. 
3 
The NR1 subunit contains three alternatively spliced exons: exon 5 in the N terminus 
(also called the Ni cassette) and exons 21 and 22 in the C terminus (also called the Cl and C2 
cassettes). These exons encode a 21 amino acid N-terminal domain (Ni) and two 21 amino acid 
C-terminal domains (Cl and C2, respectively). Splicing out the C2 cassette eliminates a stop 
codon, generating a new 22 amino acid C-terminal domain (C2'). The differential splicing of the 
exons for the NR1 subfamily generates maximally eight potential splice variants that vary 
considerably in their properties and are differentially localised in the adult and developing 
animal (Danysz & Parsons, 1998). All NR1 proteins contain either the C2 or C2' cassette. The 
splice variants are sometimes denoted by the presence or absence of these three alternatively 
spliced exons (from N to Cl to C2). NR1211 has all three exons, NRlooo has none, and NR1loo 
has only the N-terminal exon (Zukin & Bennett, 1995; Danysz & Parsons, 1998; Dingledine et 
al., 1999; see also figure 1.2). Various other terminologies have been used for the NR1 splice 
variants, naming 7 confirmed isoforms in the rat and S in humans by alternative splicing (see 
table 1.1). Since the nomenclature from Zukin & Bennett (1995) clearly shows the 
absence/presence of the various exon cassettes, this terminology will be used as standard in this 
manuscript. 
The Human NR1 gene is composed of 21 exons, exons 4,20 and 21 are identical in their 
amino-acid sequence to N l, CI and C2 in the rat, indicating that all NMDARI isoforms found 
in rat will probably also be expressed in the human brain (Danysz & Parsons, 1998). 
Table 1.1: Terminology of NR1 isoforms / splice variants 
Cassettes Length Rat Human 









Foldes et al. 
(1993 and 1994) 
- + + 938 NR1-la 
NR1A NR1oll NR1-3 
+ + + 959 NR1-lb NR1B NR1111 NR1-5 
+ 901 NR1-2a NR1C NR1oo1 NR1-2 
+ - + 922 NR1-2b NR1F NR11ot 
- + - 922 NRI-3a NR1D NR1oio 
NR1-4 
+ + - 943 (NR1-3b)* (NR1H)* (NR1 iio)* 
- - - 885 NR1-4a NR1E NR1ooo 
NR1-1 
+ - - 906 NR1-4b NR1G NR11oo 
* not yet contirmed in rat 
The NMDA2 subfamily consists of four individual subtypes, NR2A, NR2B, NR2C and 
NR2D. The more recently cloned third NMDA receptor subunit family consists of the NR3A 
and NR3B subtypes. 
4 
Classical NMDA receptor channels are formed by heteromeric combinations of two NR1 
and two (equal or different) NR2 subunits, resulting in two binding sites for glutamate (formed 
by the NR2 subunit) and two binding pockets for the co-agonist glycine (situated on NR 1), see 





© asparagine 598 
S1 - glycine binding site 
S2 - glycine binding site 
O Phosphorylation by PKA (serine 897) 
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Si - glutamate binding site 
S2 - glutamate binding site 
O Phosphorylation by CaMKII (serine 1303) 
Fig. 1.2: NRI/NR2 subunit topology. The NMDA receptor subunit is composed of four lipophilic 
regions (I - IV), three are transmembrane spanning domains (TM 1, TM Ill, TM IV), whereas 
the lipophilic region II makes a hairpin bend within the membrane and forms the channel 
pore. The NR1 subunits (left) can be alternatively spliced to generate eight different 
isoforms. Here the splice variant with all exons (NR1111) is illustrated. The agonist binding 
pockets for glutamate and glycine, respectively, are formed from two globular domains (S 1 
and S2) adjacent to transmembrane domain I (TM 1) and the TM3-TM4 loop. The figure is 
reproduced from Parsons et at (2005) with the permission of the authors. 
The glycine site is involved in one form of NMDA receptor desensitization. Upon 
binding of agonist to the glutamate binding site, the affinity of the glycine binding site decreases 
and glycine dissociates with a tau of around 300 ms. Antagonists at this site also induce a 
similar desensitization and are therefore up to 10 fold more effective in blocking plateau than 
peak responses (Parsons et al., 1993a; Danysz & Parsons, 1998). 
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In addition to the glutamate and glycine binding sites, a number of other distinct ligand 
binding domains are known, which modulate NMDA receptor pharmacology. Within the 
channel pore is the binding site for magnesium and organic agents such as phencyclidine and 
memantine. Other notable binding sites are the polyamine and Zn2+ binding sites. 
The various subunit compositions differ in their physiological and pharmacological 
properties, such as glycine sensitivity, gating properties, and magnesium sensitivity. Further 
receptor modulations are possible via the multiple phosphorylation and glycosylation sites, but 
the influence of such posttranslational modifications on receptor pharmacology has received 
little scientific attention. 
In the case of triheteromeric combinations of the NRI, NR2, and NR3 subunits, it is 
believed that one NR2 subunit is substituted by NR3 (based on the postulated NR1/NR2 "dimer 
of dimers" arrangement (Furukawa et al., 2005). These receptors, in comparison to classical di- 
heterodimers, are characterized by reduced maximal NMDA induced currents and Mg2+ 
blockade (Ciabarra et al., 1995; Das et al., 1998; Nishi et al., 2001). This has been described as 
a dominant-negative effect of the NR3 subunit on NMDA receptor function. 
Functional receptors containing only NR2 and NR3 have not been confirmed, but 
NR1/NR3 subunits were reported to form functional "excitatory" glycine receptors after 
expression in Xenopus oocytes (Chatterton et al., 2002). Due to the lack of the NR2 subunit, 
these receptors were unaffected by glutamate/NMDA, but were activated by glycine alone. 
Additionally these receptors were much less permeant to calcium and were more resistant to 
Mg2+ block. In mammalian cells, expression of both NR3 subunits (NR3A and B) together with 
NR1 has been reported to be necessary to form such functional "excitatory" glycine receptors 
(Pina-Crespo & Heinemann, 2004). 
1.2.2 Influence of NMDA subunit composition on receptor pharmacology 
NMDA receptor pharmacology is highly dependent on the subunit composition, 
especially with respect to the various NR2 subunit subtypes. As such, sensitivity to Mg2' block, 
kinetics of desensitization and offset decay, susceptibility to modulation by glycine, reducing 
agents, polyamines and phosphorylation, and affinity for agonists and antagonists are all 
dependent on subunit composition (e. g. Cull-Candy et al., 2001). For example, NR2A or NR2B 
subunit-containing NMDARs generate high-conductance channel openings with a high 
sensitivity for blockade by Mgt+, whereas NR2C- or NR2D-containing receptors show only low 
conductance openings and low sensitivity to Mg2+ (Petrenko et al., 2003). More important for 
this study, and firstly shown in Xenopus oocytes (Kutsuwada et al., 1992), glycine agonist 
affinity shows the following rank order in the presence of the different NR2 subunits: NR2A < 
NR2B < NR2C < NR2D (Dingledine et al., 1999). 
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The aspect of different pharmacological characteristics of NMDA receptors, depending 
on which subunits are associated, is very important for drug development since targeting a 
specific NMDA receptor subtype might allow better separation of therapeutic and side effects. 
This is especially important with respect to anatomical differences in expression patterns (next 
section), but developmental differences also exist (Buller et al., 1994; Wenzel et al., 1997). 
1.2.3 (Central) NMDA receptor expression pattern 
NMDA receptor subunits and splice variants are differentially distributed throughout the 
nervous system and vary with developmental status, indicating that a wide range of functionally 
distinct receptors is selectively expressed in various regions and neuronal cell types. 
Consistent with the absolute requirement for the NR1 subunit for functional NMDA 
receptor expression, the NR1 subunit is expressed ubiquitously in all NMDA receptor 
containing neurons; the splice variants are, however, variably dispersed (e. g. Buller et al., 
1994). 
For example, mRNA for double splice variants in the C1/C2 regions of the gene, such as 
NR1olj, show an almost complementary pattern to those lacking both of these inserts such as 
NRlloo; the former are more concentrated in rostral structures such as cortex, caudate, and 
hippocampus, while the latter are principally found in more caudal regions such as thalamus, 
colliculi, locus coeruleus and cerebellum (Danysz & Parsons, 1998). It was also reported that 
the predominant splice variants in cortex and hippocampus were those without the Ni insert 
whereas in the cerebellum the major variant was NR11oo i. e. containing Ni (e. g. Prybylowski et 
al., 2001). In the spinal cord most of the splice variants have been reported, but also 
predominantly with the Ni insert (Chizh & Headley, 2005). 
The NR2 subunit distribution is diverse across the central and peripheral nervous systems. 
The NR2A subtype is the most widely expressed NR2 subunit, whereas NR2B is more restricted 
to the forebrain (cortex, hippocampus, striatum, thalamus, and olfactory bulb) and is principally 
absent in the cerebellum. NR2C is also widely expressed, but at lower levels than NR2A and 
more restricted to the brainstem and the cerebellum, where it forms the predominant subtype. 
NR2D is localized mainly in the brainstem (Ishii et al., 1993; Standaert et al., 1994; Danysz & 
Parsons, 1998). 
With respect to NR2 subunit expression in the spinal cord, in general all 4 subtypes have 
been identified, however it was presumed that the positive results found for NR2B were mainly 
associated with central terminals of primary afferents, whereas NR2A were more related to the 
intrinsic neuronal cell bodies (Sundstrom et al., 1997; Chizh & Headley, 2005). 
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The most recently cloned NMDA receptor subtype, NR3, is believed to be more 
important during development than in adult animals, since NR3A expression decreased 
dramatically until the second postnatal week (Sucher et al., 1995; Ciabarra et al., 1995). mRNA 
was found in the spinal cord, brainstem, hypothalamus, thalamus, hippocampus, and amygdale 
(Sucher et al., 1995; Ciabarra et al., 1995). On the other hand, NR3B expression was also found 
in the adult rodent CNS restricted to somatic motoneurons of the brainstem and spinal cord 
(Nishi et al., 2001; Matsuda et al., 2002). 
1.2.4 NMDA receptor antagonists 
With respect to the different modulatory binding sites, functional NMDA receptor 
inhibition can best be achieved at one of four sites: competitive inhibitors at the primary 
transmitter (glutamate/NMDA) site; uncompetitive antagonists that block at the phencyclidine 
site inside the channel pore; NR2B subunit-selective antagonists acting at the polyamine site; 
and most important to this study, glycineB antagonists, which selectively bind at the strychnine- 
insensitive glycine binding pocket of the NMDA receptor complex, which is very different to 
classical inhibitory glycine receptors (Danysz & Parsons, 1998). 
Competitive antagonists at the primary neurotransmitter site are the pharmacologically 
most traditional targets, but despite the availability of selective and potent antagonists at the 
glutamate/NMDA binding site, they have not turned out to be therapeutically useful; it 
transpires that complete block of the NMDA receptor needs to be avoided because NMDA 
receptors are important for normal CNS functions and complete inhibition generates numerous 
side effects, such as memory impairment, psychotomimetic effects, ataxia and motor 
incoordination (Parsons, 2001). 
The same is true for potent, high affinity NMDA receptor channel blockers (e. g. 
phencyclidine and MK-801). In contrast, uncompetitive channel blockers with low to moderate 
affinity and fast kinetics, such as memantine, is able to differentiate between physiological and 
pathological activation and is therefore better tolerated. The postulate (Parsons et al., 1998; 
Parsons et al., 1999) is that the receptor is blocked under pathological conditions of high 
glutamate release, when receptors would otherwise be excessively activated, but remains 
available for physiological synaptic activation. 
Subtype-selective agents also seem to have a better therapeutic index than non-selective 
NMDA receptor antagonists. This is predictable since they would not produce maximal 
inhibition in neurons containing heterogeneous receptors, and/or may be anatomically selective. 
For example ifenprodil and several structurally related compounds such as eliprodil, CP- 
101,606, or Ro 25-6981 are highly selective for the NR2B subunit and show a distinct use- 
dependency in antagonizing NMDA receptors (Kew et al., 1996). On the basis of the use- 
dependency it is believed that NR2B subunit-selective antagonists would be more sensitive to 
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inhibition under pathological high agonist conditions (e. g. chronic pain states), than under 
physiological conditions with low level activation of NMDA receptors (Chizh et al., 2001). 
In theory, glycineB antagonists also offer a promising therapeutic profile. This has been 
proposed to be due to glycine-sensitive NMDA receptor desensitization (Parsons et al., 1993a) 
which might allow greater antagonism of prolonged pathological exposure to glutamate than 
short phasic synaptic activation. This occurs due to an allosteric decrease in glycine site affinity 
for agonist following binding of agonist to the NMDA recognition site. This property should 
thereby allow a differentiation between physiological and pathological effects (Parsons, 2001; 
Chizh & Headley, 2005). Indeed, receptor antagonists acting at the glycineB modulatory site 
have been reported to be free from psychotomimetic and neurotoxic effects, compared to high 
affinity uncompetitive channel blockers, while showing efficacy in animal models of chronic 
pain. However, ataxic/sedative side effects were observed and some compounds were reported 
to cause renal toxicity (Parsons et al., 1998). 
Merz Pharmaceuticals was developing a series of tricyclic pyrido-phthalazine diones 
(e. g., MRZ 2/576, and MRZ 2/596) which are moderately potent glycineB antagonists in vitro 
(Danysz & Parsons, 1998). 
During the development of selective glycineB antagonists, a consistent problem has been 
their poor brain penetration, since such compounds were intended for indications targeting the 
CNS. So far only MRZ 2/576 and L-701,324 were reported to gain clear access to the CNS (e. g. 
Danysz et al., 2005; Christoph et al., 2005). 
For the treatment of pain, GV 196771 A, showed promising activity in various in vivo 
animal models against allodynia and hyperalgesia, despite having restricted access to the brain 
(Quartaroli et al., 1999; Quartaroli et al., 2001). However, in a neuropathic pain clinical proof- 
of-concept study, GV196771A showed no significant overall benefit on subjective pain scores 
(Wallace et al., 2002). This might be an indication of translational problems and stresses the 
importance of carefully designing both preclinical and clinical trials e. g. assessing both reactive 
(e. g. allodynia/hyperalgesia) and ongoing (e. g. weight bearing/cat walk) aspects of 
nociception/pain. 
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1.3 Peripheral neurons 
Depending on the localization of their axonal projections, peripheral sensory neurons can 
be classified as intrinsic and extrinsic primary afferents. Intrinsic neurons belong to the enteric 
nervous system (ENS) and are located in the submucosal and myenteric plexuses, whereas 
extrinsic primary afferents send signals to the CNS (Kirchgessner, 2001). The functions 
controlled by the ENS are almost as complex as those in the CNS (enteric ganglia can control 
the behaviour of organs in the absence of input from the CNS). Although their involvement in 
visceral nociceptive transmission has been postulated (e. g. Patiemo et al., 2005), these neurons 
were not in the focus of the present study. 
1.3.1 Extrinsic visceral primary afferents 
The major role of visceral extrinsic primary afferent (sensory) neurons and their 
associated receptors is the conduction of information from the viscera to the CNS. Most of this 
information (such as normal gastrointestinal motility) is normally not perceived, with most 
conscious sensations restricted to discomfort and pain. Viscera are dually innervated, by vagal 
and spinal afferent neurons, containing their cell bodies in the nodose ganglia and dorsal root 
ganglia (DRG), respectively. Both vagal and spinal visceral afferent fibres respond to 
mechanical stimulation such as distension and contraction. Vagal signal encoding is limited to 
the physiological range, whereas spinal afferents respond over a wide dynamic range covering 
physiological (innocuous) as well as pathophysiological (noxious) levels of distension (Gebhart, 
2000). 
Visceral sensory terminals of the gastrointestinal tract are found in the mucosa, muscle, 
and serosa of the hollow organs. The central nerve endings of the vagal sensory neurons 
terminate in the brain stem, whereas the terminals of the DRG neurons enter the spinal dorsal 
horn, branch and spread out over up to several spinal segments; certainly the terminals 
connected to any particular visceral organ are well dispersed in the cord. Since the involvement 
of vagal afferents in acute visceral pain is thought to be negligible compared to spinal 
nociceptive transmission (Gebhart, 2000), the vagal signal transmission pathway is not further 
considered. 
Nociceptive input from the viscera reaches the CNS via the splanchnic and pelvic nerves. 
The splanchnic nerves derive from the upper abdominal organs and thorax (e. g. small intestine) 
and terminate in the lower thoracic spinal cord. The pelvic nerves innervate the pelvic organs, 
such as the lower part of the ureter, and terminate in the sacral segment of the spinal cord. In 
between, in the lumbar area, runs the sciatic nerve supplying the whole somatic tissue of the 
thigh, leg and foot, with less visceral input. 
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Visceral pain perception, especially from the intestinal tract, is generally diffuse in 
contrast to the focal quality of cutaneous pain. This is probably because the density of 
peripheral visceral afferents is low compared to the skin, and receptive fields of nociceptive 
units are large and only weakly defined. As a consequence, localization of noxious stimuli is 
poor and frequently "referred" to somatic tissue (Millan, 1999; Hunt & Mantyh, 2001). 
Several fibre types are involved in the transmission of sensory information: small 
diameter (0.4-1.2 µm) unmyelinated C-fibres (slowly-conducting: 0.5-2.5 m/s) and thinly 
myelinated (2-6 µm) AS-fibres (intermediate velocity: 6-30 m/s) convey primarily nociceptive 
information whilst heavily myelinated, large diameter (>10 µm) Aß-fibres (fast: 30-100 m/s) 
convey primarily non-nociceptive information (Millan, 1999). The given conduction velocities 
are appropriate to cat but can vary within different species. Genuine Aß-fibres seem to be 
virtually absent in the viscera, leading to the suggestion than non-noxious information from the 
viscera is transmitted by AS and C fibres (Millan, 1999). 
Despite the postulated polymodal (sensitivity to various modalities of noxious stimuli) 
character of gastrointestinal afferent C- and AS-fibres, mechanosensitivity is their most 
important modality (Gehhart, 2000). Low and high threshold mechano-receptors exist. 
Interestingly, there are also high-threshold mechanoreceptors that fail to respond under normal 
conditions. But these so-called `silent' or `sleeping' nociceptors could be woken up / activated 
by immune signals during injury or inflammation (Gebhart, 2000). Since silent nociceptors are 
also present in the gut wall, they have been deemed to be important in the genesis of chronic 
abdominal pain (Bueno et al., 2000). 
1.3.2 Classification of dorsal root ganglion (DRG) neurons 
C-fibres can be further differentiated, at least into two major subpopulations. One group 
expresses purine receptors, such as P2X3, contains the isolectin B4 (1B4) and is dependent upon 
glial-cell-derived neurotrophic factors (GDNF). The second synthesizes calcitonin-gene-related 
peptide (CGRP) and substance P (SP) and express TrkA, the high-affinity nerve growth factor 
(NGF) receptor. SP, an 11-amino acid tachykinin peptide neurotransmitter that binds 
preferentially to the neurokin 1 (NK1) receptor, was reported to be predominantly expressed in 
C-fibres originating from muscle and other deeper, dermal tissues than those innervating the 
skin (Lawson et al., 1997). Visceral afferents, in general, produce a greater amount of CGRP 
and SP (approximately 80 % to >90 % more) in comparison to skin and muscle afferents, 
indicating their importance in nociceptive transmission (Perry & Lawson, 1998). 
The capsaicin transient receptor potential vanilloid 1 (TRPV 1) receptor, transducing 
noxious chemical and thermal stimulation, is expressed by both groups (Millan, 1999; Hunt & 
Mantyh, 2001). 
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The cell bodies of sensory neurons are collected together in paired ganglia that lie 
alongside the spinal cord. These cell bodies are surrounded by satellite glial cells, which have 
much in common with the Schwann cells that ensheath peripheral axons. Very few synapses 
have been observed in these ganglia. 
DRG neurons are often categorized into three groups according to their size / diameter, 
whereas the absolute values are dependent on e. g. the species and the age (values in brackets 
correspond to rat DRG neurons, e. g. Li et al., 2004): small (< 30 µm), medium (30 - 45 µm), 
and large (> 45 µm), matching the diameter of their axons. Small cells are proposed to be 
mostly nociceptive. 
A diverse group of ligand- and voltage-gated ion channels (primarily of the TRP family; 
Vennekens et al., 2002) transduce innocuous and noxious stimuli into depolarising receptor 
potentials that generate action potentials, that are conducted along axons and finally cause 
neurotransmitter release in the spinal cord, where excitatory amino acids mediate most of the 
synaptic transmission. Similarly, a diverse group of neurotransmitter/modulator agents can be 
identified within DRG neurones and/or their axons, as can receptors for neurotransmitter agents. 
This thesis largely concerns on such neurotransmitter receptor, the NMDA receptor. 
1.33 Expression of NMDA receptors in peripheral neurons 
The involvement of central NMDA receptors, especially those situated in the spinal cord 
dorsal horn, in processing nociceptive information is well accepted. But there has been an 
accumulation of evidence over recent years that peripheral NMDA receptors also play an 
important role in nociception (Petrenko et al., 2003). 
NMDA receptors are present on the intrinsic neurones of the enteric nervous system 
(ENS) as well as on extrinsic visceral primary afferent neurons, suggesting that glutamate, the 
major excitatory neurotransmitter in the CNS, may also be an excitatory neurotransmitter in the 
periphery. NMDA receptors are abundant in the ENS. Virtually all projection neurons 
(submucosal and myenteric plexus neurons) express both NR1 and NR2A/B subunits (Burns et 
al., 1994; Kirchgessner, 2001). This was shown at both the mRNA and protein level (Liu et al., 
1997) and also demonstrated functionally (Moroni et al., 1986, Pellegrini-Giampietro, 1989; 
Kirchgessner et al., 1997) since activation and blockade of NMDA receptors by respective 
agonist / antagonist incubations could be shown in longitudinal muscle -- myenteric plexus 
preparations in vitro.. 
For the vagus nerve, one part of the extrinsic PNS, NR1 expression was detected in most 
vagal afferent neurons (Hornby, 2001), whereas the NR2 subunit subtypes were more restricted 
to subpopulations of vagal afferents. NR1, NR2B and NR2C subunit-containing NMDA 
receptors were proposed to be the most prominent (see Czaja et al., 2006a and 2006b for 
details). 
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But more central for this project was the finding that NMDA receptors are not only 
expressed by spinal cord dorsal horn neurons that are postsynaptic to primary afferent fibres, but 
also by these primary afferents themselves. After their detection in the DRG cell bodies (Sato et 
al., 1993; Ma & Hargreaves, 2000) NMDA receptor subunits were also found on the central 
terminals (Liu et al., 1994; Bardoni et al., 2004), in somatic peripheral terminals (Carlton et al., 
1998; Coggeshall & Carlton, 1998) and most recently at visceral peripheral terminals (colon and 
urinary bladder; McRoberts et al., 2001). 
The first evidence of functional expression was shown by NMDA-mediated [Ca2 J- 
changes in DRG neurons in short-term cultures. Addition of NMDA to DRG cells increased 
intracellular [Ca2+] in nearly 50 % of the cells. NMDA-mediated [Ca2+]-responses could be 
inhibited by the competitive antagonist AP-5, the voltage-dependent channel blocker Mgt+, or 
by removal of the co-agonist D-serine. NR1 was abundantly present (McRoberts et al., 2001), 
whereas experiments performed by Marvizon et al. (2002) suggested a differential distribution 
of the NR2 subunits, which will be discussed in detail in the following chapters. A splice variant 
specific evaluation of NR1 expression in the PNS has not been performed to date. 
1.3.4 Effects of inflammation on primary afferent neurons and (visceral) nociception 
Inflammatory conditions result in the release of cytokines from various immuno- 
competent cells. Interactions with adjacent neuronal cells could thus modify synaptic 
transmission and nociception. For example, substance P release was postulated to be triggered 
by interleukin 10 (IL-1 ß) in the spinal cord, and interleukin 6 (IL-6) was shown to induce 
allodynia and hyperalgesia. Allodynia in man refers to the perception of pain to a low-intensity 
stimulus which is normally not painful. Hyperalgesia on the other hand is defined as increased 
sensitivity to noxious stimuli (augmented amplitude and duration of pain). 
With respect to the gut under inflammatory conditions, both low- and high-threshold 
baroreceptors of the gut wall are activated at lower, normally ineffective, intraluminal pressures. 
Additionally, tumour necrosis factor alpha (TNFa) was reported to promote postsynaptic, 
excitatory amino acid dependent ion currents (Millan, 1999). 
Sensitization of visceral primary afferent neurons by organ inflammation is associated 
with a decrease in stimulus intensity/amplitude required for depolarization and by an increase in 
the number/amplitude of neuronal discharges in response to the stimulus. Such sensitization is 
associated with allodynia and hyperalgesia (Bueno & Fioramonti, 2002). 
Sensitization in the form of allodynia or hyperalgesia is most probably caused by 
chemical mediators that are synthesized by primary afferent fibres or released at the site of 
injury/inflammation. These chemical mediators (most of which are known to be directly 
algogenic) might be neuropeptides (e. g. SP and CGRP), adenosine triphosphate (ATP), 
bradykinin, proinflammatory cytokines, prostaglandins, neurotrophins (e. g. NGF, BNDF or 
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NT-3), nitric oxide (NO), but also excitatory amino acids (EAAs), including glutamate (Millan, 
1999; Gebhart, 2000; Hunt & Mantyh, 2001; Willert et al., 2004). Such agents might interact 
with (amongst others) voltage- and ligand-gated ion channels - the latter being more central to 
this project - including NMDA receptors. 
Cytokines, released under peripheral inflammatory conditions, may influence nociception 
by modifying NMDA receptor-mediated sensory processes in the dorsal horn (Millan, 1999). 
Alterations of spinal NMDA receptor subunit expressions after tissue injury or inflammation 
have been reported, showing an increase of NR2A but a decrease of NR2C after intraplantar 
formalin injection (Gaunitz et al., 2002). 
However, an increase of NMDA receptor expression on peripheral nerve fibres during 
inflammation has also been shown, supporting the hypothesis that peripheral NMDA receptors 
are involved in peripheral sensitization (Carlton & Coggeshall, 1999). 
As previously mentioned, NMDA receptors are located at central (dorsal horn, Liu et al., 
1997) and peripheral (e. g. colon, McRoberts et al., 2001) terminals of primary afferents and 
have been shown in both in vitro and in vivo pharmacological studies to play an important role 
in the regulation of SP and CGRP at both terminals (Bueno et al., 2000, Hunt & Mantyh, 2001). 
The increased release of EAAs, SP, and CGRP by activation of NMDA receptors (Liu et al., 
1997; McRoberts et al., 2001), which amplifies synaptic transmission/sensitizing events, most 
likely occurs via a positive feedback action since e. g. an enhancement of NMDA receptor 
responses by SP has been known for a long time (Cumberbatch et al., 1995). 
Additionally, alterations after inflammation are not limited to receptor expression levels 
but include postranslational modifications. For example, after complete Freund's adjuvant 
(CFA) treatment, NMDA receptor properties were affected by protein kinase C (PKC) resulting 
in enhanced NMDA responses at negative potentials (Guo & Huang, 2001). Besides 
phosphorylation, glycosylation of the NR1 and NR2B subunits in the spinal cord was postulated 
to be important (Guo et al., 2002). 
Changes in the phenotype by sensitizing processes are likely to result in discomfort and 
pain, i. e. in visceral hypersensitivity, which may in turn lead to functional bowel disorders. The 
exact alteration (by peripheral as well as central mechanisms) of the number, subunit 
composition, or biophysical properties of the receptors involved on visceral neurones is still 
under investigation (e. g. Gebhart, 2000). 
1.4 Visceral pain 
Visceral pain is a common form of pain produced by disease and as a consequence of this 
one of the most frequent reasons for seeking medical attention. 
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1.4.1 Principal intestinal and colonic pain-producing pathologies 
Various intestinal and colonic pathologies exist with different prevalence. Colorectal 
cancer pain plays only a minor role (5 - 60 per 10,000), inflammatory bowel diseases (IBD) 
such as Crohn's disease and ulcerative colitis affect approx. 0.1 percent of the population, but 
by far the most important pain-related pathology is irritable bowel syndrome (IBS) with a 
prevalence rate in the general population of about 5-25% (Stanghellini et al., 2003), not 
considering the patients that are not seeking medical help. 
IBS is a state of abnormal function associated with altered intestinal motility, visceral 
hypersensitivity, compliance of the gut wall, psychological disturbances, or even combinations 
of all aspects. IBS patients are subdivided according to their primary symptoms into 
constipation (IBS-C), diarrhea (IBS-D), alternated diarrhea-constipation (IBS-A), and post- 
infection (PI-IBS). The last represents a significant proportion (- 30 %) of IBS, associated with 
sensory changes of the intestines caused by infections, which then lead to disordered colonic 
motility and acute or chronic abdominal pain (Coelho et al., 2000b). 
Secondary symptoms include abnormal passage of stools, abnormal form of stools, 
increased amounts of mucus in the stool, and a subjective feeling of abdominal distension 
(bloating) as a consequence of the motor abnormalities in the gut exaggerating responses to 
intraluminal pressure. 
Visceral hypersensitivity (abnormal input from intestinal sensory nerves or abnormal 
nociceptive processing of the input from the sensory nerves to the CNS) is one of the most 
common findings in patients with functional gastrointestinal disorders such as IBS, functional 
dyspepsia, or non-cardiac chest pain (Willert et al., 2004). 
IBS is diagnosed on the basis of typical symptoms (Rome II Criteria; Alaradi & Barkin, 
2002) and the absence of other intestinal and non-intestinal diseases that might give rise to the 
symptoms. Depending on the definition of IBS, the prevalence rates are quite variable (with a 
higher rate in women, up to 70 % and approximately 50 % of the patients are older than 35 
years). Nonetheless, the numbers are substantial (e. g. Wells et al., 1997). The direct medical 
costs of IBS are estimated to be approx. 25 billion US $ in the US each year (Callahan, 2002). 
Treatment of IBS consists primarily of medication to control constipation, diarrhoea, and 
abdominal pain. Presently, only alosetron and tegaserod were specifically designed for IBS. The 
serotonin 5-HT3 (5-hydroxytryptamine) receptor antagonist alosetron was able to decrease 
postprandial nausea and bloating and was approved by the US FDA (Food and Drug 
Administration) for the treatment of diarrhoea-predominant IBS, but shortly after approval was 
withdrawn due to safety concerns with respect to occurrence of ischaemic colitis. The functional 
expression of 5-HT3 receptors on visceral spinal afferents was hypothesized to be responsible 
for the analgesic effect of the corresponding antagonists in IBS patients. On the other hand, the 
clear role of these receptors in the peristaltic reflex results in the unwanted constipating side 
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effects of the 5-HT3 antagonist, by slowing transit (Wolfe et al., 2001). A widespread clinical 
usefulness of such 5-HT3 antagonists in the treatment of visceral hyperalgesia is therefore 
limited (Kirkup et al., 2001). Due to the lack of alternative treatments and pressure from patient 
user groups, alosetron was reintroduced with restrictions limiting it to severe diarrhoea- 
predominant IBS (Stanghellini et al., 2003), indicating the influence of the strong unmet 
medical need for safe, well-tolerated medications for functional bowel disorders. Tegaserod is a 
5-HT4 partial agonist licensed for IBS-C; it reduces symptoms of abdominal pain, bloating and 
constipation. Separately, selective antagonists for neurokinin receptor type 1 and type 2 
(reducing gut motility and pain); µ opioid receptor agonists, such as loperamide in IBS-D 
patients; and kappa opioid receptor agonists have all been discussed as possible therapeutic 
approaches (Callahan, 2002). Additionally, antidepressants are widely prescribed for IBS 
(Callahan, 2002). 
Due to the lack of efficacy and the high incidence of side effects, treating the multiple 
symptoms of IBS is still a major unmet medical need. An ideal therapeutic agent should be able 
to prevent the release of sensitizing mediators under pathophysiological conditions and/or 
should reverse the sensitizing effect. The agent should nevertheless not interfere with normal 
signal transduction and so restore motility and secretion to normal (Kirkup et al., 2001). 
The role of afferent neural pathways arising from the gut gained more interest as an 
alternative to treat functional bowel disorders, besides trying to restore normal motility patterns. 
As primary afferent nerves express a wide range of modulatory membrane receptors (e. g. 
NMDA receptors) these might represent potential therapeutic targets to control visceral 
hypersensitivity (Kirkup et al., 2001). 
1.4.2 Preclinical models of visceral pain 
During the past decade, numerous models have been developed, mainly in rats, to 
investigate new targets for the treatment of visceral pain. Besides testing acute noxious stimuli 
(under physiological conditions) much effort was made to evaluate in vivo models mimicking 
the pathologies seen in humans. 
Since stress in humans is known to be responsible for gastrointestinal dysfunctions, wrap- 
restraint (harness of paper tape to restrict movement of the upper body and forelimbs) is used as 
an in vivo model for stress-induced visceral dysfunctions, showing a good correlation with IBS 
in humans (e. g. alterations in intestinal transit; Williams et al., 1988). Mother deprivation or 
direct infusion of nerve sensitizing substances (capsaicin, SP, glutamate etc. ) are also used as 
models for visceral hyperalgesia. 
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With respect to PI-IBS, several models of inflammation or chemically-induced pain have 
been developed to evaluate spontaneous pain or behavioural changes as markers of pain or 
discomfort. For this purpose, irritating agents such lipopolysaccharide (LPS), 
trinitrobenzenesulfonic acid (TNBS), formalin or acetic acid are intraluminally or 
intraperitoneally administered. The intraperitoneal injection of the endotoxin LPS (a component 
of the cell wall of Gram-negative bacteria) induces somatic and visceral pain (as well as fever 
and sickness behaviour) based on a systemic inflammation. 
Depending which model is used, the outcome of sensitization is different. LPS is known 
to induce visceral allodynia (Coelho et al., 2000a and 2000b), whereas stress induces 
hyperalgesia (Million et al., 2003). Both visceral hypersensitivity-inducing models are 
described in detail in Appendix I, due to the fact that results generated with these models 
formed the basis of the current project. 
Even though the presence of gut hypersensitivity to distension has not been demonstrated 
in all patients with functional bowel disorders, at least 40 to 70% of IBS patients were shown to 
exhibit hypersensitivity to rectal (Ritchie, 1973) and colonic (Bradette et al., 1994) distension, 
respectively. In accordance with a multifactorial origin of pain in functional bowel disorders and 
the lowered threshold of pain perception in these patients, local distension of the upper or lower 
part of the gut is used in animal models as a local mechanical stimulus. The measure of 
response may be based either on the threshold to elicit a reaction (first abdominal cramp) or on 
the intensity of the responses over time (number of abdominal cramps, number of identified 
postures, or amplitude of the cardiovascular reflex response; Bueno & Fioramonti, 2002). 
Although many substances have been tested on models of gut distension-induced 
nociception, only a few of them were evaluated in multiple animal models of hyperalgesia. 
However, the evaluation in multiple models is a prerequisite for selection of active compounds 
for human clinical trials in functional bowel disorders or other pain states such as neuropathic 
pain, in order to allow for possible translational problems from animal models to clinical 
studies. 
In animals models there is always the danger that test readouts can be confounded by the 
side effects of the compound under test. This is especially important for NMDA receptor 
antagonists, due to the fact that their muscle relaxant and ataxic side effects may influence 
motor readouts (e. g. paw withdrawal from an allodynic stimulus). The side effects are often 
observed within or near the therapeutic range, and it is therefore difficult to differentiate 
between the side effects and real antihyperalgesic or antiallodynic effects (Chizh & Headley, 
2005). 
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1.4.3 Involvement of peripheral NMDA receptors in (visceral) nociception 
Findings that glutamate receptors are expressed by primary afferent sensory fibres and 
that peripheral administration of glutamate results in nociceptive behaviours suggested that 
some of the same mechanisms described in the CNS may operate peripherally, and that primary 
afferent neurons may share some control mechanisms common to neurons in the dorsal horn 
(Carlton et al., 1998). 
In contrast to somatic nociception, which has been extensively investigated, relatively 
few studies have been published targeting visceral pain. However, experimental evidence which 
became available in the late nineties, suggested that NMDA receptor antagonists might be used 
for the treatment of visceral pain (reviewed by Petrenko et al., 2003b). 
Systemically administered NMDAR glycineB antagonists (e. g. MRZ 2/576; Danysz et al., 
1998) were shown to attenuate behavioural responses to distension of the non-inflamed rat 
ureter, but not those to somatic pain stimuli. This contrasted with the NMDA receptor channel 
blocker memantine, which inhibited both visceral and somatic noxious stimuli (Olivar & Laird, 
1999). It was suggested from these results, that extensive injury or inflammatory conditions are 
not necessary to evoke an activation of NMDA receptors after visceral noxious stimuli. Since 
glycineB antagonists act differently compared to the channel blockers, it was also hypothesized 
that the role of NMDA receptors in visceral pain processing is different or even of greater 
importance than in the pain transmission related to somatic signals (Olivar & Laird, 1999). 
Moreover, the dose of MRZ 2/576 that was effective in blocking the acute nociceptive inputs 
from the viscera (ED50 = 0.2 mg/kg, i. v. ) was much lower than that known to produce NMDA 
receptor-mediated effects in the CNS. MES studies revealed anticonvulsive effects of MRZ 
2/576 with ED50s of 7.7 mg/kg (i. p.; Parsons et al., 1997) and 20.8 mg/kg (i. p.; Danysz et al., 
2005), respectively. Because of the different potencies in these in vivo models (visceral vs. 
somatic and central) we hypothesized that NMDA receptors with a different pharmacology were 
involved. In the case of the acute visceral pain model, a peripheral site of action on NMDA 
receptors has been postulated (Parsons, 2001). 
This possible peripheral site of action was further supported by the findings of McRoberts 
et al. (2001). In combination with immunohistochemistry experiments showing NR1 subunit 
expression in DRG and peripheral nerve sections, NMDA receptor antagonists were shown to 
attenuate visceromotor responses as well as primary afferent activity to noxious colorectal 
distension. Activation and blockade of the NMDA receptors on the peripheral nerve terminals 
therefore seemed to be directly involved in visceral nociceptive processing. 
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Based on these findings, further studies were initiated by the In vitro Pharmacology 
department of Merz Pharmaceuticals in co-operation with the group of Dr. Lionel Bueno 
(Neurogastroenterology and Nutrition Unit, Ecole Superteure d'Agronomie de Purpan, 
Toulouse, France) using an in vivo model of inflammatory pain. Antinociceptive effects of the 
selective glycineB antagonists MRZ 2/576 and MRZ 2/579 were evaluated in rats after LPS- 
induced delayed rectal allodynia (see Appendix 1). Both compounds showed similar anti- 
allodynic potency. The locus of action was again most likely in the periphery, since MRZ 2/596 
was classified as non-brain permeable on the basis of MES studies (Danysz et al., 2005). 
From a therapeutic point of view, peripheral NMDA receptors involved in inflammatory 
and visceral pain would therefore offer a very attractive target for NMDA receptor antagonists 
that do not cross the blood-brain barrier, since such peripherally restricted agents might be 
predicted to be devoid of CNS side effects at doses producing powerful antinociception via 
peripheral NMDA receptors (Parsons, 2001). 
1.5 Aims and development of the study 
For a long time, glycineB site NMDA receptor antagonists attracted intense research 
interest for the potential treatment of a wide variety of CNS disorders, but the majority of such 
compounds had very limited CNS bioavailability (limited brain permeability, active efflux 
mechanisms and/or high plasma binding); see e. g. Danysz & Parsons (1998). Therefore the 
development of most such compounds was discontinued. 
However, the discovery that NMDA receptors are present not only in the CNS but are 
also functionally expressed in the periphery (in spinal and vagal primary afferents as well as in 
the ENS), together with increasing evidence of their involvement in visceral nociception / 
inflammatory pain prompted renewed interest in glycineB antagonists. 
In contrast to previous developments, the generally restricted access into the CNS of 
glycineB receptor antagonists is now seen as an advantage, since peripherally restricted NMDA 
receptor antagonists would probably show a superior therapeutic index compared to centrally 
active compounds by lacking centrally mediated side effects. Furthermore, the apparently 
greater potency of glycineB antagonists on visceral nociception in contrast to CNS functions led 
to the hypothesis that NMDA receptors expressed in the periphery have a different 
pharmacology which could be even more beneficial for the therapeutic index of glycineB 
antagonists. Based on these postulates, various aims for the current project were formulated. 
The primary aim of the project was the proof of concept for the suggested peripheral site 
of action of glycineB antagonists in attenuation of visceral nociception. The brain penetration of 
the glycineB antagonists should therefore be assessed not only under physiological, but also 
under inflammatory conditions, since the latter might facilitate access to the CNS by blood- 
19 
brain barrier (BBB) disruption. This approach was clearly feasible because an in vitro BBB 
model had been developed by colleagues and myself at Merz Pharmaceuticals before the start of 
the PhD project (see representative poster abstracts in Appendix II). 
The second part of the project addressed the postulated differences in central vs. 
peripheral NMDA receptor pharmacology. While a relatively great deal is known about the 
expression pattern and functional characteristics of NMDA receptors in the brain and spinal 
cord, at the beginning of the project there was only limited scientific know-how about the 
presence and properties of NMDA receptors in peripheral nerves. Molecular biological methods 
such as reverse transcriptase-polymerase chain reaction (RT-PCR), Western blots, and 
immunocytochemsitry investigating the expression of the NMDA receptor NR1 protein splice 
variants and the NR2 subunit subtypes in the respective tissue (including identified visceral 
primary afferents) were utilized to gain a better understanding of the pharmacology of 
peripheral NMDA receptors. 
Following these studies the patch clamp method was viewed to be the best technique for 
further comparative studies on functional NMDA receptor properties/pharmacology (with a 
focus on the glycineB site) on DRG neurons in comparison to those expressed by CNS neurones 
and with specific receptors, in stably transfected cell lines to work out, whether glycineB 
antagonists really show a different potency in the respective cultures. 
Chapter 2 details the general methods used for these studies and Chapters 3-5 detail the 
rationale for the specific studies that were undertaken, as well as the results that were generated. 
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CHAPTER II 
2 GENERAL METHODS 
All cell preparation procedures were approved by the Ethical Committee, Regional 
Council Darmstadt, Hessen, Germany and performed in accordance with the recommendations 
and policies of the German animal welfare law and the U. S. National Institutes of Health 
Guidelines. 
Cell culture plastics were supplied by Corning (Schiphol-Rijk, Netherlands) unless 
otherwise stated. 
2.1 Compounds and Drugs 
Chemicals and reagents (e. g. for preparation of buffer solution etc. ) were purchased from 
Sigma-Aldrich (Taufkirchen, Germany) unless otherwise stated. The (active) test compounds 
used in the experiments described in Chapter 3 (brain permeability studies in vitro and in vivo) 
and Chapter 5 (patch-clamp and binding experiments) are summarized in table 2.1. All 
antibodies applied in the immunological methods are listed in detail in Chapter 4. 
Table 2.1: Summary of test compounds (including distributors) used in the various experiments. 
GABAA antagonists: 
(-)-Bicuculline [R-(R*, S*)]-5-(6,8-Dihydro-8-oxofuro[3,4-e]-1,3- Sigma-Aldrich, Taufkirchen, 
methiodide benzodioxol-6-yl)-5,6,7,8-tetrahydro-6,6-dimethyl- Germany 
1,3-dioxolo[4,5-g]iosoquinolinium iodide 
Picrotoxin 1: 1 mixture of picrotoxinin and picrotin Tocris Bioscience, Bristol, 
U. K. 
AMPA / Kainate antagonists: 
UBP30I (aS)-a-Amino-3-[(4-carboxyphenyl)methyl]-3,4- Tocris Bioscience 
dihydro-5-iodo-2,4-dioxo-1(2H)- 
pyrimidinepropanoic acid 
NMDA receptor agonists: 
NMDA N-methyl-D-aspartate Sigma-Aldrich 
Competitive NMDA receptor antagonists: 
AP-5 
APV 
2-Amino-5-phosphonopentanoic acid / 
2-Amino-5-phosphonovaleric acid 
Sigma-Aldrich 
['H]-CGS 19755 cis-4-phosphonomethyl-2-piperidine carboxylic acid PerkinElmer 
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NMDA receptor channel blockers: 
Memantine-HCI 1-amino-3,5-dimethyladamantane hydrochloride Merz Pharmaceuticals 
GmbH, Frankfurt, Germany 
(+)-[ H]-MK-801 (+)-5-methyl- 10,11 -dihydro-5H-dibenzocyclo- PerkinElmer, Rodgau, 
hepten-5,10-imine maleate Germany 
[ C]- 1,3,3,5,5-pentamethyl cylohexylamine Merz Pharmaceuticals GmbH 
Neramexane-HCI hydrochloride 
NMDA receptor NR2B selective antagonists: 
Eliprodil a-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1- Tocris Bioscience 
piperidineethanol 
Ro 25-6981 (aR, ßS)-a-(4-Hydroxyphenyl)-ß-methyl-4- Tocris Bioscience 
maleate (phenylmethyl)-1-piperidinepropanol maleate 
NMDA receptor glycineB site agonists: 
glycine Aminoacetic acid Sigma-Aldrich 
D-Serine (R)-2-Amino-3-hydroxypropionic acid Sigma-Aldrich 
NMDA receptor glycineB site antagonists: 
['H]-CGS 19755 cis4-phosphonomethyl-2-piperidine carboxylic acid PerkinElmer 
5,7-DCKA 5,7-Dichlorokynurenic acid, Tocris Bioscience 
5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid 
[ H]-5,7-DCKA 5,7-Dichlorokynurenic acid PerkinElmer 
L-689,560 trans-2-Carboxy-5,7-dichloro-4- Tocris Bioscience 
phenylaminocarbonylamino-1,2,3,4- 
tetrahydroquinoline 
L-701,252 7-Chloro-3-(cyclopropylcarbonyl)-4-hydroxy- Tocris Bioscience 
2(1 H)-quinolinone 
L-701,324 7-Chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1IO- Tocris Bioscience 
quinolinone 
MDL-105,519 (E)-3-(2-phenyl-2-carboxyethenyl-4,6-dichloro- I H- Sigma-Aldrich 
indole-2-carboxylic acid 
[ H]-MDL- (E)-3-(2-phenyl-2-carboxyethenyl)-4,6-dichloro-IH- GE Healthcare, Freiburg, 
105,519 indole-2-carboxylic acid Germany 
MRZ 2/501 8-chloro-1,4-dioxo-1,2,3,4-tetrahydropyridazino Merz Pharmaceuticals GmbH 
(4,5-b) quinoline 
MRZ 2/502 8-chloro-4-hydroxy-l-oxo-1,2-dihydropyridazino Merz Pharmaceuticals GmbH 
(4,5-b) quinoline-5-oxide 
MRZ 2/576 8-chloro-4-hydroxy-l-oxo-1,2-dihydropyridazino Merz Pharmaceuticals GmbH 
(4,5-b) quinoline-5-oxide choline salt 
MRZ 2/596 8-chloro-1,4-dioxo-1,2,3,4-tetrahydropyridazino Merz Pharmaceuticals GmbH 
(4,5-b) quinoline choline salt 
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NMDA receptor partial agonists: 
ACPC 1-Aminocyclopropanecaboxylic acid Sigma-Aldrich 
D-cycloserine (R)-4-Amino-3-isoxazolidone Sigma-Aldrich 
(+R)-HA-966 (R)-(+)-3-Amino-l-hydroxypyrrolidin-2-one Sigma-Aldrich 
Functional BBB marker: 
[ 14C]-Sucrose a-D-Glucopyranosyl ß-D-fiuctofuranoside GE Healthcare 
Cytokines: 
IL-lß Interleukin-1 ß Sigma-Aldrich 
IL-6 Interleukin-6 Sigma-Aldrich 
LPS lipopolysaccharides from Escherichia coli; 0111: B4 Sigma-Aldrich 
TNF-a tumor necrosis factor-a Sigma-Aldrich 
The preparations of stock and test solutions are described in detail in the corresponding 
chapters. 
Merz Pharmaceuticals GmbH glycine6 site NMDAR antagonists 
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Fig. 2.1: Structures of Merz Pharmaceuticals GmbH NMDA receptor channel blockers 
(memantine, neramexane) and glycineB site antagonists (MRZ 2/576, MRZ 2/596) 
2.2 In vitro blood-brain barrier (BBB) co-culture model 
The experiments described in Chapter 3, using the in vitro BBB model, were all 
performed with cells that had previously been prepared and stored in liquid nitrogen by Tanja 
Bauer and myself before starting the PhD project. The cell preparation is therefore described 
only briefly. 
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2.2.1 Preparation and cultivation of bovine brain capillary endothelial cells (BBCEC) 
The preparation and cultivation of endothelial cells was performed as described by Sladek 
et al. (2007) and was based on a method previously described by Dehouck et al. (1990). 
Brain microvessels were isolated by mechanical, enzyme free, homogenisation and 
filtration from the cerebral hemispheres of freshly slaughtered bovine brain (Meresse et al., 
1989) and seeded onto dishes coated with an extracellular matrix (ECM) secreted by bovine 
corneal endothelial cells, prepared according to Gospodarowicz & Tauber (1980), in the 
presence of Dulbecco's modified Eagle's Medium (DMEM; Biochrom, Berlin, Germany) 
supplemented with 15 % calf serum (CS; HyClone, Utah, USA), 2 mM glutamine (Biochrom), 
and 50 pg/ml of gentamycin (Biochrom) to generate pure cultures of BBCEC microvessels. 
During this selection step, only capillaries adhere to the ECM and contaminating 
arterioles and venules that could form leaky areas during cultivation in the endothelial cell (EC) 
monolayer can easily be discarded. Microcolonies of endothelial cells emerging from the 
capillaries were microtrypsinized (with trypsin-EDTA, Biochrom) and seeded onto 35-mm- 
diameter gelatine-coated dishes in the same medium as described for the microvessels. Bovine 
basic fibroblast growth factor (bFGF, 146aA, 1 ng/ml; Roche Diagnostics, Mannheim, 
Germany) was added every second day. Confluent cells were sub-cultured at the split ratio of 
1: 20. Cells at the third passage were stored in liquid nitrogen and used for co-cultivation / 
transport studies until passage 6. 
2.2.2 Preparation and cultivation of rat cortical astrocytes 
Astrocytes were also prepared mechanically from cerebral cortices of four newborn 
Sprague-Dawley rats (Charles River, Sulzfeld, Germany) as described by Booher & 
Sensenbrenner (1972). The cortical tissue was disintegrated with a nylon sieve (pore size 80 
µm; ZBF, Zürich, Switzerland) after removal of the meninges, and carefully triturated. 
The cell suspension was seeded in T75 culture flasks and cultivated in DMEM containing 
10 % foetal calf serum (FCS; HyClone), 2 mM glutamine and 50 µg/ml gentamycin at 37°C in 5 
% CO2 and 95 % air humidity (Cytoperm 8080, Kendro, Hanau, Germany). Two days later, 
culture flasks were shaken at 140 rpm in the incubator for two hours to remove contaminating 
cells, such as microglia. The medium was changed twice a week. After three weeks of 
cultivation, the astrocytes had differentiated and were cryopreserved in liquid nitrogen. 
2.2.3 Co-Cultivation 
For transport studies, BBCEC in passages 4-6 were seeded onto 60-mm diameter 
gelatine-coated dishes. Once they reached confluency, cells were seeded on Transwell filter 
inserts (polycarbonate membrane, 0.4 µm pore size, 108 pores/cm2) coated with rat tail collagen 
and placed into 12-well plates containing the cryopreserved astrocytes, which had been seeded 
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on the bottom of the well 3 days before the co-cultivation for the improvement of the barrier 
characteristics by secretion of soluble factors but without direct cell-cell-contact. 
The preparation of rat tail collagen was performed according to a method modified from 
Bornstein (1958). The medium used for the co-culture was DMEM, supplemented with 15 % 
CS, 2 mM glutamine, and 50 gg/ml gentamycin. bFGF (1 ng/ml) was added when seeding and 
after the first medium exchange (modified after Dehouck et al., 1990). 
Blood-brain barrier in vitro 







abluminal (brain) side 
Fig. 2.2: Scheme of the blood-brain barrier (BBB) in vitro model mimicking the in vivo 
situation. During cell preparation, isolated bovine brain capillaries (A) are seeded 
onto extracellular matrix (secreted by bovine corneal endothelial cells)coated dishes 
and endothelial cells migrate out of the capillary (B). Confluent bovine brain 
capillary endothelial cell (BBCEC) monolayers (C) are microtrypsinized and seeded 
on rat tail collagen-coated Transwell filter inserts (Corning) and co-cultured with 
cryppreserved rat cortical astrocytes (D) in the lower compartment (on the bottom of 
a multiwell plate) for the induction of barrier characteristics by soluble factors 
released by the astrocytes. The filter insert simulates the luminal side of the BBB, 
which is separated from the brain side (the well with astrocytes) by a collagen coated 
membrane mimicking the basal membrane. Scale bars: 100 pm (A, B, C); 25 pm (D). 
25 
2.3 BBB transport studies in vitro 
Luminal (blood side) to abluminal (brain side) transport studies were performed with the 
endothelial cells after 11 to 14 days of co-cultivation with astrocytes (Sladek et al., 2007). 
The transport studies were performed in Krebs-Ringer buffer (KR: NaCl 114 mM, KCl 5 
mM, CaC12 1.25 mM, MgC12 1.1 mM, NaHCO3 20 mM, Na2HPO4 1.65 mM, NaH2PO4 0.3 mM, 
glucose 25 mM, and HEPES 10 mM; pH 7.3; all from Sigma-Aldrich, Taufkirchen, Germany), 
containing the test substance on the luminal (blood) side of the filter. 
The amount of substance passing the filter insert (with or without endothelial cell 
monolayer) after 10,20, and 30 minutes was measured by taking 100 µl samples from the 
abluminal side of the filter (n = 4). The sample volume was replaced by adding the equivalent 
amount of KR buffer. Under these conditions, hydrostatic pressure did not interfere with the 
permeability (Pe) measurement. Additionally, 50 µl samples from the luminal compartment 
were taken at the beginning and the end of the experiment, also necessary for later permeability- 
coefficient and substance balance sheet calculations. 
The studies were performed on a shaker at 140 rpm in the incubator to minimize the 
thickness of the aqueous boundary layer on the cell surface, which would influence the 
permeability of lipophilic solutes (Cecchelli et al., 1999). Test compounds pass through the 
collagen-coated microporous membrane differently, so collagen-coated filters without cells 
were used in parallel as a control, to predict the drug transport across the endothelial monolayer 
alone. 
Due to the fact that a morphological control of the endothelial cell culture is not possible 
on the polycarbonate membrane and to ensure an intact blood-brain barrier in vitro, the 
permeability of ['4C]-sucrose (a functional marker for a tight BBB; GE Healthcare) was 
determined every day as a control before each set of transport studies. Endothelial cells were 
only used for transport studies if the actual ['4C]-sucrose permeability coefficient was a 
maximum of 20 % higher then the mean (0.69 x 10"5 cm/s) of all performed sucrose 
permeability studies. 
2.3.1 Sample analysis and permeability coefficient calculations 
Test samples were stored at - 20 °C for later quantitative analysis using the HPLC-MS 
(High Performance Liquid Chromatography - Mass Spectroscopy) or HPLC-MS/MS (High 
Performance Liquid Chromatography - Tandem Mass Spectroscopy) technology. The analysis 
was performed by the `Biological Analytics' department of Merz Pharmaceuticals GmbH as an 
internal CRO as no analysis equipment was available in the In vitro Pharmacology department. 
Amounts of radioligand-labelled substances were directly measured using a liquid scintillation 
counter. 
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Permeability calculations were performed according the clearance principle (Siflinger- 
Birnboim et al., 1987) to obtain a concentration-independent transport parameter; for details see 
Chapter 3.2.2. 
2.4 Cell viability and cytotoxicity measurement of BBCEC 
The viability of the endothelial cells was assessed using the cytotoxicity assay WST-1 
(Roche Diagnostics) and the Cyto Tox 96 Non-Radioactive Cytotoxicity Assay from Promega 
(Mannheim, Germany). 
The BBCEC were cultured alone on gelatine-coated 96-well plates or co-cultured on 
HTS-Transwell-96 filter inserts at a density of 2x 104 cells/well. The same cultivation period 
was used for these experiments as in the transport studies, then cells were used for the 
cytotoxicity assay. The BBCEC were pre-incubated with various pro-inflammatory agents 
(LPS, TNFa, IL-6, and IL-1ß) for different incubation times (see chapter 3.2.3 for details) in 
DMEM without supplements at 37°C in humidified 5% C02/95% air. 
Cytotoxicity was morphologically examined using a phase contrast microscope and 
quantified biochemically by measuring cell viability reflected by the mitochondrial activity 
(WST-1 test) or by measuring cell death via the lactate dehydrogenase (LDH) release from 
lysed cells (Cyto Tox 96 Non-Radioactive Cytotoxicity Assay). 
The WST-1 assay measures the reduction of a tetrazolium component into a soluble 
formazan product by the mitochondria of living cells. After incubation with the dye solution for 
3 hours at 37°C, the absorbencies of the wells were read using a multi-mode 96-well plate 
reader (Fusion, PerkinElmer, Rodgau, Germany) at a wavelength of 450 nm (reference 
wavelength = 650 nm). The amount of colour produced is directly proportional to the number of 
viable cells (% viability). 
LDH is a stable cytosolic enzyme that is released upon cell lysis. Released LDH is 
measured after agent application via the culture supernatant using a 30-minute coupled 
enzymatic assay that results in the conversion of a tetrazolium salt into a red formazan product. 
The amount of colour formed is proportional to the number of lysed cells. Visible wavelength 
absorbance data were collected using the multi-mode 96-well plate reader at an absorbance 
wavelength of 490 nm. 
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2.5 Brain microdiaiysis in vivo 
Brain microdialysis experiments were performed by Jens Nagel (PhD) from the `In vivo 
Pharmacology' department of Merz Pharmaceuticals, due to the fact that this technique is very 
challenging and time consuming to learn. Additionally, the experimenter needs approval by the 
Ethical Committee, Regierungsprasium Darmstadt (F77/75). The method is therefore not 
described in detail. 
Male Sprague-Dawley rats were used for microdialysis experiments. All animals were 
individually housed and kept under constant temperature (21 ± 2°C) and light-dark cycle (12 / 
12 h). Food / water were available ad libitum. 
The brain microdialysis techniques used here were described in detail by Nagel & Hauber 
(2002). Using standard stereotaxic procedures, guide cannula were implanted unilaterally in 
pentobarbital (Merial GmbH, Hallbergmoos, Germany; 50 - 60 mg/kg; intraperitoneal, i. p) 
anaesthetized animals targeting the Caudate Putamen (CPu) 4 days before the experiments. The 
microdialysis probe was lowered through the guide cannula to the CPu at least 16 hours before 
the onset of microdialysis experiments. Perfusion with artificial cerebrospinal fluid (aCSF) at a 
flow rate of 2 µl / minute was started one hour before sampling (20 minute fractions). After one 
baseline sample was taken, the drug was applied i. p. followed by sample collection for 120 
minute. For all compounds, assessment of concentrations in biological fluids was corrected 
according to recovery ratios determined in vitro. 
To investigate the BBB permeability of MRZ 2/596 under the same inflammatory 
conditions as performed in an in vivo model for Irritable Bowel Syndrome (IBS, LPS-induced 
visceral allodynia, see Appendix I), rats were treated with LPS (1 mg/kg) for 10 h before the 
microdialysis experiments. 
Test samples were stored at - 20 °C and analysed as described above (Chapter 2.3.1). 
2.6 Retrograde staining of visceral dorsal root ganglia (DRG) neurons 
To identify DRG neurons connected to definite regions of the viscera, the lipophilic 
fluorescent retrograde tracer 1,1, -dilinoleyl-3,3,3', 3', -tetramethylindocarbocyanine perchlorate 
(Fast DiIf Oil; Invitrogen, Karlsruhe, Germany) was used. According to the manufacturer, 
these carbocyanine membrane dyes are particularly suitable for long-term labelling due to the 
fact that they exhibit minimal cytotoxicity, while cell viability, cell-development and other 
physiological properties are not affected. Once applied to the tissue of interest, the lipophilic 
chemical structure of the tracer enables its uptake into the lipophilic part of the plasma 
membrane of viable cells, and the dye then diffuses laterally within the plasma membrane and 
stains the whole cell. Transfer of dye between intact membranes should be negligible. In this 
experiment, the dye migrated retrogradely from the peripheral nerve terminals to the cell bodies 
in the DRG. 
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Diffusion of lipophilic carbocyanine tracers from the point of their application to the 
termini of a neuron can take several days to weeks, but using Fast DiI, the migration is at least 
50 % faster due to the introduction of diunsaturated linoleyl tails in place of the saturated 
octadecyl tails as in classical DiI probes, resulting in a transportation rate in living tissue of 
approximately 6 mm per day (according to the manufacturer's brochure). Additionally, the 
perchlorate salt of FAST DiI Oil does not crystallize and is a viscous oil and therefore easier to 
handle. Due to its orange-red fluorescence (absorbance: 549 nm, emission: 565 nm) DiI was 
observed with standard rhodamine optical filters (Filter set 14; Carl Zeiss Microimaging GmbH, 
Göttingen, Germany) with an excitation of 510-560 nm and emission of 590 nm. 
The identification of visceral DRG neurons by retrograde labelling was performed 
according to the method described by Gold et al. (2002). Male Sprague-Dawley rats (21-25 day 
old) were anaesthetized with pentobarbital sodium (60 mg/kg, i. p. ). The small intestine was 
exposed by a midline abdominal incision. DiI was dissolved in equal parts of miglyol 812 (used 
as a detergent in parenteral feeding) and methanol (50 mg/ml), not in dimethylsulfoxide 
(DMSO) or ethanol as recommended by the manufacturer, in order to reduce toxic effects of the 
solvent. A total volume of 25 pl Dil was injected by slow subserosal injections (ca. 4 mm) at 7- 
10 sites (2-3 pl per site) into the muscle wall of the duodenum, jejunum and ileum using a gas- 
tight Hamilton glass syringe fitted with a 26 gauge needle (it was not possible to use smaller 
needle diameters due to dye viscosity) held nearly parallel to the course of the intestine, so the 
tip of the needle was still visible through the intestinal wall. Correct dye injection resulted in a 
slowly spreading staining of the tissue, which was not observed if the dye was accidentally 
injected into the lumen. To minimize dye leakage, the needle was kept in the tissue for 15 - 20 s 
after injection to allow the dye to settle. Any DiI that leaked from the injection site was 
carefully wiped away with cotton swabs and the area rinsed with warm (37°C) and sterile 0.9% 
sodium chloride solution (Fresenius Kabi AG, Bad Homburg, Germany) according to Gold et 
al., 2002). The abdomen was sutured in layers and the animal allowed to recover from 
anaesthesia. The DRG segments were isolated for cell culture or cryo-sectioning 11-12 days 
after labelling (see Chapters 2.5 and 2.9, respectively). 




2.7 Preparation and cultivation of dorsal root ganglia (DRG) neurons 
During the PhD project, the method for preparation and cultivation of DRG neurons was 
improved continuously. For example, the collagen digestion of the DRGs was performed using 
various enzymes, incubation times and temperatures, and even preparations without enzymatic 
digestion were tested. The composition of the culture medium and addition of nerve growth 
factors (NGF) were also crucial factors. The final protocol for the preparation of the DRG 
neurons was performed according to the method described by Samoriski & Gross (2000) and 
McRoberts et al. (2001), to generate vital cell cultures from young adult rats. 
5 week old male Sprague-Dawley rats were overdosed with pentobarbital (100 mg/kg, 
i. p. ) and decapitated. The back was disinfected with ethanol (70 %, Sigma-Aldrich) and the 
vertebral column was exposed by a midline dorsal incision. The vertebral column was isolated 
into two parts (thoracic 5-13 and lumbar/sacral L1-S1) and collected in ice cold Cat+- and Mgt+- 
free Phosphate Buffered Saline (PBS-CMF, supplemented with 4 g/1 glucose, pH 7.3, 
Biochrom). After opening the vertebral column on both sides to separate the dorsal from the 
ventral part, the spinal cord was removed and the dorsal root ganglia were harvested bilaterally 
from the thoracic (T5-13), lumbar (L1-2, and L6) and sacral (Si) regions in order to investigate 
neurons with visceral input, belonging to the splanchnic and pelvic nerves, respectively. They 
were collected in ice-cold Cat+- and Mg2+-free Hank's Buffered Salt Solution (pH 7.3), 
containing 4 g/1 glucose (HBSS-CMF) in a 12-well plate. Ganglia were then transferred to 35 
mm dishes (maximum of 4 ganglia per dish) with fresh ice-cold HBSS-CMF and cleared from 
contaminating connective tissue and the dura mater spinalis to improve the subsequent ganglia 
digestion. For further washing, purified ganglia were placed back in a 12 well plate containing 
fresh ice cold HBSS-CMF. After cutting the ganglia with small scissors, the ganglia digest was 
performed in 6-well plates by adding collagenase D (Roche Diagnostics) dissolved in HBSS- 
CMF (to approximately 1.6 mg/ml, depending on the batch) and incubating at 37°C in an 
incubator for approximately 30 minutes on a rotating platform. Collagenase D was selected due 
to its low trypsin concentration to preserve the cell membrane, as the cultivation time is 
relatively short for patch-clamp experiments and therefore a gentle cell preparation is crucial. 
The rate of digestion was regularly checked optically under the microscope. 
Enzymatic digestion was terminated by centrifugation at 180 g for 2 minutes and rinsing 
the cells with Neurobasal A medium (Invitrogen) without supplements but containing 1 mg/ml 
Soybean trypsin inhibitor (Sigma-Aldrich, to stop digestion by trypsin) and 0.1 mg/ml DNase I 
(Roche Diagnostics). After another centrifugation step at 180 g for 2 minutes, the cells were 
suspended in Neurobasal A medium containing 2% B-27 supplement (Invitrogen, enabling 
serum-free conditions), L-glutamine (0.5 mM), and gentamycin (0.05 mg/ml), and then 
mechanically dissociated by trituration. Since growth factors and hormones contained in the 
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serum might considerably effect the culture characteristics, it was deemed more pertinent to use 
serum-free medium for the DRG cultures to ensure constant culture conditions. 
The cell suspension (400 µl, giving 2-4 ganglia per dish) was plated onto 35-mm culture 
dishes coated with poly-DL-omithine (Sigma-Aldrich) and mouse laminin from Invitrogen 
containing flexiPERM inserts (Greiner bio-one, Frickenhausen, Germany). 
The coating of the cell culture dishes was performed two days before the cell isolation. 
Autoclaved flexiperm cylinders were placed in 35 mm cell culture dishes to reduce the cell 
culture area to approximately 1 cm2 for better handling and to increase the number of cell 
culture dishes. The dishes were then coated with 400 pl 0.1 % poly-DL-ornithine in 0.15 M 
boric acid (sterile filtered) per cylinder and incubated overnight in an incubator at 37°C in a 
humidified atmosphere. After washing twice with PBS-CMF, dishes were additionally coated 
with 400 pl mouse laminin (10 µg/ml in PBS-CMF) under the same conditions as for poly-DL- 
ornithine. Before the cell seeding, the coated dishes were washed twice with culture medium 
without supplements. 
Two hours after seeding, when the cells had settled and attached to the bottom of the dish, 
the inserts were removed. After an overnight incubation, a 75% medium exchange was 
performed. Depending on the purity of the culture, the mitotic inhibitor cytosine-ß-D- 
arabinofuranoside (AraC, 5 µM, Sigma-Aldrich) was added to suppress proliferation of 
contaminating cells such as Schwann cells by inhibition of DNA polymerase. The cultures were 
maintained at 37°C in a humidified atmosphere of 95% air and 5% C02. 
Additionally, 100 pM DL-APV (2-Amino-5-phosphonovaleric acid, Sigma-Aldrich) was 
added to prevent toxic effects by the NMDA receptor itself. DRG neurons were used for 
electrophysiological recordings or immunohistology 24-72 hours after cell preparation. 
2.8 Preparation and cultivation of hippocampal neurons 
Cell preparation was performed as previously described by Parsons et al. (1998b). All 
possible practical steps were performed in order to avoid suffering to the dam and embryos. The 
female Sprague-Dawley rat was sacrificed by placing in a saturated CO2 euthanasia chamber 
under further quiet C02-influx followed by cervical dislocation. Under these conditions the rat 
lost consciousness after a few seconds (CO2 euthanasia is in accordance with §4 of the German 
animal welfare law). 
After opening the abdominal cavity, embryos (E20) were removed and stored in ice cold 
HBSS-CMF. Hippocampi were then isolated from the brains of at least 8 embryos after 
decapitation, transferred into ice cold HBSS-CMF and washed 3-4 times. During the isolation 
of the hippocampi, one had to ensure that the CNS tissue was always kept moist with fresh 
HBSS-CMF. 
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Hippocampi were pre-incubated for 8 minutes with a 0.66% trypsin (Sigma-Aldrich) 
and 0.1% (20 U/ml) DNase (Sigma-Aldrich) solution in Ca2+-free PBS, supplemented with 1.5 
g/1 MgSO4 *7H2O, and washed 3 times with HBSS-CMF. Cells were then mechanically 
dissociated by trituration in a PBS-CF solution containing 0.05% (10 U/ml) DNAase and the 
trypsin inhibitor ovomucoid (0.3%) to stop further digestion (all from Sigma-Aldrich). The cells 
were then centrifuged at 180 xg for 10 minutes, and the cell pellet re-suspended in basal 
minimum essential medium (MEM, Invitrogen), again carefully triturated to ensure maximal 
dissociation, and finally plated in the flexiPERM inserts at a density of 15 x 103 cells/cm2 (0.5 
ml/insert) onto poly-DL-ornithine and mouse laminin pre-coated plastic petri dishes (coated as 
decribed in Chapter 2.7). After 1 hour the cells become attached to the bottom of the dish and 
the inserts could be removed. The cells were then nourished with 2 ml basal hippocampal 
neuron culture medium (9.52 g/1 MEM, 2.14 g/1 NaHCO3,5.96 g/1 HEPES, 2.4 g/l glucose, 37.5 
mg/l insulin, pH 7.2) supplemented with 5% heat inactivated FCS and 5% heat inactivated horse 
serum and incubated at 37°C with 95% air and 5% CO2 at 95% humidity. After 4 days in vitro 
(DIV) further glial mitosis was inhibited by adding 10 µl AraC (to give an end concentration of 
5 µM). The medium was completely exchanged after an additional 2 days DIV and a partial (50 
%) exchange was performed after 8 DIV. The cells were used for electrophysiological 
recordings after 11-15 DIV. 
2.9 Generation and cultivation of stable human NR1o11/NR2A expressing 
HEK293 cells 
I developed a cloning strategy to enable a combination of one stable NR1 expressing cell 
line with various NR2 or NR3 subunits. Apart from the experimental design, the vector cloning, 
transfection procedure and selection of stable expressing cell clones was performed in 
cooperation with an external Contract Research Organisation (CRO, Cell Culture Service, CCS, 
Hamburg, Germany). The human NRI011 and NR2A NMDA receptor subunit cDNA clones 
(accession codes NM 007327 and NM 000833, respectively; OriGene Technologies, 
Rockville, USA) were used for transfection. A HEK293 cell line was thus generated that stably 
expresses human NR1-3 (representing the rat terminology NR1o11 which is further used for 
simplification; Zukin & Bennett, 1995; Foldes eta!., 1993) and NR2A proteins. 
If the target receptor had been constantly expressed, glutamate from the medium may cause 
excessive receptor activation and excitotoxicity, and therefore the LacSwitchll inducible 
expression system from Stratagene (La Jolla, USA), was used. Since the expression of one 
NMDA receptor subunit subtype does not lead to the formation of functional receptors and 
could therefore not be toxic for the cell, the first objective was to generate a HEK293 cell line 
which constitutively expresses the human NR1o11 subunit. 
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After amplification by PCR from the original OriGene vector (pCMV6-XL4), the NR101 1 
cDNA was cloned in the pCMV-IRES-Hyg (containing a hygromycin resistance). This vector 
enables the production of two proteins due to the fact that the open reading frame (ORF) of the 
first protein is combined via a so-called internal ribosome entry site (IRES-sequence) with the 
second ORF. The second ORF amplified by PCR, the Lac-repressor, was cloned in the vector 
for triggering the inducible vector of the LacSwitch system, leading to a bicistronic Vector 
pCMV-IRES-NRI-3-Lacl-Hyg. The vector cloning was checked by restriction analysis as well 
as by sequencing of the gene of interest. 
For the generation of the stable cell line, 1x107 HEK293 cells (European Collection of 
Cell Cultures, ECACC, via Sigma-Aldrich) were transfected with the described bicistronic 
vector, using Fugene (Roche Diagnostics) as the transfection reagent according to 
manufacturer's instruction. Selection was performed by the addition of 100 pg/ml hygromycin 
(CalBiochem, Darmstadt, Germany). Two positive clones (# 57 and # 77) out of 78 were 
identified by immunohistochemistry using mouse-anti-Lacl (clone 9A5, Upstate/Millipore, 
Schwalbach, Germany) in combination with anti-mouse Alexa488 (Molecular 
Probes/Invitrogen, Karlsruhe, Germany) for pre-selection and goat-anti-NMDARI (C-20) from 
Santa Cruz in combination with anti-goat Alexa568 (Molecular Probes/Invitrogen) as proof for 
the expression of the gene of interest. The immunostainings showed a clear Lac-Repressor 
expression in the nuclei and a cytoplasmic staining of the NR1011 subunit. The cell clone 77 was 
chosen due to it having a uniformly distributed subunit expression pattern and sufficiently large 
NMDA-activated currents after transient transfection with the NR2A containing vector, and was 
used for further transfection with NR2A. These transiently transfected cells were used for 
preliminary electrophysiological characterization. 
The second half of the desired NMDA receptor heteromeric assembly, subunit NR2A, 
was consequently cloned in the same way as described above in the inducible LacSwitch 
System pOPI3, providing the pOPI3-NR2A with a neomycin resistance. This vector contains 3 
Lac operators which should lead to a maximal repression of the receptor expression. Because 
the presence of the operators is crucial, the operator region was also checked by sequencing, in 
addition to the sequencing and restriction enzyme analysis of the gene of interest. 
After confirming the correct coding sequence and presence of 3 Lac operators, the vector 
was stably transfected in the hNR1011-expressing HEK293 cells and clones were selected 
according to neomycin and hygromycin resistance. The presence of NR2A in the 52 isolated 
cell clones was evaluated by RT-PCR. The RNA was isolated using the RNeasy Mini-Kit 
(Qiagen) followed by DNaseI treatment (DNA-free Kit, Ambion/Applied Biosystems, 
Darmstadt, Germany) to digest possible genomic DNA. Reverse transcription was carried out 
with the SuperScriptlll RT-PCR system (Invitrogen). All kits were used in accordance to the 
manufacturer's instructions. 
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This resulted in seven positive cell clones on the RNA level, but only 3 were positive in 
the immunofluorescence und functional patch-clamp assessment. One clone showed particularly 
large NMDA activated currents, which was shown to have a pharmacological profile 
characteristic for this subunit combination, and was therefore used for the further experiments. 
The HEK293 cells stably transfected with human NRloll and NR2A subunits were 
cultured in DMEM (Biochrom) supplemented with 10% heat inactivated foetal calf serum 
(FCSi, Sigma-Aldrich), 2 mM Glutamax (Invitrogen), 100 µg/ml gentamycin, 500 µg/ml G418 
(Calbiochem) and 500 pM ketamine (Sigma-Aldrich) at 37°C in a humidified atmosphere of 5% 
C02/95% air. The addition of ketamine in the culture medium was necessary because the 
expression of the NR2A subunit was not completely repressed, despite the 3 Lac operators, 
resulting in a weak NMDA receptor background i. e. "leaky" expression without induction. Sub- 
cultivation by trypsination was carried out every 2 to 3 days. 
The cells were seeded onto 35 mm dishes 24 hours prior to the patch-clamp experiments. The 
medium composition was changed to DMEM supplemented with 10% dialysed foetal calf 
serum (FCSd, Sigma-Aldrich), 1 mM Glutamax, 100 pg/ml gentamycin, 1 mM IPTG (isopropyl 
(3-D-thiogalactopyranoside, Stratagene) to induce transcription of the NR2A mRNA, and 500 
µM D-APV was added to prevent excitotoxicity after the induction of NMDA expression, as 
this low affinity competitive ligand is easier to wash out than the uncompetitive antagonist 
ketamine which shows intracellular accumulation in lysosomes (similarly to memantine, see 
Honegger et al., 1993). 
The proportion of hNRI/2A transfected cells remained stable, showing characteristic 
morphology and NMDA activated currents, at least until passage 50. 
2.10 mRNA Detection 
2.10.1 Total RNA Isolation 
Total RNA for use in Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) was 
isolated from tissue samples and cell cultures using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany) as described by the manufacturer. This technology enabled the binding of up to 100 
pg of RNA to a silica-based membrane by using a specialized high-salt buffer. 
Whole DRGs were isolated as described above (Section 2.7) and collected in RNAlater 
(Qiagen), a RNA preservation reagent, in order to minimize RNA degradation and therefore 
ensure reliable gene expression analysis, before freezing in liquid nitrogen and long term 
storage at -80°C. 
Cortex, cerebellum, and midbrain tissue samples were also isolated to serve as positive 
controls for the later RT-PCR experiments. The different brain areas were dissected with a 
micro-dissection knife into pieces of maximum length, depth and breadth of 3 mm and 
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immediately stored in RNAlater solution (Qiagen) until further processing. Additionally, tissue 
samples from different sections of the small intestine, representing the original target tissue of 
the PhD project, were isolated by opening the abdomen with small scissors, without injuring the 
bowel and removing the intestine by cutting the mesentery as closely as possible to the gut. 
Duodenum, jejunum, and ileum were separated and cut open for washing with ice-cold Krebs 
Ringer solution. Each part of the small intestine was cut into pieces of maximum 5 mm length 
and stored in RNAlater solution. 
Unlike the rotor-stator homogenisation of the intestinal and brain tissue, the frozen DRGs 
were disrupted by using a mortar and pestle and ground to a fine powder under liquid nitrogen. 
Due to the high collagen content in the DRGs and the relatively small amount of neural tissue, 
other methods lead to insufficient disruption and/or to excessive sample loss. 
The highly denaturing guanidine-thiocyanate-containing RLT lysis buffer (RNeasy Mini 
Kit), which also inactivates RNase, was added to the frozen samples and the samples were 
further processed as quickly as possible. 
The lysates were directly centrifuged through a QlAshredder spin column (Qiagen) for 
further homogenisation to reduce the viscosity of the lysates by shearing high-molecular-weight 
genomic DNA and other high-molecular-weight cellular components released during disruption. 
Ethanol (70%) was added to the homogenized sample to create conditions that promote 
selective binding of the RNA to the silica-based membrane when applied to the Mini spin 
columns. In this binding step the denatured total RNA is separated from other contaminants and 
also from smaller RNAs (like rRNA and tRNAs). The retained RNA was then washed once 
with RW 1 and twice with RPE buffer (both from the RNeasy Mini Kit) for further purification 
and eluted with 30 - 50 µl RNAase-free water. All binding, washing, and elution steps were 
performed by centrifugation in a micro-centrifuge. 
In the case of cell cultures, total RNA was directly isolated from cultures. Cells grown in 
35 mm dishes or in 6 well plates were washed with PBS-CMF, trypsinized according the 
standard procedure and pelleted by centrifugation. Due to the fact that not more than 1x 107 
cells should be used per mini spin column to ensure optimal yield and purity of the RNA, the 
number of cells was measured by means of a Coulter counter. Cells were disrupted with the 
appropriate amount of RLT lysis buffer under trituration and then further processed as described 
for the tissue samples. 
The concentration and purity of the RNA was determined by measuring the absorbance at 
260 nm and 280 nm in a spectrophotometer (BioPhotometer, Eppendorf, Hamburg). An 
absorbance reading of 1 at 260 nm equals 40 µg/ml and the ratio between both wavelength gives 
an estimate of the RNA purity which should be between 1.9 and 2.1 for pure RNA. Purified 
RNA was stored at -80°C until the RT-PCR experiments were performed. 
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2.10.2 Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) 
For identification of the messenger ribonucleic acid (mRNA) of interest (Chapter 4.1.2), 
suitable candidate primers were designed to have similar annealing temperatures, low 
complementarity, minimal folding, and approximately 40 - 60 % guanine (G) and cytosine (C) 
content, all calculated using the Sigma Genosys online DNA calculator (https: //www. sigma- 
genosys. com/order DNACalc. asp). The primer sequences were then screened for specific 
binding using the National Centre for Biotechnology BLAST search facility 
(www. nebi. nlm. nih. govBLAST/). The primers were ordered from Sigma-ARK (Darmstadt, 
Germany). 
The Primer melting temperature (Tm) was estimated by using equation 1, where n 
accounts for the number of the nucleobases: adenine (A), tymine (T), guanine (G) and cytosine 
(C): 
Tm =2x n(AT) +4x n(GC) (1) 
First-strand copy deoxyribonucleic acid (cDNA) synthesis and PCR reaction was 
performed in the same tube by using a specially formulated enzyme blend provided in the 
OneStep RT-PCR kit from Qiagen. The temporal separation of both steps is enabled by heat 
activation (95°C for 15 minutes) of the HotStarTaq DNA Polymerase (Qiagen) after reverse 
transcription and simultaneous inactivation of the Omniscript reverse transcriptase (Qiagen). 
The use of the gene-specific primers for the eDNA synthesis reduces non-specific amplification 
products. 
The RT-PCR was performed as described in the protocol included in the OneStep RT- 
PCR kit. 
For this purpose, the template RNA, primer solutions, deoxyribonucleosidetriphosphate 
(dNTP) mix, 5x reaction buffer, and RNase-free water were thawed and placed on ice. A master 
mix was prepared, containing all components except the template RNA, and dispensed in the 
PCR tubes. The template RNA (not more than 2 pg/reaction) was added as the last step before 
starting the RT-PCR program in the thermal cycler. In every experiment, negative controls were 
included by preparing samples with nuclease-free water instead of template RNA to detect 
possible contaminations originating from the reaction components. 
The reaction mixture was first heated and incubated at 50°C for 30 minutes in order for 
the reverse transcription reaction to take place. This reaction is inactivated as the first step of the 
PCR reaction by heating the mixture for 15 minutes to 95°C. The PCR cycle was performed 35 
times, including denaturation at 94°C for 1 minute, annealing at various temperatures 
(depending on the primers, 4-5°C below their melting temperature, Tin), and extension at 72°C 
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for 1 minute. After a final extension at 72°C for 10 minutes, the products were cooled to 4°C, 
and electrophoresed along with a DNA ladder on a2% agarose gel containing ethidium 
bromide (0.5 pg/ml) at 80 - 100 V for approximately 80 minutes. 
DNA-gels were visualized with a transiluminator using a gel documentation system 
(Biostep, Jahnsdorf, Germany). The separated bands were documented according their intensity 
and their relative position to the DNA ladder (e. g. Gene Ruler DNA Ladder Plus) with the help 
of the Grapper v3.01 and Phoretix 1D Gel Analysis v5.10 software (Nonlinear Dynamics, 
Newcastle upon Tyne, U. K. ). 
2.11 Immunoblotting 
2.11.1 Protein isolation for Western blots 
All the procedures were performed at 4°C using pre-cooled reagents and working on ice. 
DRG from thoracic, lumbar, and sacral spinal cord, as well as cortex and cerebellum tissue 
samples, were rapidly dissected out from 5 week old Sprague-Dawley rats and collected 
separately in PBS. DRG were freed from contaminating tissue and the samples were washed 
once with PBS containing a protease inhibitor mix from Sigma. Before further treatment, the 
tissue samples were placed in liquid nitrogen and then transferred into a -80°C freezer. 
Frozen tissue was homogenized using 10 strokes of a polytron on ice in ice-cold 
homogenization buffer containing tetrasodium pyrophosphate (20 mM), sodium phosphate (20 
mM), MgCl2 (1 mM), EDTA (0.5 mM), sucrose (300 mM) and protease inhibitor cocktail (100 
µU10 ml homogenization buffer), all from Sigma. 
The protein preparation obtained at this point is very crude, but nonetheless suitable for 
Western analysis. Further purification / centrifugation steps to remove residual tissue and nuclei 
(low speed spins) or to isolate membrane proteins (high speed spins) were not performed due to 
accompanied massive protein loss, comparable to the RNA isolation from the DRG. 
Sonification was used in some cases to reduce viscosity resulting from release of 
deoxyribonucleic acid (DNA). The protein concentration was determined in triplicates 
according to the method of Lowry et al. (1951) with some modifications Hartfree (1971). 
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2.11.2 Western blotting 
Total protein samples (in general 25 - 30 µg/lane) were suspended in denaturing sample 
buffer containing Tris-HC1 (50 mM, pH 6.8), dithiothreitol (DTT, 100 mM), 2% sodium 
dodecyl sulfate (SDS, a detergent which covers the charge of the protein to ensure a constant 
charge allocation), 0.1 % bromphenol blue, and 10 % glycerol in H2O (all from Sigma; 
according to the method of Sambrook et at (1989) and resolved according to their molecular 
weight by SDS / polyacrylamide gel electrophoresis. 
Some protein samples were additionally heated to 95°C for 10 minutes to dissolve 
possible retained associations between receptor subunits or with interacting proteins because 
this may increase aggregation, even though tissue samples are usually not boiled for SDS- 
PAGE analysis. NMDA receptor subunits should be completely solubilized with 2% SDS, but 
boiling in SDS might be beneficial to disrupt interactions with PDZ-containing proteins, such as 
PSD-95. 
Self-made polyacrylamide gels (concentrations: 7.5 - 10 %) or gradient gels (4 - 12 %) 
from Cambrex (Verviers, Belgium), depending on the size of the protein to be detected, were 
used at 110 - 126 V for approximately 80 - 105 minutes in running buffer (25 mM Tris base, 
250 mM glycine, 0.1 % SDS, pH 8.3) until the bromphenol blue in the samples reached the end 
of the gel. A recombinant protein molecular weight marker (e. g. Rainbow Marker, 10 - 250 kD, 
GE Healthcare) was always present for later band identification. 
Separated proteins were then transferred from the polacrylamide gel via semi-dry blotting 
onto Polyvinylidene fluoride membranes (Hybond-P PVDF, GE Healthcare). For this purpose, 
the wet gel was put on the PVDF membrane which was pre-soaked in methanol (Merck, 
Darmstadt, Germany) washed with distilled water and equilibrated in blot-buffer (25 mM Tris, 
190 mM glycine, 20 % methanol) at least 10 minutes before blotting. Methanol in the blot- 
buffer enabled a fixation of the proteins on the membrane. Both were then embedded in 
chromatography paper (Whatman, Dassel, Germany; 6 slices on each side) after moistering with 
blot buffer. For accurate blotting, direct contact between the filter paper, the gel and the 
membrane was essential in order to prevent a short-circuit between the filter papers. 
During the blot at 0.8 mA/cm2 (i. e. 68 mA for two mini gels) for 70 - 75 minutes, the 
negatively charged proteins migrated down unto the PVDF-membrane towards the anode. 
The blot was removed from the transfer apparatus and immediately placed into blocking 
buffer containing 5% non-fat dried milk or ChemiBlocker blocking agent (Chemicon) in TTBS 
(tris buffered salt solution: 20 mM Tris base, 137 mM NaCl, pH 7.6) containing 0.1% Tween 
20, Sigma) overnight at 4°C on an orbital shaker to block non-specific binding sites. 
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After briefly rinsing the membrane with TTBS, the immunodetection of the protein of 
interest was performed by incubating the membrane for 1 hour at room temperature with the 
primary antibody diluted in TTBS. To reduce the amount of reaction volume/antibody the blots 
were put in small plastic bags. 
The membrane was then rinsed with TTBS followed by another four washing steps (once 
for 15 minutes and 3 times for 5 minutes) before revealing the immunoreaction by incubation 
with the secondary antibody for 1-1.5 hour at room temperature. The horseradish peroxidase 
(HRP) secondary antibodies were diluted 1: 10000 - 1: 20000 in TTBS. 
The non-specifically bound secondary antibodies were removed by another washing 
procedure before the chemiluminescence detection was performed using the ECL Plus western 
blotting detection reagents (GE Healthcare) according to the manufactures protocol in the dark 
room. 
The ECL detection reagents A und B were mixed in a ratio of 40: 1 and incubated on the 
blot for 5 minutes. Excess detection reagent was drained off and the membrane was dried 
carefully on a fresh sheet of tissue paper. The exposure of the chemiluminescant membrane to 
the autoradiography film (Hyperfilm ECL, GE Healthcare) was performed in an x-ray film 
cassette for 5s- 600 s depending of the intensity. The X-ray films were then manually 
developed by successively dipping in developing and fixation solution (Kodak via Sigma- 
Aldrich) for 30 to 45 s. Resulting films were digitalized and analysed using the Phoretix gel 
documentation software (Nonlinear Dynamics, Newcastle, U. K. ). 
2.12 Immunofluorescent staining 
2.12.1 Isolation of DRG sections for immunostaining 
DRG with approximately 5 mm of the dorsal root attached were isolated from 5 week old 
rats as described in the DRG cell culture preparation section and immediately fixed for 2 hours 
at room temperature with 4% paraformaldehyde (1.3 M, PFA) in PBS-CMF. For cryoprotection, 
DRGs were placed in 30% sucrose in PBS-CMF overnight at 4°C. 
Once the DRG had equilibrated, they were stored at -20°C or directly embedded in tissue 
freezing medium (Leica Instruments, Nussloch, Germany) placed in a liquid N2 / iso-pentane 
bath for cryo-sectioning. 
Sections of 7- 10 µm were cut from the DRGs on a cryostat and thaw-mounted onto 
gelatine-coated slides and allowed to air-dry. They were then encircled with an immunoedge 
(hydrophobic resin) pen to reduce the volume of reagents in the following staining procedure. 
Slide mounted-sections were permeablized at room temperature for 30 minutes with 0.1% 
Triton X100 (Sigma-Aldrich). 
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2.12.2 Preparation of DRG cultures for immunostaining 
Cell medium was aspirated and cells washed twice in phosphate buffered saline 
containing magnesium and calcium (PBS, Biochrom). They were fixed by a 15 minute 
incubation with 4% PFA in PBS-CMF at room temperature, followed by a 15 minute 
incubation in 0.1 % Triton X100 in PBS-CMF at room temperature to permeablize the cell 
membrane. 
2.12.3 Immunofluorescent staining of DRG sections and DRG cultures 
DRG sections or cell cultures were washed three times for 5 minutes with PBS-CMF and 
blocked for 2 hours at room temperature with 1% bovine serum albumin (BSA) and 2% goat 
serum (Invitrogen) or 2% rabbit serum (Sigma-Aldrich) in PBS-CMF, depending on the host 
for secondary antibody production. 
The sections / cells were incubated with the primary antibodies, diluted in blocking 
buffer, overnight at 4°C in a humidified atmosphere unless otherwise stated. After three 10 
minute washes in PBS-CMF, the fluorescein isothiocyanate- (FITC) conjugated secondary 
antibodies were applied in blocking buffer for 2h at room temperature and a further 5 washes in 
PBS-CMF followed. Cells were mounted in Vectashield mounting medium (Axxora, Grünberg, 
Germany) containing 4', 6-diamidino-2-phenylindole (DAPI; I pg/ml; Molecular Probes, 
Leiden, Netherlands) as blue nuclear staining where required. Stained cells were examined 
using a Zeiss Inverse Microscope (Axiovert 10) with appropriate filter sets (filter set 5: 395-440 
nm extinction with 470 nm emission for viewing the DAPI staining and filter set 9: 450-490 nm 
extinction with 520 nm emission for the FITC staining; Zeiss, Germany). Pictures were 
recorded using the LuciaG Laboratory Imaging Software (Nikon, Düsseldorf, Germany). 
Secondary antibody controls (without primary antibody) were performed for all staining 
procedures. 
Control experiments were performed using blocking buffer without primary antibody as 
secondary antibody controls for all staining procedures. If control peptides were available for 
the primary antibodies these were also used for antibody selectivity controls by a2h pre- 
incubation at room temperature of the primary antibody with a5- 10 fold excess of the control 
peptide before the actual antibody incubation on the sample. 
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2.13 Electrophysiology 
2.13.1 Whole cell patch clamp recordings from DRG neurons, hippocampal neurons and 
human NRloll/2A expressing HEK293 cells 
In accordance to Li et al. (2004), who also investigated NMDA receptors in rat DRG 
neurons with a focus on nociceptive AS- and C-fibers, here only small to medium sized DRG 
neurons (approximately 20 - 40 µm in diameter) were used 1-3 days after the cell preparation. 
Hippocampal neurons were kept in culture for 11-15 days before the patch-clamp experiments. 
The stable hNR1/2A transfected cells were used 1-2 days after seeding and 1 day after induction 
of the receptor expression. All experiments were performed at room temperature. 
Cells were visualised using an inverted microscope (Zeiss Axiovert200) and chosen based 
upon their position, morphology and cell size (in comparison to the diameter of the patch- 
pipette tip). In case of DRG neurons, some were retrogradely labelled by injection of Fast DiI 
Oil in the muscle walls of the small intestine, visceral neurons were identified by their 
fluorescence, which was visualised using a Zeiss filter set 14 attached to the microscope 
(excitation: 510-560 nm, emission: 590 nm). 
Patch pipette 
Patch clamp pipettes were pulled from borosilicate glass (Hilgenberg, Malsfeld, 
Germany) using a horizontal puller (P-97 Puller, Sutter Instruments, USA) and had resistances 
of I-3 M92 when filled with intracellular solution. Tight seals (> 1 Gf2) were procured by 
applying negative pressure between the pipette and cell membrane and the membrane then 
disrupted using additional suction in order to obtain the whole cell configuration. The cells were 
allowed to stabilize for 1-2 minutes before recordings were initiated. 
Application pipette 
Test substances were applied to the cell of interest by switching channels of a modified 
stepper motor-driven, double-barrelled theta glass application pipette. Squared-walled theta 
glass (700 x 700 µm internal dimensions per barrel; Warner Instruments LLC, U. S. A. ), was 
pulled manually to a smaller opening of around 250 x 250 pm over a Bunsen burner and then 
cleanly separated into two new perfusion pipettes using a diamond cutter. The internal `dead' 
volume of the application pipettes was then reduced to a minimum. Silicon-glass tubing (S. G. E. 
GmbH, Germany) was inserted as far as possible towards the tips of the theta glass pipettes 
(usually ending around 2-3 mm from the tip). The open ends of the silicon-glass tubing were 
blocked with glue and the pipettes were then reverse filled with molten wax almost to the open 
tips of the silicon-glass tubing. The glued ends of the silicon-glass tubing were then cut free and 
attached via conventional polyethylene tubing (Clay Adams, U. S. A. ) to low volume 6-port 
manifolds (Warner Instruments LLC, U. S. A. ). 
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Perfusion system 
The manifolds were connected to a home-made gravity-driven perfusion system made 
up of further polyethylene tubing and including manifold valves (Lee Hydraulische 
Miniaturkomponenten GmbH, Germany). Syringes containing the solutions to be applied to the 
cells were fixed above the valves, to which they were connected via polyethylene tubing. 
The valves were set up to switch flow on and off in combination with the movements of 
the stepper motor (Perfusion Fast-Step, SF-77B, Hugo Sachs Elektronik - Harvard Apparatus 
GmbH, March-Hugstetten, Germany) holding the double-barrelled application pipette in order 
to expose cells to either agonist-free or agonist-containing solutions in presence or absence of 
antagonist. The perfusion was controlled using a TIB 14S digital output trigger interface in 
conjunction with the EPC-10 amplifier and the TIDA 5.0 data acquisition system (both from 
HEKA, Germany) which was also used for the recording of the currents and subsequent 
analysis. Valves were driven by a custom-made valve driver to provide the necessary power 
(490 mW per valve) and spiked voltage jumps. 
Optimal positioning of the application pipette was determined by using solutions of 
different osmolarity to visualize the interface between solutions under phase contrast 
microscopy and by measuring the change in potential as the application pipette moved so that 
the recording pipette was exposed to the other solution. The best angle for compound 
application was found to be approximately 45° and care was taken to keep the lower edge of the 
application pipette tip parallel to, and as close as possible to, the bottom of the dish without 
scratching the plastic during the stepping motor movement. The tip of the application pipette 
was positioned 150 - 250 gm from the relevant cell. Solution exchange time around a lifted cell 
of approximately 10 µm in diameter was measured to be 20 ms. When a test solution was not 
being applied, the cell was continuously perfused with extracellular solution. 
Recordings 
Voltage clamp recordings were made in the whole cell patch clamp configuration at a 
holding potential of -70 mV with the aid of an EPC-10 amplifier (Heka, Lambrecht, Germany) 
in combination with a pipette manipulator from Luigs & Neumann (Feinmechanik und 
Elektrotechnik GmbH, Ratingen, Germany). 
Offset compensation was performed for each open patch pipette before reaching the cell 
using the EPC-10 in order to ensure that the command potential was equal to the membrane 
potential. The liquid junction potential was measured using a3M potassium chloride-agar 
bridge (in a plastic casing) in place of the usual silver chloride pellet as the ground electrode. 
Liquid junction potential was measured by filling one perfusion chamber with intracellular 
solution as the reference, and the other chamber with extracellular solution. The liquid junction 
potential was measured to be 3.4 mV for the solutions used here. 
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Series resistance was measured (the mean value measured for the stably transfected HEK 
293 cells was 4.22 ± 0.14 MSS; n=15) and accordingly compensated for in conjunction with 
capacitance. Fast capacitive currents were corrected for by the EPC-10 upon formation of the 
gigaseal, and whole cell capacitance correction was performed after the cell was opened. These 
procedures were performed semi-automatically using the amplifier and TIDA software. Upon 
triggering the compensation procedure, a train of square-wave pulses is applied (5 mV), and the 
resulting capacitative transients averaged and fitted using an exponential curve to calculate the 
corrections necessary to cancel the current. 
The current signal was filtered by the EPC-10 amplifier using the 3-pole pre-filter with 
Bessel 10 kHz bandwidth and the 4-pole filter set to 2.9 kHz with Bessel characteristic. Current 
measurements were acquired at a rate of 10 kHz and A/D conversion carried out by an LIH 
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Fig. 2.3: Flow diagram of the experimental set-up composition for patch-clamp recordings of cultured 
cells. Arrows indicate the direction of information transfer. Abbreviations are as follows: 
CPU - central processing unit and HS - headstage. 
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The intracellular solution used when recording NMDA receptor-mediated currents from 
the DRG and hippocampal neurons and also from the transfected HEK293 cells consisted of 
physiological concentration of: CsCl (120 mM), HEPES (10mM), EGTA (10 mM), MgC12 (1 
mM), CaC12*2H20 (200 µM), glucose (10 mM), tetraethyl ammonium chloride (TEA-Cl, 20 
mM), and was adjusted to pH 7.38 with CsOH. The EGTA, MgC12, CaC12 was used as a Ca2+ 
buffer system, ensuring constant free intracellular Ca2-concentrations of approximately 10 nM. 
CsCI replaces K+ and reduces leak currents through potassium channels since such channels are 
impermeable for Cs'-ions. Furthermore, TEA-Cl served as intracellular potassium channel 
blocker. The corresponding physiological extracellular bath solution contained: NaCl (140 
mM), KC1(3 mM), glucose (10 mM), HEPES (10 mM), CaCI2 (1.5 mM) and sucrose (4.5 mM), 
and was supplemented with tetrodotoxin (0.3 µM, TTX, Tocris) to block voltage-activated 
sodium channels (VASCs) and (-)bicuculline (20 µM, Sigma-Aldrich) to block GABAA 
receptors when recording from DRG cultures. It was adjusted to pH 7.35 using NaOH. Since 
Ca2+ is an important cation for membrane stability, 1.5 mM CaC12 was always present. The 
blocking kinetics of open channel blockers such as memantine might be influenced by the Ca2- 
dependent desensitization of NMDA receptors, but this was not in the focus of these 
experiments. Mg2+-free solutions were used to allow maximal responses at negative membrane 
potentials (-70 mV). 
Within this project, `cumulative' compound application protocols were used, in which the 
agonists NMDA (200 µM) and glycine (10 µM) are applied, then 5 concentrations of antagonist 
(in a log3 progression, e. g. 0.3,1,3,10 and 30 µM) are sequentially coapplied before the 
antagonist is removed and the current is allowed to recover. The protocol should ideally be 
performed in both directions i. e. using increasing or decreasing concentrations of antagonists. 
This is because binding to the glutamate site affects the affinity of the glycine site and visa 
versa (Parsons et al., 1993a). However, this is not possible for high affinity ligands, as these 
have very slow offset kinetics. In this case, only increasing concentrations of antagonist can 
easily be tested. 
The cumulative protocol enables a fast determination of the concentration-dependency of 
blockade - i. e. cells do not have to remain stable for long recording durations (which was 
especially important for the DRG neurons). However, they give little useful information on the 
kinetics of block and desensitization/rundown correction is more of a problem. In `kinetic' 
protocols (such as those used in Parsons et al., 1997), the current is allowed to recover after the 
coapplication of each concentration of antagonist, which is useful for accurate correction for the 
effects of current rundown/desensitization, and the onset and offset kinetics for the antagonist 
can be determined. However, these protocols take longer, and it should be noted that the 
cumulative protocols have been shown internally at Merz Pharmaceuticals GmbH to produce 
very similar IC50 determinations as kinetic protocols. 
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2.13.2 Analysis of data 
Data were analysed using TIDA 5.0. Data were pooled with the help of Microsoft Excel 
2000, and GraFit 5.0 software (Erithacus Software Ltd., Surrey, U. K. ) was used to fit the data 
e. g. with the four parameter logistic equation for determining IC50 values. 
IC50 values are given as mean ± S. E. M. (standard error of the mean). Statistical 
comparisons were made via correlation analysis of pIC50 and pEC50 values. The distributions 
of these logarithmically transformed mean values were always normal. 
2.14 [3H]-MDL-105,519 binding assay 
MDL-105,519 (Baron et al., 1996 and 1997; Hofner & Wanner, 1997) is a selective, high 
affinity antagonist at the NMDA receptor glycineB site, commercially available from GE 
Healthcare and was therefore used as radioligand for displacement studies at the glycineB 
binding site. 
Tissue preparation was performed according to Foster & Wong (1987) with some 
modifications. Male Sprague-Dawley rats (200-250 g, Janvier, Le Genest-Isle, France) were 
anaesthetised by CO2 inhalation, decapitated and their brains were removed rapidly. The cortex 
was dissected out and processed as described by Parsons et al. (1997). For isolation of the cell 
membranes, the cortices were homogenized in 20 volumes of ice-cold 0.32 M sucrose (Sigma- 
Aldrich) using a glass-teflon homogenizer. The homogenate was centrifuged at 1000 xg for 10 
minutes, the pellet was discarded and the supernatant centrifuged at 20,000 xg for 20 minutes. 
The resulting pellet was re-suspended in 20 volumes of distilled water and centrifuged for 20 
minutes at 8000 x g. The supernatant and the buffy coat were then centrifuged three times 
(48,000 xg for 20 minutes) in the presence of 50 mM Tris-HCI, pH 8.0 (assay buffer). All 
centrifugation steps were carried out at 4°C. After resuspension in 5 volumes of 50 mM Tris- 
HCI, pH 8.0, the membrane suspension was frozen rapidly at -80°C. On the day of assay, the 
membranes were thawed and washed four times by resuspension in 50 mM Tris-HC1, pH 8.0, 
and centrifugation at 48,000 xg for 20 minutes. Extensive washing of the membrane 
preparation is needed for enhancement of specific binding by removing the endogenous ligand. 
The final pellet was suspended in assay buffer. The amount of protein in the final membrane 
preparation was determined according to the method of Lowry (1951) with some modifications 
(Hartfree, 1971). The final protein concentration used for our studies was 400 µg/ ml. 
The Tecan robotic system designed for binding assays was loaded with the membrane 
solution, a 96 well stock plate containing the solutions for bound control (bufferfDMSO 10%), 
unlabeled glycine (1 mM) for evaluation of non-specific binding, all compounds to be tested (at 
20-fold concentrations), various empty 96we11 plates for dilutions and the final assay plates, as 
well as a 96-well plate filled with the radioligand. 
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Before performing displacement studies, saturation experiments were performed to 
determine the equilibrium dissociation constant (K 1) of [3H]-MDL-105,519, which is a 
parameter for the affinity of the radioligand to the binding site. The protein/receptor 
concentration is held constant whereas the specific bound radioligand is determined with 
increasing concentrations of the ligand. 
On the basis of the saturation experiments, a final [3H]-MDL-105,519 concentration of 2 
nM was selected. Firstly, the assay plates were loaded with membrane solution and were shaken 
at 4°C. The mother plates were then prepared by pipetting the compounds (n = 4) into assay 
buffer/10% DMSO to obtain the desired final concentrations. After transferring radioligand into 
the assay plates, the compounds were added (including the non-specific binding control 
containing glycine) . 
The final DMSO concentration was always 0.5 %. The assay plates were 
incubated and shaken at 4°C for 1 h, before the mixture was exhausted as rapidly as possible via 
a vacuum manifold using the Multiscreen HTS glass fibre (type B) filter plates (Millipore, 
Schwalbach, Germany) under a constant vacuum of 450 mbar. The membranes were washed 
four times with cold assay buffer (100 µL). 50 µL of Ultima Gold scintillation cocktail 
(PerkinElmer) were added to the wet filter plates and incubated at room temperature overnight 
before counting the disintegration per minutes using a liquid scintillation counter (MicroBeta, 
PerkinElmer). 
For the evaluation of the test compound binding affmity to the glycineB binding site and 
its potency to displace [3H]-MDL-105,519, the measured radioactivity of the radioligand alone 
was set as 100 % bound control and the non-specific binding of the radioligand (which could 
not displaced by glycine, 1 mM) represented the 0% control. The residual radioactivity after 
displacement of the test compound was then corrected with respect to the set controls. 
2.15 Statistical verification 
Where relevant, data were statistically verified by performing an analysis of variance test 
(ANOVA) followed by post-hoc analysis (e. g. Tukey test) if appropriate, with the help of Sigma 
Stat 3.5 software. P values of < 0.05 were considered significant. 
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CHAPTER III 
3 BRAIN PENETRATION OF GLYCINEB ANTAGONISTS 
UNDER PHYSIOLOGICAL AND INFLAMMATORY 
CONDITIONS IN VITRO AND IN VIVO 
3.1 Introduction 
An important advance in our understanding of the potential involvement of NMDA 
receptors in the processing of nociceptive inputs from the viscera - as already mentioned in the 
general introduction (Chapter 1.4.3) - was provided by a study in an acute model of visceral 
pain. In this model MRZ 2/576 - an antagonist of the modulatory glycineB site - and the NMDA 
receptor channel blocker memantine, were shown to attenuate cardiovascular nociceptive 
responses to distension of the non-inflamed rat ureter following systemic (i. v. ) administration 
(Olivar & Laird, 1999). Interestingly in these experiments the potency of MRZ 2/576 (ED50 = 
0.2 mg/kg i. v. ) was much higher than in the maximal electroshock (MES) induced convulsions 
test in vivo (ED50 = 20.8 mg/kg i. p. ) - assessed in separate experiments (Danysz et al., 2005). 
On the other hand, memantine was less effective against visceral nociceptive responses (ED50 = 
14.5 mg/kg i. v. ) than in the MES test (ED50 = 5.93 mg/kg i. p. ). In this regard, it should be noted 
that the MES model was used as a pharmacodynamic test implying antagonism at CNS NMDA 
receptors. 
The role of NMDA receptors in mediating visceral nociceptive signals became even more 
interesting following the concrete postulation of a peripheral site of action for NMDA receptor 
antagonists (McRoberts et al., 2001) which was already implicated by the data from Olivar & 
Laird (1999). Such peripheral receptors would represent an extremely attractive target for 
NMDA receptor antagonists that do not penetrate to the brain, because they would be essentially 
devoid of all classical CNS NMDA receptor-mediated side effects, such as memory impairment, 
psychotomimetic effects, ataxia and motor incoordination (Parsons et al., 1998a; Parsons, 
2001). 
This fact applies particularly for glycineB site NMDA receptor antagonists which were 
pursued for a wide variety of therapeutic applications targeting the CNS, but the majority of 
which - in contrast to MRZ 2/576 - proved to lack any significant CNS bioavailability due to 
either low brain penetration or, when BBB permeable, by active efflux out of the brain (Danysz 
& Parsons, 1998; Hesselink et al., 1999b). The development of most such compounds was 





Based on these findings, knowledge of the brain permeability of the various glycineB 
antagonists seems to be a crucial factor for the development of potential anti-nociceptive 
compounds for visceral pain - it seems possible that non CNS penetrant agents might, in fact, 
be preferred. This issue was addressed using an in vitro model of the blood-brain barrier 
(Chapter 2.2) and comparing such data with an in vivo model addressing CNS NMDA receptor 
activity, i. e. the MES test. 
The in vitro model of the BBB was realized by sub-cultured bovine brain capillary 
endothelial cells in co-culture with cryo-preserved rat cortical astrocytes. This model was 
refined and optimized from the initial method described by the group of Cecchelli (Dehouck et 
at, 1990) by colleagues and myself at Merz Pharmaceuticals GmbH (Danysz et at, 2005; 
Sladek et al., 2007). 
Further investigations were then initiated to evaluate the antinociceptive effects of brain 
permeant and non-permeant glycineB site NMDA receptor antagonists in co-operation with the 
group of Dr. Lionel Bueno (Neurogastroenterology and Nutrition Unit, Ecole Sup6rieure 
d'Agronomie de Purpan, Toulouse, France) who has established several well accepted rat 
models for visceral pain related to irritable bowl syndrome (IBS; Coelho et al., 2000a). In these 
models, the number of abdominal muscle contractions induced by rectal distension is recorded 
as electromyographic (EMG) activity from electrodes implanted in the abdominal muscles and 
this activity is used as an indication of pain responsiveness to visceral distension stimuli that 
elicit aversive responses. In one model of inflammation-induced IBS, the effects of drugs are 
assessed 10 hours after induction of rectal hypersensitivity by an inflammatory stimulus using I 
mg/kg (i. p. ) lipopolysaccharide (LPS, see Appendix I for more details). In the first set of such 
LPS-induced visceral pain experiments MRZ 2/576 and MRZ 2/596 were tested, because of 
their postulated different brain bioavailability. The exchange of nitrogen (MRZ 2/596) by a 
nitric oxide group (MRZ 2/576) in the tricyclic ring was predicted to improve the blood-brain 
barrier (BBB) permeability of the latter glycinea, antagonist. This difference in brain 
permeability was confirmed by the MIES studies. Here, in contrast to MRZ 2/576, MRZ 2/596 
was completely inactive, at least at doses of 50 mg/kg (i. p. ), indicating a lack of CNS activity 
due to its restricted access to the brain (Danysz et al., 2005). 
Interestingly, in the model of LPS-induced visceral hypersensitivity, both glycineB site 
antagonists MRZ 2/576 and MRZ 2/596 showed similar anti-allodynic effects, despite their 
apparent difference in brain permeability, at the low intravenous (i. v. ) dose of 0.1 mg/kg (see 
Appendix I; Sladek et at, 2002), supporting the assumption for the involvement of peripheral 
NMDA receptors in visceral nociception, at least under hypersensitive inflammatory conditions. 
48 
The endotoxin LPS is a component of the cell wall of gram-negative bacteria, that 
activates the immune system by triggering various cellular and hormonal responses, for example 
the production and release of the pro-inflammatory cytokines such as tumour necrosis factor 
alpha (TNF-a), interleukins (IL-1 and IL-6) or interferons. TNF-a and IL-1 provoke the 
inflammatory response and ultimately result in sickness behaviours such as hyperalgesia, fever, 
reduced food intake, inactivity etc. by stimulating afferent sensory signals through the vagus 
nerve (Coelho et al., 2000b). 
Inflammation, e. g. induced by LPS, is also known to have a negative effect on the 
functional and molecular properties of the BBB (Jaworowicz et al., 1998); Gaillard et al., 2001; 
Xaio et al., 2001; Huber et al., 2001 and 2002). As a consequence, it was important to test 
whether the antinociceptive effect of the brain impermeant glycineB antagonists was really due 
to their lack of penetration to the CNS or possibly due to BBB break down under the tested 
inflammatory conditions. 
Our established in vitro BBB model only simulates physiological conditions, in contrast to 
the LPS-induced inflammatory conditions as used in the IBS in vivo model for visceral pain 
discussed above. It was however important to test the influence of LPS on BBB integrity per se. 
Due to an initial lack of available in vivo models to directly target a possible BBB breakdown 
after LPS application, this point was evaluated in vitro. 
For this purpose the direct effect of this endotoxin as well as the downstream pro- 
inflammatory cytokines TNF-a, IL-1(3, and IL-6, the release of which is triggered by LPS (Xaio 
et al., 2001), was investigated on the integrity of the BBB in vitro using transport studies 
comparing sucrose, a functional marker for a tight BBB, and MRZ 2/596 which was found to 
have a low brain permeability under physiological conditions. It should be noted that IL-1 ß and 
TNF-a reproduced the effects of LPS in the visceral IBS pain model described above (Coelho et 
al., 2000a). 
Additionally, the viability of the BBB was assessed using the cytotoxicity assays WST-1 
(Roche Diagnostics, Mannheim) and Cyto Tox 96 Non-Radioactive Cytotoxicity Assay 
(Promega, Mannheim). 
One of the major drawbacks of this in vitro approach is that the investigated time frame 
for the possible impact of the inflammatory mediators might not be representative of the in vivo 
situation. The direct influence of the inflammatory mediators on the endothelial monolayer and 
resulting functional and molecular changes in the cells can indeed be investigated in vitro, but 
the downstream signalling of the inflammatory pathway in vivo is difficult to simulate in vitro. 
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Fortunately, brain microdialysis techniques again became available at Merz 
Pharmaceuticals during the course of my PhD work, which gave us the opportunity to perform 
microdialysis experiments under exactly the same inflammatory conditions as in the LPS- 
induced visceral pain model. This was intended to give further insights whether the LPS induced 
inflammation causes opening of the BBB under in vivo conditions, since an increase of 
compound concentration in the dialysate would be expected after BBB disruption. 
Alternatively, in vivo receptor occupancy studies with peripherally restricted glycineB 
antagonists (e. g. MRZ 2/596) after a LPS inflammatory challenge might have also been a 
sensible approach. Using a radioactively labelled, brain permeable glycineB site antagonist, this 
technique would allow to analyse possible increase of brain permeability as well as possible 
changes in antagonist affinity under inflammatory conditions. The performance of such 
experiments was not possible for various reasons. In vivo binding experiments under 
inflammatory conditions demand special approval by the Ethical Committee and was not offered 
by an external CRO, additionally, so far only L-701,324 is known as brain permeable glycineB 
site antagonist but is not commercially available as radioligand. 
Another approach to address brain penetration of compounds of interest is to radiolabel 
the compound and detect concentrations in brain homogenates ex vivo. However, this method 
cannot differentiate between extracellular and intracellular levels, and only the former are 
relevant for the glycineB site. 
It should be noted that the in vivo and in vitro BBB techniques used are mutually 
supportive. The former gives insights into the in vivo relevance, the latter into possible 
mechanisms. 
3.2 Experimental protocols 
All compound stock solutions were prepared fresh before the actual experiments by 
dissolving in adequate solvent (see table 3.1 and 3.2). 
3.2.1 Prediction of NMDA receptor antagonist brain permeability in vitro 
In vitro transport studies, as described in Chapter 2.3, were performed with various kinds 
of standard NMDA receptor antagonists (channel blockers, competitive antagonists, and 
glycineB site antagonists), reflecting a very wide range of brain permeability. Additionally 
sucrose was tested as a control for an intact/tight BBB in vitro. 
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Table 3.1: Preparation of test compounds for BBB in vitro transport studies and summary of detection 
methods used. 
Compound Stock solution Test 
solution 
Assay method Limit of 
quantification 
[µM] solvent [µM] [nM] 
[ 14C]-Neramexane 602.12 H2O 10 Scintillation counting 4.0 
(+)-[ H]-MK-801 40 Ethanol 0.2 Scintillation counting 0.009 
[ 14C]_Sucrose 311 3% Ethanol in H2O 1 Scintillation counting 0.35 
[ H]-5,7-DCKA 63.30 Ethanol 0.5 Scintillation counting 0.012 
[3H]-CGS 19755 15 10 mM K2PO4 
(pH 3) 
0.1 Scintillation counting 0.003 
[ H]-MDL-105,519 2.53 Ethanol 0.020 Scintillation counting 0.003 
Memantine 4546.5 H2O 10 HPLC-MS 80 
MRZ 2/501 10000 20 mM NaOH 10 HPLC-MS/MS 10.1 
MRZ 2/502 10000 20 mM NaOH 10 HPLC-MS/MS 10.9 
MRZ 2/576 907.83 H2O 10 HPLC-MS/MS 10.0 
MRZ 2/596 872.27 H2O 10 HPLC-MS/MS 10.0 
The test concentration for the BBB in vitro transport studies was generally set as 10 µM 
in Krebs Ringer buffer (KR; NaCI 114 mM, KCl 5 mM, CaC12 1.25 MM, MgC)2 1.1 mM, 
NaHCO3 20 mM, Na2HPO4 1.65 mM, NaH2PO4 0.3 mM, glucose 25 mM, and HEPES 10 mM). 
The main reason for this was to ensure high enough sample concentrations for analytical 
detection, especially for those compounds, that permeate the BBB only reluctantly. For the 
radioactive labelled compounds the test concentration depended on their specific activity and 
the solvent of the stock solution. The maximal possible concentration was used ensuring a 
maximal readout without influence of the solvent on the integrity of the BBB as evaluated 
experimentally in previous experiments (data not shown, ethanol end-concentrations were not 
higher than 0.5 %). The different test concentrations of the radioligands is not problematic - at 
least in the case of passive diffusion - due to the later data analysis which generates a 
concentration-independent substance transport parameter (see below). 
3.2.2 In vitro permeability calculations 
The transport studies indicate the amount of substance (n) passing the filters during the 
various sample intervals (dt). The mean abluminal substance concentrations for each time point 
had to be summed to estimate the total amount of substance passing through the filter from the 
luminal to the abluminal side. Due to the addition of KR buffer during each sampling, the 
abluminal substance concentration was diluted in a stepwise manner. This dilution step was 
accounted for in the calculation of the amount of substance passing the filter after each time 
point. 
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The abluminal concentrations were converted into total amount of substance by 
multiplication with the abluminal solution volume. For the radioactive labelled substances, the 
detected radioactivity per sample was converted to amount of substance by multiplication with 
the specific activity of the substance. 
The resulting abluminal amount of substance was subtracted from the initial luminal 
amount at the beginning of the experiment for determination of the decreasing amount of 
substance in the luminal compartment during the experiment, assuming that there was no 
adsorption to the cell culture material and no metabolism of the substance. 
To obtain a concentration-independent substance transport parameter, the clearance 
principle was used (Siflinger-Birnboim et al., 1987) by calculation of the volume of substance 
cleared from the Iuminal side to the abluminal side for every sample interval (clearance, CL): 
CL[ml] = 
nabluminal [nmol ]_ CahluminaJ [nmol / ml] *Y ablumrnal [MI] r2] 
Cluminal [nmol /ml] ciumina, [nmol /ml] 
L 
where ngbl,,, ,,, ar is the analysed amount of substance in the abluminal compartment, c/um,,, ar 
is the initial luminal substance concentration, cabjuminal is the abluminal substance concentration, 
and Vab, um,,, Ql is the solution volume in the abluminal compartment (for details see also 
Cecchelli 
et al., 1999 and Garberg et al., 2005). During the experiment, the clearance volume increases 
linearly with time so long as no saturation of active substance transport occurs. 
These calculations were performed separately for the mean values of the control-filters 
(coated only with collagen) and the EC-filters (endothelial cells grown on a collagen coated 
filter). 
For the determination of the clearance volume of the endothelial monolayer alone, the 
clearance volumes of the control-filter had to be subtracted from the clearance volumes from the 
EC grown on the collagen coated filter: 
1_11 
CLEI CLEC-filter CLcontrol 
-filter 
The transendothelial permeability of each substance is given by the clearance rate 
(clearance/time) from the endothelial monolayer and the surface (filter) area. 
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For substances that penetrate into the brain very easily, near infinity permeability 
coefficient (Pe-coefficient) values are possible, due to the fact that the Pe-coefficient rises 
exponentially with decreasing differences in the clearance values between control filters and EC 
filters (see figure 3.1). In this case the percentage of the control value, obtained by comparing 
the slopes of the clearance curves of the EC filters and the control filters, gives a more accurate 
parameter for the compound permeability evaluation. 
Additionally, a substance balance sheet was drawn up to control for possible loss of 
substance (e. g. substance binding to the plastic material) etc., by comparing the luminal amount 
of substance at the beginning of the experiment with the total amount of substance found in the 
luminal and abluminal compartment at the end of the experiment. The latter value would be 
lower in the case of loss of substance. Results are given as mean ± standard deviation (SD). 
3.2.3 Effect of inflammatory mediators on the BBB in vitro 
To evaluate the influence of inflammatory mediators on the endothelial monolayer, the 
BBCEC (bovine brain capillary endothelial cells, alone or in co-culture with the astrocytes) 
were pre-incubated with either LPS (1,10, and 1000 ng/ml), TNF-a (1,10,100 ng/ml), IL-6, or 
IL-Iß (both 10 ng/ml), respectively, for 2,6, and 22 hours in Dulbecco's modified Eagle's 
Medium (DMEM) without supplements at 37°C in humidified 5% C02/95 % air before the 
actual experiments (transport studies and cell viability tests). The test concentrations and 
incubation times of the inflammatory agents were chosen from similar in vitro experiments 
published in the literature (e. g. de Vries et al., 1996), since it was not possible to estimate the 
effective concentration of the inflammatory agents on the BBB in vivo after i. p. application of 1 
mg/kg LPS, to simulate exactly the same conditions as in the IBS model, which was the original 
rationale for these experiments. 
Table 3.2: Preparation of pro-inflammatory mediators 
Compound Stock solution Test solution 
[µg/ml] solvent [ng/ml] solvent 
LPS (E. coli 0111: 4) 2500 H2O 1000,10,1 DMEM 
TNF-a 100 H2O 100,10,1 DMEM 
IL-lß 160 H2O 10 DMEM 
IL-6 100 H2O 10 DMEM 
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5 mg of LPS from Escherichia coli 0111: 4 was dissolved in 2 ml H2O to generate a 2.5 
mg/ml stock solution. A1 µg/ml working solution (1: 2500 dilution) was then prepared in 
DMEM which was then further diluted (1: 100 and 1: 1000) resulting in 10 ng/ml and 1 ng/ml 
LPS test solutions. 10 pg rat recombinant TNF-a was reconstituted in 100 µl H2O. A 1: 100 
diluted working solution was then used for preparation of the 100 (1: 10), 10 (1: 100) and 1 
(1: 1000) ng/ml test-solutions. The 10 ng/ml test solution of the rat recombinant IL-lß was 
prepared in exactly the same way. IL-6, also rat recombinant, was provided as a 160 µg/ml 
stock solution in 40 % acetonitrile and 0.1 % TFA containing 50 µg bovine serum albumin 
(BSA) per pg IL-6. This stock solution was further diluted in DMEM to 1 µg/ml followed by a 
1: 100 dilution to generate a 10 ng/ml working solution. 
3.2.4 Transport studies under inflammatory conditions 
Transport studies were performed after pre-incubation of the inflammatory mediator on 
co-cultured EC with sucrose (a functional marker for a tight BBB) and with MRZ 2/596, both of 
which showed similar low brain permeability under physiological conditions. Transport studies 
under `physiological' conditions were used as controls. 
To indicate compound permeability changes under the simulated inflammatory 
conditions, the compound permeability through untreated BBCEC was set as 100 percent of 
control (mean ± SD, n= 4). One-way ANOVA statistical analysis followed by a Holm-Sidak 
correction were performed to identify any concentration and time dependence of the LPS 
treatment. 
The majority of experiments were performed in the presence of LPS due to the fact that it 
was used in the inflammatory model of visceral pain. 
3.2.5 Sytol3 staining 
After incubation with the pro-inflammatory agents and performing the transport studies, 
cells were washed with KR buffer and stained with the membrane permeable stain Sytol3 (5 
µM) for 10 minutes at 37°C as a marker of cell viability. After staining, the EC were washed 
with Ca2+ and Mg2+ free Phosphate Buffered Saline (PBS-CMF) and mounted in Vectashield 
mounting medium. 
Possible changes in cell morphology were examined under a Zeiss inverted microscope 
(Axiovert 35). Pictures were taken with the imaging system Lucia G (Nikon). 
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3.2.6 Cell viability / toxicity assay parameters 
Due to the fact that it is difficult to examine the endothelial cells cultured in filter inserts 
morphologically, cell viability was assessed with additional techniques. Cytotoxicity assays 
(WST-1 from Roche assaying the mitochondrial activity and Cyto Tox 96 Non-Radioactive 
Cytotoxicity Assay from Promega, measuring lactate dehydrogenase release) were performed 
after pre-incubation with LPS, TNF-a, IL-6, or IL-1 ß), as described above, to evaluate 
quantitatively their influence on EC viability (see Chapter 2.4). The experiments were 
performed on EC/astrocyte co-cultures as well as on EC alone to investigate a possible 
protective role of the astrocytes under such conditions. 
Untreated cells were used as 100 % viability controls for the mitochondrial activity in the 
WST-1 assay. Maximal cell death and lactate dehydrogenase (LDH) release, respectively, was 
achieved by incubation with 0.1 % Triton X 100 to generate a 100 % cell death control for the 
Cyto Tox Assay Kit from Promega. All results are given as mean f SEM (n = 6) and were 
further analysed statistically for a possible time and concentration dependence of the LPS 
treatment (One Way ANOVA corrected by the Holm-Sidak method for multiple comparisons). 
3.2.7 Microdialysis in vivo 
Microdialysis studies were performed as described in Chapter 2.5 with systemically 
applied MRZ 2/596 either under normal physiological conditions or after a 10 h treatment with 
LPS (1 mg/kg, i. p. ) to mimic exactly the same inflammatory conditions as in the LPS-induced 
visceral hypersensitivity in vivo experiments. Previous microdialysis experiments with non- 
brain-permeable compounds ensured that the dialysis probe does not contribute to an 
inflammatory process resulting in BBB damage. 
After dissolving freshly in saline, MRZ 2/596 was given at a very high dose of 30 mg/kg 
(i. p. ) to allow a comparison with former studies investigating the brain permeable MRZ 2/576 
(Hesselink et al., 1999b). Data are shown as mean ± SEM and were statistically analysed using 
a Two Way ANOVA for the different treatments and sample intervals. 
3.3 Results 
3.3.1 BBB permeability of NMDA receptor antagonists in vitro under physiological 
conditions 
The penetration rate in vitro of the glycineB site NMDA receptor antagonists 5,7-DCKA 
and MDL-105,519 was very low (Pe-coefficients of 0.56 ± 0.02 x 10" cm/s and 0.20 ± 0.01 x 
10's cm/s) comparable to the functional BBB integrity marker sucrose (0.54 ± 0.02 x 10"5 cm/s). 
The tested NMDA receptor channel blockers memantine, neramexane, and (+)-MK-801 showed 
very good penetration through the in vitro BBB reflected by Pe-coefficients of 57.15 1 9.88, 
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51.14 t 7.09, and 50.93 ± 4.94 x 10-5 cm/s, respectively. The competitive NMDA receptor 
antagonist CGS 19755 showed an intermediate BBB permeability of 5.52 ± 0.43 x 10"s cm/s. 
The glycineB antagonists from Merz Pharmaceuticals showed different BBB penetration 
rates, despite having similar core structures. Only quinolines with a NO-substitution in the 
tricyclic ring such as MRZ 2/502 (free base, Pe-coefficient: 63.02 ± 7.09 x 10'5 cm/s) and MRZ 
2/576 (choline salt, Pe-coefficient: 32.77 ± 6.34 x 10'5 cm/s) could pass the blood-brain barrier, 
in contrast to compounds without a NO-substitution like MRZ 2/501 (free base, Pe-coefficient: 
1.50 ± 0.12 x 10'5 cm/s) and MRZ 2/596 (choline salt, Pe-coefficient: 1.02 ± 0.06 x 10'5 cm/s) 
showing Pe-coefficients in the range of sucrose. As expected, the salt status (free base vs. 
choline salt) had no influence on the Pe-coefficient, reflected by similar in vitro brain 
permeabilities of the free bases and choline salts of the tested quinolines (figure 3.2). 
Due to the fact that the Pe-coefficients rise exponentially with decreasing differences in 
the clearance values between control-filters and EC-filters for highly permeant compounds, Pe- 
coefficients are difficult to interpret for highly BBB permeable compounds. For this reason, the 
percentage of control value, obtained by comparing the slopes of the clearance curves of the EC 
filters and the control filters, was also analysed to generate a more accurate parameter for the 
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Fig. 3.1: Clearance diagram examples of blood-brain barrier (BBB) in vitro transport studies 
performed with sucrose (A) and memantine (B). Sucrose, used as functional marker for a 
tight BBB in vitro, showed a very low permeability through the endothelial monolayer, 
represented by a big differences of the clearance slopes. In contrast, memantine is highly 
permeable, as indicated by the nearly similar clearance through the endothelial cell filters 
(EC-filters) vs. the control-filters (collagen coated without endothelial cells). 
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Indeed, the importance of the percentage of control value was particularly apparent when 
comparing the Pe-coefficients of MRZ 2/502 and MRZ 2/576. Here, the Pe-coefficient 
suggested a 2-fold better BBB permeability of MRZ 2/502 but the percentage of control values 
clearly show that the difference in ability to pass through the endothelial monolayer is almost 
negligible (80.58 ± 2.35 % and 69.31 ± 6.73 %, respectively, figure 3.2). This fact becomes 
clear by performing Pearson correlations of the two different transport parameters, first for the 
whole data set and then only for the five compounds with the high transport rates, showing a 
very good correlation (correlation coefficient = 0.98, p<0.001) for the whole set of test 
compounds, whereas there was a much weaker relationship for the latter data set (correlation 
coefficient = 0.86, p=0.06). 




















Fig. 3.2: In vitro blood-brain barrier (BBB) penetration of NMDA receptor channel blockers, 
competitive and glycineB site antagonists in comparison to sucrose, a functional marker for a 
tight BBB, using bovine brain capillary endothelial cells (BBCEC) after co-cultivation with 
rat cortical astrocytes. Results are given as permeability coefficients (Pe-coefficient, black 
bars) and percentage of control values (white bars), comparing the slopes of the clearance 
curves of the endothelial cell filters (EC-filters) with those of the control-filters without cells 
(mean ± SD, n= 4). 
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3.3.2 Effect of pro-inflammatory mediators on the integrity of the BBB in vitro 
Sucrose permeability, starting from a basal value of 0.74 x 10-5 cm/s, was only 
significantly increased (p < 0.001) after longer incubation times (22 h) and higher 
concentrations (1 pg/ml) of LPS. After 22 hours of incubation there was an 8-fold and 20-fold 
boost of sucrose permeability with 10 ng/ml and I pg/ml LPS, respectively. Nevertheless, 
concentrations of 1 and 10 ng/ml already led to an approximately 2-fold increase of sucrose 
after the first 6 hours of LPS incubation, compared to a 5-fold increase when treated with 1.0 
pg/ml LPS (figure 3.3 A). The Sytol3 staining of the EC on the filter inserts revealed that this 
permeability increase was associated with a change in morphology from the spindle shaped 
form (figure 3.3 B) to a more "chubby" cell morphology (figure 3.3 C), probably due to 
decomposition of the tight junctions. Similar results were obtained with MRZ 2/576, leading to 
a doubling of its Pe-coefficient after 6 hours of 10 ng/ml LPS in comparison to the control Pe- 
coefficient (1.52 x 10-5 cm/s, data not shown). 
Effect of LPS on bovine brain capillary endothelial cells 
A) 
2400 
















"\ " . 
fir ý 




Fig. 3.3: A) Influence of various lipopolysaccharide (LPS) concentrations and incubation times (white 
bar 2h, hatched bar 6h, and black bar 22h) on the sucrose permeability through bovine brain 
capillary endothelial cells (BBCEC) as an indicator for the BBB integrity in vitro (n = 4). 
Permeability of sucrose through untreated endothelial cells is defined as 100 % control. 
Syto13 staining (B, C; scale bar: 25 µm) and phase contrast (D, E; scale bar: 50 µm) 
micrographs of BBCEC after various incubation times (C: 6 h, E: 22 h) of I µg/ml LPS in 
comparison to untreated controls (B, D). 
58 
01 10 1000 
LPS concentration [ng/mI] 
In summary, it could be shown that brain permeability of normally non-permeable 
compounds is increased in vitro after incubation with LPS, but it still had to be clarified whether 
this was due to cytotoxic effects or by more subtle modulation of barrier properties (for example 
by down regulation of tight junctions). With the help of the live/dead assay systems, the 
viability status of the cells could be evaluated. The boost of sucrose permeability after longer 
incubation times and higher concentrations of LPS was reflected in an increased number of dead 
cells. Morphological examination of an EC monoculture treated with 1 gg/ml LPS showed that 
all cells were "rounded off' and, to some extent, detached from the surface after a 22 h 
incubation time, suggesting complete cell death/pathology (figure 3.3 E). However, 
measurements of LDH release indicate that, despite the fact that the all cells lost their 
characteristic morphology, only half of the cells were lysed after 22h of 1 µg/ml LPS in 
comparison to the Triton X 100 treated control EC (100% cell death, figure 3.4 A). In general 
the LDH measurements showed a clear concentration dependent effect of LPS starting after 6h 
of incubation (p < 0.01) as well as a clear time dependency at concentration of at least 10 ng/ml 
(p < 0.05). 
A parallel test of cell viability was undertaken by investigating mitochondrial activity. In 
this case cell viability dropped dramatically after 22h of high concentrations of LPS in 
comparison to untreated control EC (100 % viability, figure 3.3 B). But even more interesting, 
the lower LPS concentrations (1.0 and 10 ng/ml) had a biphasic effect on mitochondrial activity. 
After 2 hours of incubation there was a 50 percent increase of activity (in contrast to LDH 
measurement, where after a2h challenge of LPS no effect on the EC was observed) which then 
decreased to control levels after 6 hours and finally (22 hours) ended in a cytotoxic effect for all 
LPS-test concentrations. This was verified statistically by a clear time dependent effect of LPS 
for all test concentrations (p < 0.001, n= 6). 
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Fig. 3.4: Influence of various lipopolysaccharide (LPS) concentrations and incubation times (white bar 
2 h, hatched bar 6 h, and black bar 22 h) on endothelial cell (EC) viability as measured by 
lactate dehydrogenase (LDH) release (A) as an indicator for cell lysis/cell death (Cyto Tox 96 
Non-Radioactive Cytotoxicity Assay) and mitochondrial activity (B) using the WST-1 test (n 
=6 for both tests). Treatment with Triton X 100 (0.1 %) resulted in maximal cell death and 
was therefore defined as 100 % control cell death, whereas in the WST-1 test untreated 
endothelial cells were defined as 100 % control viability. 
Beside the direct assessment of the endotoxin effect on BBB integrity, the role of pro- 
inflammatory cytokines (TNF-a, IL-6, and EL-1p), which are further down the inflammatory 
cascade, was also investigated. TNF-a (tested at concentrations of 1.0 and 10.0 ng/ml) as well 
as IL-6 and EL-lß (both 10.0 ng/ml) did not change functional BBB characteristics as shown by 
unaltered sucrose permeability after the same incubation times used for LPS intoxication. This 
is in line with the cell death assay showing no LDH release even at TNF-a concentrations of 
100 ng/ml. But, similar to LPS, a biphasic effect of TNF-a was observed resulting in a 
approximately 20 % increase of mitochondrial activity after 6 hours at concentrations of 1.0 and 
10.0 ng/ml and a 10 % decrease after 22h for 10 ng/ml TNF-a. However, the tested interleukins 
did not show any effect on cell viability/cell death at 10 ng/ml (data not shown). 
3.3.3 In vivo brain penetration of MRZ 2/596 under physiological and inflammatory 
conditions 
Microdialysis studies in awake rats confirmed the very low BBB permeability of MRZ 
2/596 that had been determined in vitro. After systemic administration of a very high dose of 
MRZ 2/596 (30 mg/kg) the calculated mean concentration in the extracellular fluid (ECF) was 
110 f 53 (SEM) nM over the tested time period of 120 minutes, with a maximum of 183 ± 93 
nM measured after 40 minutes (n = 3). Even under the same inflammatory conditions as used in 
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the IBS model (10 hours of I mg/kg LPS, i. p. ) similar (not statistically significant, p=0.84) low 
brain concentrations were obtained as under more "physiological" conditions. The results 
showed a mean concentration of MRZ 2/596 in the ECF of 98.4 ± 37.1 nM over 120 minutes, 
with a sample peak of 233 ± 73 nM, after 40 minutes. All test samples were clearly above the 
HPLC-MS/MS detection limit (10.0 nM, see table 3.1). Both treatments showed a significant 
time dependence over the sample intervals (p < 0.001), but an interaction between saline and 
LPS treatments and time could not be detected (p = 0.70). 
MRZ 2/576, a compound structurally very similar to MRZ 2/596, but which permeates 
the BBB with somewhat better efficacy, was determined in an earlier experiment to be present 
at an almost ten fold higher peak concentration of 1339 ± 408 nM in brain ECF 20 minutes after 
application of the same dose used here (i. e. 30 mg/kg; Hesselink et al., 1999b). Under the 
inflammatory conditions used in the present study this poorer penetration of MRZ 2/596 was 
unchanged, indicating that the use of LPS had no negative functional consequenses on BBB 
permeability (figure 3.5). All the data were corrected for in vitro recovery. 
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Fig. 3.5: Brain microdialysis studies of glycineB site NMDA receptor antagonist MRZ 2/596 (30 
mg/kg, i. p. ) under physiological (open triangles) and inflammatory (1 mg/kg LPS, i. p., 10 h 
before compound application) conditions (filled triangles) in comparison to MRZ 2/576 
(already published by Hesselink et al., 1999b, reproduced in left panel), mean ± SEM. Note 




The results from the in vitro blood-brain barrier transport studies evaluating the brain 
permeability of various glycineB NMDA receptor antagonists detailed here correlate very well 
with in vivo results known from the literature. The effects of NMDAR antagonists on MES 
induced convulsions were always in the same rank order of potency as BBB permeation. For 
example, the poorly permeant glycineB antagonists MDL-105,519,5,7-DCKA, and MRZ 2/596 
were also ineffective in MES tests in vivo. On the other hand, MRZ 2/502, its choline salt MRZ 
2/576, (+)MK-801, and memantine showed good anticonvulsive potency at plasma 
concentrations close to their known potency for NMDA receptors (Parsons et al., 1997; Danysz 
et al., 2005) and were all highly permeant in the in vitro BBB model used (Danysz et al., 2005; 
Sladek et al., 2007). These data were further confirmed by brain microdialysis experiments for 
the brain permeable compounds (Hesselink et al., 1999a and 1999b; Parsons et al., 2000). With 
respect to the correct classification of the tested compounds in the BBB in vitro model (as very 
low, medium and high brain permeable) we feel that this model is indeed highly suited for 
compound screening at early stages of drug development (for further characterization of the 
BBB model see Sladek et al., 2007). 
Aside from these experiments under "physiological" conditions, our unpublished results 
indicated that such techniques can also be used to address mechanisms of actions of 
inflammatory mediators on ECs, even though quite heterogeneous data have been reported in 
the literature. Depending on which in vitro model was used, a different sensitivity to the 
inflammatory challenge was apparent which could challenge the interpretation of this literature. 
For example, 24 h of 100 µg/ml LPS had no effect on the barrier integrity of mouse brain 
EC tested by BSA transport (Verma et al., 2006). But in agreement with the present 
experiments are data from Descamps et al. (2003), who investigated the effect of LPS on BBB 
injury using a very similar BBCEC/astrocyte co-culture in vitro model. The experiments 
focused on the protective effect of glial cells against LPS mediated disruption of the barrier 
characteristics. A luminal application of 10 ng/ml LPS for 14 h on the EC co-cultivated with a 
pure astrocyte culture (as in our model) revealed an increase of sucrose permeability 
comparable to the present results. In contrast to this, the presence of a mixed culture of 
astrocytes, oligodendrocytes, and microglia in the well nearly abolished the increase of the 
sucrose permeability, but when the EC where challenged alone a much higher breakdown of the 
barrier was observed. 
These transport studies showed clearly that the protective effect and also the time course 
of inflammatory changes depends on the cultivation status of the EC and the glial micro- 
environment respectively. As a consequence, the presence of the pure astrocyte culture during 
the LPS challenge was probably the reason for the only two fold, non significant, increase in 
permeability at lower concentrations (1 and 10 ng/ml) of LPS, enabling to some extent a 
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protective effect. Had the EC been challenged in the absence of any co-cultured cells, there 
would probably have been more disruption of permeability. On the other hand, the additional 
presence of oligodendrocytes and microglia together with astrocytes might have offered 
complete protection. 
Increased permeability was not only accompanied with a presumed decline of the tight 
junctions but also with robust cell death, at least at higher LPS concentrations. This was not 
only determined morphologically but was also evident from the experiments measuring LDH 
release into the medium. Such cell degradation was reported by Patrick et al. (1992), where 
whole bacteria and purified LPS (greater than 10 ng/ml) caused a clear cytotoxicity in a similar 
in vitro BBB model. This contrast to results from Tunket et al. (1991) who used rat 
microvascular endothelial cells and claimed statistically significant increases of albumin 
permeability after 0.1 and 1.0 pg/ml LPS, without any evidence of cell death (also measured by 
LDH release). 
Huber et al., (2001 and 2002) reported a clear correlation between functional and 
molecular BBB properties and peripheral inflammatory pain models (acute: formalin, short 
term: X-carrageenan, and long term: complete Freund's adjuvant, see also Rabchevsky et al., 
1999). Peripheral inflammation significantly increased the uptake of sucrose into the cerebral 
hemispheres in a biphasic manner, with correlated alterations in tight junction protein 
expressions. In general, occludin expression significantly decreased with increased BBB 
permeability, whereas zonula occludens-1 significantly increased, and claudin-1 protein 
expression remained unchanged during inflammation. Additionally, an increase of the adhesion 
molecule ICAM-1 (intercellular adhesion molecule 1) was shown in the same in vivo model 
(Huber et al., 2006) illustrating the progress of inflammation. The observed higher 
mitochondrial activity during the first hours after LPS application in our model could therefore 
be explained by the energy demand triggered in the early phase of the inflammatory process 
representing alterations of the expression levels of e. g. tight junction-associated proteins as well 
as adhesion molecules. 
Beside the modulatory/disruptive effect of LPS on the BBB in vitro, the inflammatory 
cytokines, which are induced by the pro-inflammatory mediators, were also tested. 
For TNF-a the present results investigating changes in BBB integrity, are perfectly in line 
with results published by Deli et al. (1995) and Miller et al. (2005) using a similar in vitro 
model of the BBB. In the latter, a4h treatment with 12 ng/ml of TNF-a had no effect on the 
paracellular transport of sucrose; additionally occludin expression was unchanged after this 
TNF-a challenge. The unchanged characteristics of the BBB in vitro after the TNF-cc treatment 
was possibly due to the low concentrations tested. In the very recently published paper by 
Silwedel & Forster (2006) it was shown that 10 nM (= 173 ng/ml) TNF-a led to a decrease of 
transendothelial resistance in cerebral and cerebellar EC associated with a decrease of tight 
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junction associated proteins (occludin and claudinsl-3) and an increase of adhesion molecules 
(VCAM-1, vascular cell adhesion molecule 1 and ICAM-1). These in vitro results, with TNF-a 
regulating the protein levels of tight junction-associated proteins as well as adhesion molecules, 
fit very nicely to the in vivo experiments of Huber et al. (2002). 
De Vries et al. (1996) investigated the influence of cytokines on the BBB in vitro and 
could show a decrease of transendothelial electrical resistance (TEER) in rat cerebral 
endothelial cells after TNF-a, IL-1ß, and IL-6 application. However clear effects were only 
seen at higher concentrations of IL-1 13 and IL-6 (100 ng/ml). Effects of 5 ng/ml IL-1 ß and 10 
ng/ml IL-6 were much less pronounced. Bolton et al. (1998) reported disruption of the BBB 
combined with a loss of occludin and ZO-1 immunoreactivity in the EC after intra-cerebral 
injection of IL-1ß, supporting the in vitro results published by de Vries (1996). The fact that 
they used a different BBB in vitro model might explain why these cytokines did not show any 
effect in the present experiments. 
Without knowledge of the microdialysis data, our attempts to simulate the in vivo 
inflammatory challenge, together with the available literature, would possibly have led to the 
false assumption that the inflammatory conditions in the IBS model damage the BBB and, as a 
consequence of this that the positive effect of MRZ 2/596 was only due its access to the CNS 
enabled by BBB disruption. One of the major drawbacks of the described in vitro studies for 
addressing this particular aspect - as already mentioned in the introduction - is the fact that the 
exact downstream signalling of the inflammatory pathway in vivo is unknown with respect to 
the time frame as well as the specific concentrations of inflammatory mediators acting on the 
endothelial cells especially after the relevant LPS (1 mg/kg i. p. ) challenge. This problem was 
identified by Reyes et al. (1999). At the beginning of the PhD project the in vitro system was 
the only possibility for addressing the issue of possible BBB disruption under LPS 
inflammation. 
With the option to investigate the status of the BBB in the LPS-induced delayed rectal 
hypersensitivity model by means of microdialysis experiments, in vitro inflammatory 
experiments were not of further interest. 
The microdialysis results clearly show an unaltered brain permeability of MRZ 2/596 10 
hours after 1 mg/kg LPS (i. p. ) treatment (see figure 3.5, noting the different scales in the two 
panels) and therefore the presence of an intact BBB could be assumed under these conditions. 
But when using other application routes for LPS the effect on the BBB and the corresponding 
time course might be different; for example Jaworowicz et al. (1998) showed clearly increased 
brain sucrose levels after intracisternally administered LPS at the same dose. 
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3.5 Conclusion 
The results described in this chapter clearly imply (mainly through the microdialysis 
experiments in vivo) that peripheral (as opposed to central) NMDA receptors are important in 
mediating visceral pain transmission; this conclusion follows from the anti-nociceptive effect in 
models of visceral pain by glycineB antagonists that are non-brain permeable even under 
conditions of LPS-induced inflammation. The postulate of a peripheral NMDAR-mediated 
mechanism was further supported by Christoph et al. (2005) demonstrating an antinociceptive 
effect of the peripherally restricted glycineB antagonist 5,7-DCKA in two different models of 
neuropathic pain (chronic constriction injury and spinal nerve ligation). 
Peripheral NMDA receptors therefore offer a very attractive target for NMDA receptor 
antagonists that do not cross the BBB for the treatment of various pain indications. Such agents 
might be predicted to be devoid of CNS side effects at doses producing powerful 
antinociception on peripheral NMDA receptors (Parsons, 2001; Christoph et al., 2005). 
Additionally the different potencies of the NMDA antagonists in the in vivo models 
targeting the CNS vs. the peripheral NMDA receptors led to the suggestion that the latter have a 
different receptor profile (and therefore functional pharmacology) compared to those NMDA 
receptors expressed in the CNS. 
For the development of specific antagonists for peripheral NMDA receptors it was 
therefore necessary to investigate possible differences at the molecular level that might explain 




4 DETECTION OF VARIOUS NR1 SPLICE VARIANTS AND 
NMDA RECEPTOR SUBUNITS IN DRG NEURONS 
4.1 Introduction 
The previous chapter indicated the involvement of peripheral NMDA receptors (NMDAR) in 
visceral nociceptive pathways, since NMDA receptor antagonists that were active in models of 
visceral pain (see Appendix I) showed restricted brain permeability - even under inflammatory 
conditions. Additionally, these peripheral NMDA receptors were suggested to have different 
physiological and pharmacological properties in comparison to central NMDARs, as glycineB 
site antagonists showed a higher potency in the visceral pain models vs. maximal electroshock 
(MES) studies (directed to the CNS). This variation might be explained by diversity of NMDA 
receptor subtype expression between visceral and CNS tissues. 
Receptor pharmacology is dependent upon the receptor subunit composition, as reviewed 
e. g. by Quartaroli et al. (1999). For example, the inclusion of different combinations of NR2 
subunit subtypes in the NMDA receptor complex is one reason for diversity in functional 
properties/pharmacology. This was addressed by Monyer et al. (1992), who showed that glycine 
sensitivity and receptor activation/deactivation kinetics depend on the type of NR2 subunit 
combined with NR1. These findings are in line with results from Kutsuwada et al. (1992) who 
determined differing glycine and glutamate potencies in recombinant NMDA receptor subtypes 
expressed in Xenopus oocytes. Agonist and co-agonist were both weaker in NR1/NR2A vs. 
NR1/NR2C, and as a consequence, the antagonist ICso-values were correspondingly more potent 
at NR1/NR2A in the presence of similar levels of agonist (Ishii et al., 1993). This is paralleled 
by the findings of Priestley et al. (1995) where the glycine affinity was 10-fold weaker in 
human NRloll/NR2A vs. NR1o11/NR2B receptors in stably transfected cell lines. Despite some 
heterogeneity in the published results, electrophysiological studies revealed, in general, a 
progressive decrease in glycine affinity from NRloi1/2D > NR1011/2C > NRloll/2B > NR1o21/2A 
(Danysz & Parsons, 1998). Here and in the future NR1 splice variants are specified according to 
the terminology of Zukin & Bennett (1995). 
Differences in the co-agonist binding affinity for NR1 splice variants has also been 
postulated but, aside from binding results with transiently transfected homomers showing a two- 
fold difference in the inhibitory constant (K; ) of a glycine site antagonist between NRI011 and 
NRlooo (Grimwood et al., 1995), there appear to be no further reports in the literature. This is 
somewhat surprising as this subunit contains the glycine binding site, and different splice 
variants of NR1 are known to influence other properties of NMDA receptor subunit assemblies 
such as affinity for agonists at the NR2 subunit and differential potentiation by polyamines 
(Durand et al., 1993; Dingledine et al., 1999) - this latter effect being mainly due to the 
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presence or absence of the N-terminal cassette. The effects of protein kinase C (PKC) on the 
NMDA receptor also differ with the NR1 splice variant and NR2 subunit composition (Durand 
et al., 1993; Grant et al., 1998; Logan et al., 1999; Dingledine et al., 1999). More recent 
findings by Bradley et al. (2006) indicated that NR1 splice variants also affect downstream 
signalling pathways differentially (e. g. NMDAR-induced cyclic adenosine monophosphate, 
cAMP, response element-dependent gene expression). 
Another source of potential differences in receptor properties might be post-translational 
modifications such as serine/threonine/tyrosine phosphorylation or glycosylation. For example, 
Kawamoto et al. (1995) hypothesised (with the help of binding assays in combination with 
Western blot analysis) that glycosylation is necessary for the binding of the glycineB site 
antagonist 5,7-dichlorokyurenic acid (5,7-DCKA). In conjunction with other publications, 
Dingledine et al. (1999) suggested that glycosylation may not necessarily be crucial for the 
subunit clustering but instead for receptor function. 
With respect to this project, phosphorylation of the NMDAR subunits might seem to be 
of particular relevance. Zhou et al. (2006a) reported induction of serine phosphorylation of the 
NR1 subunit in the enteric nervous system (ENS) after 2,4,6-trinitrobenzenesulfonic acid 
(TNBS)-induced colitis, which leads to activation of the receptor by promoting plasma 
membrane delivery of the NMDA subunits from the endoplasmic reticulum to the plasma 
membrane (e. g. Carroll & Zukin, 2002). This agrees with the findings of Zou et al. (2000) and 
Caudle et al. (2005) who reported NR1 phosphorylation in the spinal cord following peripheral 
inflammation. But most importantly for this project, the same is also true for NMDA receptors 
located in dorsal root ganglia (DRG). Recent findings by Li et al. (2006) demonstrated 
hypersensitivity/upregulation/phosphorylation of NMDA receptors in DRG neurons as a 
consequence of TNBS-induced colitis, but here, phosphorylation of NR2B was held responsible 
for the activation. All of these findings suggest that NMDA receptor subunit phosphorylation is 
an important factor associated with inflammatory nociceptive conditions. 
Further knowledge concerning the subunit composition of NMDA receptors, as well as 
their glycosylation and phosphorylation state, in the tissue of interest, would therefore be very 
helpful to understand the observed differences in peripheral vs. central NMDA receptor 
pharmacology. This aspect is very important for possible ensuing drug development to 
specifically target only those NMDA receptor subtypes/phosphorylation/glycosylation states 
responsible and relevant for the pathology, in order to allow for better separation between 
therapeutic and side effects. 
This PhD project is focused on the extrinsic first order neurons localized in the DRGs 
(visceral primary afferent neurons projecting to the spinal cord) that function as nociceptors. 
NMDA receptors expressed in vagal primary afferents (Czaja et al., 2006a) or in intrinsic 
neurons of the ENS (in the myenteric or submucosal plexus, Burns et al., 1994) were not the 
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focus of the present work, despite their obvious physiological and pharmacological importance 
(Hornby, 2001; Kirchgessner et al., 1997 and Kirchgessner, 2001, respectively). An 
involvement of enteric neurons in the nociceptive pathway has also been discussed (e. g. 
Patierno et al., 2005). 
The decision to focus this thesis on DRGs rather than the ENS or vagal afferents was 
based on the hypothesis that the antinociceptive effects of NMDAR antagonists observed in 
models of visceral pain was due to their action on spinal visceral afferents. This is supported by 
the fact that these compounds also attenuated cardiovascular nocifensive responses to distension 
of the non-inflamed rat ureter (Olivar & Laird, 1999), an organ that is supposed to lack both 
intrinsic neurons and vagal innervation (McRoberts et al., 2001). Therefore, assuming a 
peripheral site of action, only spinal visceral primary afferents could be involved. 
The differences in the expression pattern of NMDA receptor subunits throughout the 
CNS, and the possible consequences thereof for NMDA receptor pharmacology, was discussed 
at length in the early nineties (reviewed e. g. by Dingledine et al., 1999 and, with more focus on 
the glycine binding site, by Danysz & Parsons, 1998), but less was known about NMDA 
receptor expression in the PNS, especially regarding DRGs. The first studies focusing on the 
periphery started almost 10 years later (e. g. performed by Marvizon et al., 2002, concentrating 
on the different expression of NR2 subunits), although the general presence of NMDA receptors 
in primary afferent neurons was shown earlier; in DRG cell bodies (Sato et al., 1993), in central 
terminals (Liu et al., 1994; Bardoni et al., 2004), later also in somatic peripheral terminals 
(Carlton et al., 1998; Coggeshall & Carlton, 1998) and most recently at visceral peripheral 
terminals (McRoberts et al., 2001). 
Despite the large amount of evidence supporting NMDA receptor expression in DRGs, a 
quantitative differentiation between the expression levels of NMDA receptor subunits in the 
CNS vs. the peripheral nervous system (PNS, e. g. DRGs) does not seem to be available in the 
literature. 
A possible difference in NRI splice variants has not yet been reported and was therefore 
chosen as the starting point for NMDA receptor characterization in DRG neurons. This was 
undertaken at the messenger ribonucleic acid (mRNA) level, with the help of reverse 
transcriptase - polymerase chain reaction (RT-PCR), by designing splice variant specific 
primers. Because the detection of mRNA is no proof for the presence of the receptor protein, 
immunofluorescence staining and Western blots were also used in DRG cryosections and DRG 
cultures to allow comparison of the in vivo and in vitro situation, especially with respect to 
subsequent electrophysiological studies in cultured DRGs. 
For the characterization of NMDA receptor expression in DRG, it was furthermore 
deemed to be important to differentiate between somatic neurons and those that are connected to 
the viscera, due to the fact that only about 10 - 15 % of DRG neurons are of visceral origin 
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(Perry & Lawson, 1998; Holzer, 2001). Additionally, the role of NMDA receptors in somatic 
and visceral nociception seem to differ - at least under physiological conditions (Cervero & 
Laird, 1999; McRoberts et at, 2001) which might also be explained by a different receptor 
composition. 
For the identification of DRG neurons that are connected to the viscera (via the 
splanchnic and pelvic nerve) retrograde staining experiments applying fluorescent tracers in 
different regions of the small intestine were therefore performed. 
Further classification of the DRG neurons (e. g. Lawson et al., 1993; Perry & Lawson, 
1998; see also Chapter 1.3.2 for further details), in particular regarding the presence of 
nociceptive markers and possible co-localization with NMDA receptors, was not considered 
necessary at this stage of the project as it has already been published elsewhere (e. g. 
Plenderleith & Snow, 1993; Ma & Hargreaves, 2000; Marvizon et al., 2002). 
4.2 Experimental Protocols 
4.2.1 RT-PCR 
For identification of the different NR1 splice variants (accession codes: U08261, U08263, 
U08262, U08264, U08265, U08266 U08267, and U08268) in rat tissue, specific primers were 
designed that target the three alternatively spliced exon cassettes (NI, Cl, and C2). The 
annealing position of the sense/antisense primers was selected to be before, in, or even between 
the relevant cassettes (figure 4.1). By different combinations of these primers it was then 
possible to investigate the presence/absence of the various exons in the target sample. To ensure 
relatively small PCR products, however, the N-terminal and the C-terminal cassettes were only 
investigated separately, therefore the exact identification of all eight splice variants was not 
possible. A similar but more basic approach was published by Liesi et al. (1999) and more 
recently by Zhou et al., (2006b) and Li et al. (2006). 
Total RNA isolation and RT-PCR were performed as described in Chapter 2.10. Various 
tissue/culture samples were chosen for different reasons. Whole DRGs and cultured DRG 
neurons (both pooled from the spinal regions T9-S1) were the key samples of interest. The 
transfer RNA (tRNA) samples isolated from the whole brain and specific brain regions (cortex, 
cerebellum and midbrain), respectively were chosen as positive controls due to the fact that 
heterogeneous and developmentally-dependent levels of splice variant expression have been 
reported throughout the CNS (e. g. Laurie & Seeburg, 1994). Tissue from small intestine 
(duodenum, jejunum and ileum) was of interest with respect to the visceral terminals of the 
DRG neurons (McRoberts et al., 2001) as was the presence of NR1 mRNA in the enteric 
neurons (Burns et al., 1994), although the latter were not the focus of this investigation. As an 
additional control of the RT-PCR protocol and the specificity of the primers targeting the Ni 
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cassette, cloned rat NRloll copy deoxyribonucleic acid (cDNA) and capped RNA were also 
tested. Copy DNA is used for transfections, whereas capped mRNA is usually used for in vitro 
transcription e. g. for protein expression in Xenopus oocytes. The 5' cap is vital for the 
translation and also prevents degradation by exonucleases. Further use of such controls for the 
assessment of the C-terminal exons was not considered necessary, amongst other things the 
antisense primer 3-NR1-II binds outside the coding sequence and therefore would not detect the 
cloned DNA/RNA. 
Although more splice variant specific primers were designed (with the help of Sigma 
Genosys online DNA calculator, https: //www. sigma-genosys. com/calc/DNACalc. asp), only 
those primers that displayed similar melting temperatures (see table 4.1) and presented no risk 
of cross-dimerisation (also checked with the online DNA calculator) were combined for the RT- 
PCR experiments. 
The kainate receptor is also known to be present in these tissues, so RT-PCR experiments 
targeting the G1uR5 and G1uR6 subunits of the kainate receptor were also performed as positive 
controls to ensure that the tRNA isolation from the DRGs was successful. 
Table 4.1: List of sense (A) and antisense (B) primers for the identification of various NR1 splice 
variants and kainate receptor subunits (G1uR5 and G1uR6), including the primer 
combinations used (C). 
A) Sense primers 
Primer name Description of 
recognition site 




5-NR I -I shortly before N1 GCG AGT CTA CAA CTG GAA CCA 52.4 64 
5-NR1-N 1 in NI CCT CGA CCA ACT GTC CTA TGA C 54.5 68 
5-NR1-II before Cl GAC AGC CCC TGG AAG CAG AA 60.0 64 
5-NRI -C 1 C2' in C1 and C2' CAA AGA CAC GCA GTA CCA TCC 52.4 64 
5-G1uR5 AAC CGA AAC CGA ACC TTG ATG C 50.0 66 
5-G1uR6 CCA GCC AGT GGC CTG AAT ATG A 54.5 68 
B) Antisense primers 
Primer name Description of 
recognition site 




3-NR1-I after Ni GAC GTA CAC GAA GGG CTC TTG 57.1 66 
3-NR1-C 1 C2 in Cl and C2 CGG TGC TCG TGT CTT TGG AG 60.0 64 
3-NR1-C2 in C2 GGC AGC ACT GTG TCT TTT TGG 52.4 64 
3-NR1-II after C2/C2' CCT GGG AAA GGT CAG AGA CAA 52.4 64 
3-G1uR5 CCC ATT CCA TTC CCC TTT GTC A 50.0 66 
3-G1uR6 TGG AGA GTG CTT TGG GCA TGA G 54.5 68 
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C) Primer combinations and resulting PCR products 
Sense primer Antisense 
Expected PCR product Annealing 











5-NR1-N1 3-NR1-I 711 NR1, x; --- --- 62.5 
5-NR1-I 3-NR1-I 779 NRIo ; 842 NRl, xx 60.5 
5-NRI-II 3-NRl-CIC2 420 NR1x,, --- --- 60.0 
5-NR1-CIC2' 3-NRI-II 592 NR1x, o --- --- 59.5 











5-G1uR5 3-G1uR5 1370 GluR5 --- --- 63.0 
5-GluR6 3-GluR6 632 G1uR6 --- --- 65.0 
Splice variants are termed according to Zukin & Bennett (1995). The presence of the exon cassettes 
(NI, Cl, and C2) is represented by '1' and the absence by `0'. `X' is used when an exact statement 
regarding the presence or absence of the exon cassette is not possible. 
Primer recognition site at various NR1 splice variants 
Sense Primers 
C1 
I N1 IIU C2' 






Cassettes: Ni C1 C2 C2' 
Fig. 4.1: Illustration of the various primer recognition sites on the eight different NRI splice variants. 
Sense primers (5-NRI-) are given in grey, antisense primers (3-NRI-) are in blue. 
Unfortunately, co-amplification of internal controls using transcripts of housekeeping 
genes like GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was not performed at this 
early stage of the project because the general presence of the NMDA receptor mRNAs was 
deemed to be the primary interest and not their relative abundance, even though this approach 
would also have attested the quality and concentration of the RNA samples (in addition to the 
photometric analysis). 
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Specific bands were identified according to their relative position in the agarose gel in 
comparison to the bands of the DNA ladder. The exact base pair length of the bands was 
calculated with the help of the Phoretix 1D Gel Analysis v5.10 (nonlinear dynamics) software. 
The band intensity was also measured (volume under the curve) but only used for qualitative 
analysis since it is not possible to deduce a different mRNA abundance from the band thickness 
because short PCR products are amplified much faster than longer ones, resulting in more PCR 
product. 
4.2.2 Western Blotting 
Immunoblots were performed as described in Chapter 2.11 in order to evaluate the 
protein expression in DRGs of different spinal cord regions (T9-T12, L4-L5, and L6-S1, 
representing inputs of the splanchnic, sciatic, and pelvic nerves, respectively) in comparison to 
CNS tissue (cortex and cerebellum). All protein samples were isolated from 5 week old rats. 
The primary and secondary antibodies used in the Western blotting experiments are 
summarized in table 4.2. 
No control peptides were available for the listed antibodies (table 4.2) at the time of the 
experiments but the specificity of the NMDA antibodies used was shown by Prybylowski & 
Wolfe (2000); Al-Hallaq et al. (2001) and Heidinger et al. (2002), e. g. by distinct bands in 
transfected HEK293 cells (not by control peptides). Secondary antibody controls were 
performed for all secondary antibodies and tested protein samples to ensure that the presented 
bands in the experiments are due to first antibody binding. 
Band densities of the various samples were measured on the developed films from their pixel 
intensity (volume under the curve) with the help of Phoretix ID Advanced 5.1 Software. Exact 
quantitative analysis was however not possible due to a non-linear relation of the band density 
and the amount of protein in the case of intense bands/high protein levels. This fact was 
evaluated by a dilution series of cortex protein tested against a constant NR2A antibody 
concentration (data not shown). 
Unfortunately, as with the RT-PCR experiments, house keeping genes were not 
investigated in parallel to the genes of interest. Examining house keeping genes, whose 
expression level would be expected to be constant in all tested tissue samples, would have been 
essential to control the amount and functionality of total protein applied to the gel and to enable 
a normalization of the expression levels. The resulting expression levels of the NMDA receptor 
subunits were therefore only listed in a rough rank order (no expression at all, low expression, 
medium expression, and high expression) on the basis of the relative band intensities including 
the correction for the applied protein concentration. 
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Table 4.2: Summary of primary and secondary antibody combinations used in the Western blotting 
experunents. 
Distributor/ Secondary Distributor/ 
Primary antibody Dilution Dilution 
order no. antibody order no. 
Mouse anti- NMDA Ri Chemicon/ Sheep anti- GE Healthcare/ 1: 1000 1: 20000 
(all splice variants) MAB 1586 mouse HRP NA931 
Chemicon/ Donkey anti- GE Healthcare/ Rabbit anti-NMDA Rl (C2) 1: 280 1: 10000 
AB 1516 rabbit HRP NA934 
Chemicon/ Donkey anti- GE Healthcare/ 
Rabbit anti-NMDA R1 N1 1: 2500 1: 10000 
AB5044P rabbit HRP NA934 
Chemicon/ Donkey anti- GE Healthcare/ Rabbit anti-NMDA RI Cl 1: 2500 1: 10000 
AB5046P rabbit HRP NA934 
Chemicon/ Donkey anti- GE Healthcare/ Rabbit anti-NMDA RI C2 1: 2500 1: 10000 
AB5048P rabbit HRP NA934 
Chemicon/ Donkey anti- GE Healthcare/ 
Rabbit anti-NMDA R1 C2' 1: 2500 1: 10000 
AB5050P rabbit HRP NA934 
Chemicon/ Donkey anti- GE Healthcare/ 
Rabbit anti-NMDA R2A 1: 1000 1: 5000 
AB 1555P rabbit HRP NA934 
Chemicon/ Donkey anti- GE Healthcare/ 
Rabbit anti-NMDA R2B 1: 2000 1: 10000 
AB 1557P rabbit HRP NA934 
Rabbit anti-NMDA R2C Chemicon/ Donkey anti- GE Healthcare/ 
1: 1250 1: 10000 
(R2C + R2A/B) AB 1592P rabbit HRP NA934 
Upstate/ Goat anti-rabbit Santa Cruz/ 
Rabbit anti-NMDA R3A 1: 500 1: 6000 
07-356 HRP sc-2004 
Upstate/ Goat anti-rabbit Santa Cruz/ 
Rabbit anti-NMDA RIB 1: 500 1: 6000 
07-351 HRP sc-2004 
Rabbit anti- G1uR2/3 Chemicon/ Donkey anti- GE Healthcare/ 
1: 200 1: 10000 
(AMPA) AB 1506 rabbit HRP NA934 
4.2.3 Immunofluorescence 
Immunofluorescence staining of DRG cryosections and cell cultures was performed as 
described in chapter 2.12 using primary and secondary antibodies as listed in table 4.3. Besides 
using the primary antibodies from Chemicon, as in the Western blots, immunostaining was also 
performed with the same Santa Cruz antibodies that were employed by Marvizon et al. (2002) 
for their NMDA receptor characterizations in DRG sections. 
DRG sections and cultures from T9 - T11 were mainly used for immunofluorescence 
staining because Pierau et al. (1984) showed that the major consistent projection of the 
splanchnic nerve sensory afferents was in this area of the spinal cord. 
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Unlike the Chemicon antibodies for NR1 and NR2, the NR3 antibodies from Upstate 
were not considered for immunostaining, due to many unspecific low molecular weight bands in 
the Western blots. As a replacement a NR3A specific antibody, which was very recently 
generated at the Karolinska Institute (Sweden), could also be used within the scope of a 
collaboration with Merz Pharmaceuticals. This antibody was shown to be specific in Western 
blots of transfected HEK293 cells (internal report). 
Table 4.3: Summary of primary and secondary antibody combinations used for the immunostaining 
experiments (+ control peptides, if available). 
Distributor/ Secondary Distributor/ 
Primary antibody Dilution Dilution 
order no. antibody order no. 
Goat anti-mouse 
Chemicon/ Sigma/ 
Mouse anti-NR1 1: 100 FITC (absorbed 1: 64 
B 363 F-8771 
with rat serum) 
Santa Cruz/ 
Goat anti-NR1 1: 100 Rabbit anti-goat Sigma/ 
sc-1467 1: 400 
(control peptide) (1: 20) FITC F-7367 (sc-1467P) 
Chemicon/ Goat anti-rabbit Sigma! 
Rabbit anti-NR1 1: 100 1: 80 
AB 1516 FITC F-0382 
Chemicon/ Goat anti-rabbit Sigma! 
Rabbit anti-NR2A 1: 200 1: 80 
AB 1555P FITC F-03 82 
Santa Cruz/ Rabbit anti-goat Sigma/ 
Goat anti-NR2A 1: 100 1: 400 
sc-1468 FITC F-7367 
ABR/ Goat anti-rabbit Sigma/ 
Rabbit anti-NR2A 1: 200 1: 80 
OPA 1-04021 FITC F-0382 
Chemicon/ Goat anti-rabbit Sigma/ 
Rabbit anti-NR2B 1: 200 1: 80 
AB 1557P FITC F-0382 
Santa Cruz/ 
Goat anti-NR2B 1: 100 Rabbit anti-goat Sigma/ 
sc-1469 1: 400 
(control peptide) (1: 20) FITC F-7367 (sc-1469P) 
Rabbit anti-NMDA Karolinska Goat anti-rabbit Sigma/ 
1: 250 1: 80 
R3A FITC F-03 82 
For the identification of visceral neurons in the DRG cryosections, retrograde staining 
was performed 11 - 12 days before tissue preparation, as described in chapter 2.6, by applying 
Fast DiI Oil into the muscle wall of the small intestine. 
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4.3 Results 
4.3.1 NR1 splice variant specific mRNA detection 
In the first part of the molecular-biological characterization of DRG neurons regarding 
NMDA receptor expression, the presence of the various NRl splice variants in DRG neurons 
and small intestine in comparison to brain tissue (cortex and cerebellum) was investigated at the 
RNA level. No bands were seen in any negative control lanes using nuclease-free water in place 
of the RNA template. 
As a positive control for the RNA isolation and the RT-PCR protocol, the presence of 
kainate subunit GluR5 and GluR6 mRNAs were shown in different preparations of DRGs (raw 
data not shown) as kainate receptor expression is well established in DRG neurons (e. g. Sato et 
al., 1993). 
RT-PCR experiments with various primer pair combinations, overlapping the splice sites 
or directly binding in these, showed the presence of mRNAs coding theoretically for all splice 
variants in various tissues (brain, small intestine, and DRG neurons). However, due to the 
separate determination of N-terminal and C-terminal cassettes and not the whole sequence of 
the NR1 splice variants, a definite prediction that the N-terminal and C-terminal cassettes were 
part of the same RNA sequence was not possible. 
Table 4.4 provides a summary only of the qualitative results of the RT-PCR experiments, 
because it is not possible to evaluate possible quantitative differences in the expression levels by 
using normal RT-PCR without comparison to house keeping genes. Even in experiments with 
primers producing different PCR products, depending on the splice variant, the comparison of 
the band-intensity gives only a rough impression about dominant mRNAs, as the efficiency of 
the PCR depends on the sequence and the size of the template. Only when the larger PCR 
product shows a thicker band in comparison to the smaller products it is indeed likely that more 
mRNA from this template was present in the sample. This was true for all DRG and cerebellum 
samples when N1-cassette overlapping primer pairs were used, indicating that the mRNA of 
N1-cassette-containing splice variants is the predominant form in such tissues. In the same 
experiment, midbrain samples showed equivalent bands for NRIoxx and NR11xx, whereas with 
cortex samples (tissue and cultures) the smaller PCR-product (NRIoxx) was more prominent. 
Cloned NRlol1 DNA and RNA samples are lacking the N1-cassette and therefore only the small 
PCR product appeared on the gel (figure 4.2). 
However, in experiments using a sense primer that binds exactly in exon 5, the presence 
of the N1-cassette could also be clearly detected in those samples where NR11xx was not so 
apparent with NI-cassette encompassing primers (raw data not shown). 
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RT-PCR experiments examining the presence of the NI cassette 
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Fig. 4.2: Example of RT-PCR experiments targeting the NR1 NI-cassette by using primer pairs which 
overlapped the N-terminal splice site, resulting in two amplification products; 842 bp 
represents the inclusion of exon 5,779 bp represents its excision. The various total RNA 
samples were isolated from the following tissues: (1) cortex, (2) cerebellum, (3) midbrain (all 
three brain samples were prepared from 5 week old rats), (4) cloned NRI0 DNA, (5) DRG 
(from 5 week old rat), (6) DRG (from 15 days old rat), (7) cultured DRG neurons (from 15 
days old rats), (8) cultured rat cortical neurons, (9) cloned NR 10 capped RNA, (10) ileum, 
(11) jejunum, (12) duodenum (all three small intestine samples were prepared from 5 week 
old rats), as described in chapter 2.10.1. 
The preferential production of small PCR products was even more obvious when primers 
were used that bind outside the C-terminal cassettes resulting in four different PCR products 
(NRlx>>: 1355bp, NRIx01: 1243 bp, NRIxio: 995 bp, and NRIxOo: 882 bp). Here, the NRlxoo 
band (the smallest amplification product) was particularly strong compared to the other products 
for all tested samples (see figure 4.3 A as an example for the DRG samples). The same was true 
for the experiments targeting NR 1 x (the larger product) and NR1 xo i (the smaller product, see 
figure 4.3 B) simultaneously. The apparent low mRNA level of NR 1 x from the latter 
experiments was contradicted when a reverse primer specifically binding between the C1 and 
the C2 cassette (for detection of NR 1 xj I) was used, since a positive band was seen in all tested 
samples (data not shown). 
76 
Finally, a specific sense primer recognizing the interface between C1 and C2' could 
identify the mRNA of the NRl x1o (592 bp) splice variants (see figure 4.3 C as example for the 
DRG samples). 
RT-PCR experiments examining the presence of the C-terminal cassettes 
A) 57 B) 
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Fig. 4.3: Example for RT-PCR experiments targeting the NR I C-terminal cassettes by using various 
primer pairs: (A) Primers overlapping Cl and C2 results in a maximum of four amplification 
products, 1339 bp reflecting the presence of both C-terminal exons, 1228 bp lacks Cl but 
contains C2; 983 bp contains C1 and C2', and 872 bp represents the excision of both C- 
terminal exons. (B) The reverse primer binds in the C2-cassette giving rise to two 
amplification products, 461 bp for the inclusion of both C-terminal splice sites and 350 bp for 
C2 without C I. (C) The forward primer binds in the CI /C2' interface identifies only those 
RNA samples that contain Cl and lack the C2-casette. Total RNA samples were isolated 
from (5) DRG (5 week old rat) and (7) cultured DRG neurons (15 day old rats), as described 
in chapter 2.10.1. 
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Table 4.4: Summary of the RT-PCR results on the basis of all detected PCR amplification products 
representing various NRl splice variants (and kainate receptor subunits). 
For the evaluation of the presence and absence of the N- and C-terminal exon cassettes in the 
different mRNA samples (brain, small intestine, and DRG neurons), experiments were 
performed with various primer pair combinations targeting the individual splicing sites. 
Primers were designed with annealing positions before, in, or even between the relevant exon 
cassettes. 
NR1, xx NRloxx NRlxll NR1xa1 NRlx, a NRlx00 G1uR5 GluR6 
Duodenum (P15) + + + + + + n. t. n. t. 
Jejunum (P 15) + + + + + + n. t. n. t. 
Ileum (P15) + + + + + + n. t. n. t. 
DRG (P 15) + + + + + + n. t. n. t. 
DRG (P35) + + + + + + n. t. n. t. 
Cultured DRG neurons (P15) + + + + + + + + 
Whole brain (E 18) n. t. n. t. + + + + + + 
Cortex (P35) + + + + + + n. t. n. t. 
Cerebellum (P35) + + + + + + n. t. n. t. 
Midbrain (P35) + + + + + + n. t. n. t. 
Cultured cortical neurons (E 17) + + + n. t. n. t. n. t. + + 
Cloned cRNA NRloll - + n. t. n. t. n. t. n. t. n. t. n. t. 
Cloned DNA NR1o11 - + n. t. n. t. n. t. n. t. n. t. n. t. 
n. t.: not tested, +: positive results, -: no mRNA could be detected 
4.3.2 Protein detection via immunoblots 
Beside the suggested more prominent expression of NR11xx splice variants compared to 
those lacking the N1-cassette, the RT-PCR results indicate that NMDA receptor mRNA studies 
cannot be used to clarify the specific pharmacology of the DRG neurons, especially since the 
detection of mRNA is not full proof for the respective presence of the protein. The expression of 
NMDA subunits was, therefore, further investigated at the protein level. 
Western blotting experiments were performed against various NMDA receptor subtypes 
and splice variants. As suggested in the material and methods section (chapter 2.11.2) additional 
boiling of the protein samples before electrophoresis (to improve protein denaturation) did not 
change the band appearance in the Western blots and were therefore not pursued further 
(corresponding gel slots are not shown in the figures). 
Secondary antibody controls (experiments without primary antibody incubation) did not 
generate bands on the Western blots and therefore ensured that all detected bands in the 
experiments derived from primary antibody reactions. 
78 
C' WS tissue (cortex and cerebellum) served as positive control for the protein isolation and 
Western blotting experiments, but was also used for the semi-quantitative evaluation of receptor 
expression in the DRG tissue. In general, the NMDA receptor expression in DRG samples 
seemed to be much weaker in contrast to brain tissue (cortex or cerebellum). As a consequence 
of this, smaller protein samples were used in the ensuing experiments for the CNS tissue. 
As an additional positive control of the whole procedure, an AMPA-specific antibody 
(G1uR2-3) was also tested, giving rise to clear specific bands of approx. 108 kDa for all 
peripheral as well as central test samples (data not shown). 
Detection of the NR1 subunit splice variants 
Similar to the RT-PCR approach to detect various splice variants of the NR1 subunit, 
commercially available splice variant specific antibodies were used in Western blotting 
experiments. In contrast to the RT-PCR findings, the N1-cassette could not be detected in DRG 
samples, whereas the cortex sample gave a positive signal (figure 4.4 A). Immunoblots targeting 
the C-terminal cassettes showed weak bands for CI, C2, and C2' in comparison to the brain 
samples (figure 4.4 A-E). For the C2-cassette two different antibodies were used, which showed 
different sensitivities. With antibody AB5048P nearly no selective bands were detectable, 
whereas antibody AB 1516 revealed a clear band at approx. 110 kDa, but also several other 
bands of higher and lower molecular weight, possible due to overly high antibody (AB) 
concentrations. 
The potentially most interesting finding within these experiments against the C-terminal 
cassettes of NR1 was the presence of one or more higher molecular weight bands, besides the 
specific band around 110 kDa. These higher bands were more prominent in the DRG samples 
than in those from the cortex. This finding was especially clear in the case of the C2' specific 
antibody (figure 4.4 D), but were also detected with the general (not splice variant specific) 
NR1 AB (figure 4.4 F). In these experiments, the DRG protein samples showed a bright higher 
molecular weight band (of -140 kDa), whereas signals at the expected heights for the NR1 
bands where almost undetectable. In contrast to this, the cortex sample only showed one band 
with the expected molecular weight (of -110 kDa). These bands have been claimed by the 
distributor of the antibodies (personal communication with the technical support and datasheet 
(ABR) to be a post-translationally modified form of NR1. 
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Western blots against various NR1 splice variants 
C) NRlxxi (C2, # AB5048P) 
kD cortex cereb. T9-12 L4-5 L6-S1 
25 pg 25 pg 25 pg 25 pg 25 pg 
160-- 
r 
# 105 -- 
E) NRlxxi (C2, #AB1516) 
kD cortex cereb. T9-12 L4-5 L6-S1 
2.0 pg 20 pg 30 pg 30 pg 30 pg 
160-- rim 
105 -- 
B) NR1x, x (Cl, #AB 5046 P) 
kD cortex cereb. T9-12 L4-5 L6-S1 






D) NR1xxo (C2', #AB5050P) 
kD cortex cereb. T9-12 L4-5 L6-S1 







F) NR1 xxx (# AB1586) 
kD cortex cereb. T9-12 L4-5 L6-S1 




Fig. 4.4: Western blots performed with NR1 splice variant specific (A-E) or unspecific (F) antibodies 
against crude membrane preparations of cortex, cerebellum and DRGs from different regions 
of the spinal cord isolated from 5 week old rats, as described in chapter 2.11.1. Specific 
bands are expected at 100 - 120 kDa, according to the distributor. 
Detection of NR2 subunits 
Western blots against the NR2 subunits of the NMDA receptor were performed only 
against NR2A, NR2B, and NR2C. NR2D subunit-specific antibodies (i. e. those that do not cross 
react) were not commercially available at the time of the experiments. NR2D antibodies 
provided by Santa Cruz were shown to cross react with NR2C (Marvizon et al., 2002). 
Weak NR2A specific bands could be identified in DRG tissue, compared to the large 
amounts of NR2A in cortex and cerebellum (figure 4.5 A). In the case of NR2B, no directly 
corresponding band to that from the cortex at 180 kDa was found in the DRGs but there were 
several bands of higher molecular weight, which also appeared in cerebellum samples (figure 
4.5 B). The bands at approx. 145 kDa seen with the NR2A and NR2B antibodies were most 
probably unspecific as such bands are known from the same antibodies of other distributors 
(Affinity BioReagents, Golden, USA). 
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Western blots against NR2C were negative in the DRG samples; only nearly undetectable 
bands were found at 180 kDa in T9-12 and L4-5, corresponding to the NR2A/B subunits, 
matching the fact that this antibody cross reacts with NR2A/B. Cerebellum, as expected, 
showed a high expression level of NR2C and a slightly lower expression of NR2A/B. In cortex, 
in contrast, NR2A/B was the predominant band (figure 4.5 Q. However, it should be taken into 
account that the NR2A/B band intensities detected in the Westerns against NR2C are not 
directly comparable to those obtained with the specific NR2A and NR2B because of very 
different relative affinities for their epitopes. 
According to the band intensities, NR2A and NR2C expression seems to be lower in L4-5 
DRG samples compared to those from the thoracic (T9-12) and sacral (L6-S1) parts of the 
spinal cord, but possible differences in the applied protein concentration could not be excluded, 
due to the fact that comparison with a house keeping protein is lacking. 
Detection of NR3 
Additional Western blots of the crude protein preparations from 5 week old rats against 
the NR3 subunits revealed several unspecific bands of lower molecular weight than those 
expected for these subunits. But in the case of NR3A, the specific band at 130 kDa could be 
detected in all DRG samples, even though a band at about 100 kDa was the most prominent one 
(figure 4.5 D). 
For NR3B, no specific bands (98 kDa) could be found in any sample (data not shown). 
The lower migrating bands might have been degradation products, which can occur even 
in the presence of a number of protease inhibitors. Since the possibility of unspecific binding of 
the antibody could not be excluded, these antibodies were deemed not to be suitable for 
immunostaining, especially given that these unrelated bands showed a higher band intensity. 
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Western blots against various NR2 / NR3 subunits 
A) NR2A (# AB1555P) B) NR2B (# AB 1557P) 
kD cortex cereb. T9-12 L4-5 L6-S1 kD cortex cereb. T9-12 L4-5 L6-S1 
25025 
pg 25 pg 25 pg 25 pg 25 pg 2.0 pg 20 pg 30 pg 30 pg 30 pg 
-- 
250 -- 






C) NR2C + NR2A/B (# AB1992P) D) NR3A (# 07-356) 
kD cortex cereb. T9-12 L4-5 L6-S1 kD cortex cereb. T9-12 T13-L1 L2-3 
25 25 pg 25 pg 25 pg 25 pg 20 pg 20 pg 25 pg 25 pg 25 pg 250 -- -- 
160-- 
160-- t*, .' 
105 -- 105-- 
Fig. 4.5: Western blots performed with antibodies directed against NR2 and NR3 subunits of crude 
membrane preparations of cortex, cerebellum and DRGs of different regions of the spinal 
cord isolated from 5 week old rats, as described in chapter 2.11.1. According to the 
distributor, specific bands for NR2A/B are expected at 180 kDa, at 140 kDa for NR2C, and at 
130 kDa for NR3A. 
All Western blotting results were confirmed by at least one repeated experiment. Table 
4.5 shows the relative band intensities of the various samples in comparison to the sample with 
the highest protein expression (no expression at all = -, low expression = +, medium expression 
= ++, and high expression = +++). 
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Table 4.5: Summary of Western blotting experiments against (A) NR1 splice variants and (B) various 






















Cortex +++ - +++ - +++ + +++ + +++ - 
Cerebellum ++ - + - + + + + ++ + 
DRG T9-12 + + - - - + + + + ++ 
DRG L4-L5 + - - - + + - - - + 




G1uR2/3 NR2A NR2B NR2C NR3A NR3B 
Band (kDa) 108 180 180 > 180 140 180 115 130 98 
Cortex +++ +++ +++ - + +++ - - - 
Cerebellum ++ +++ + + +++ ++ - - - 
DRG T9-12 + + - + - + + + - 
DRG L4-L5 + + - + - - +* +* 
DRG L6-S 1 + + - ++ - + n. t. n. t. n. t. 
* DRG L2-3 
4.3.3 Protein detection via immunostaining 
After evaluation of the expression levels of the NMDA receptor subunits in protein 
samples isolated from DRGs of 5 week old rats, the expression pattern was investigated 
histochemically in DRG cryosections and DRG cultures. 
All immunofluorescence experiments using the DRG cryosections were combined with a 
retrograde staining procedure of the small intestine with Fast DiI Oil 2 weeks before tissue 
isolation to enable identification of visceral primary afferent neurons. 
The first staining was performed with the selected Chemicon antibodies that had already 
been used in the Western blots. However, because no control peptides were available for these 
NMDA receptor antibodies, and also because a weak unspecific band of lower molecular weight 
was seen for each antibody, all of the following experiments were performed with NMDA 
antibodies supplied by Santa Cruz. These antibodies were provided with control peptides and 
(useful for comparisons) were also those used by (Marvizon et at, 2002) for their 
characterization of NMDA receptors in DRGs. 
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Incubation with the secondary antibodies alone did not produce staining (e. g. FITC 
conjugated goat anti-rabbit, left corner of figure 4.6 A), therefore all detected fluorescence 
appeared to be specific for the primary antibodies. 
Immunofluorescence directed against NRI (figure 4.6 A), NR2A (figure 4.7 A), and 
NR2B (figure 4.8 A) revealed, albeit shown slightly out of focus here, cytoplasmic staining of 
the neurons in the DRG sections, but nuclei were not stained by the antibody. Differential 
staining depending on cell size could not be detected. 
Immunostaining of DRG cryosections / cultures against NR1 
W 
r Ar so 
Fig. 4.6: Immunofluorescence staining (FITC, green) with (two different) antibodies directed against 
the NRI subunit in DRG sections (A) and cultures (B). DRG sections (T10), isolated from a 
young adult rat, were incubated with AB 1516. An FITC-conjugated secondary antibody 
control is shown in the left corner, scale bar = 25 µm. DRG cultures (2 days in vitro, L2-3), 
also isolated from young adult rats, were incubated with sc-1467; nuclei were stained with 
DAPI (blue). In the left corner the corresponding immunostaining after pre-incubation with 
blocking peptide is shown. Scale bar = 50 µm. 
Regarding the role of NMDA receptors in visceral nociception, it was important to 
determine whether visceral primary afferent neurons (identified by the red staining of Fast Dil 
Oil) were also stained against the NMDA receptor subunits (white arrows in figures 4.7 and 
4.8). On the basis that 10 - 15 % of DRG neurons are expected to be of visceral origin (Perry & 
Lawson, 1998; Holzer, 2001), figure 4.7 is not representative as it shows a much higher ratio 
(approximately 30 %) of DiI positive cells. Additionally, the relatively high background 
staining in some of the retrogradely labelled sections might be due to cell permeabilization by 
Triton X-100 within the immunostaining process. The risk of dye leakage out of the plasma 
membrane is reported in the Molecular Probes product information sheet, therefore sulfonated 
derivatives of DiI, which are claimed to persist after permeabilization treatments, might have 
been a better alternative. A difference in the expression levels / patterns between Dil-labelled 
(visceral neurons) and unlabelled cells (visceral and somatic neurons) was not observed within 
this dataset. 
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Immuno- / retrograde staining of DRG cryosections against NR2A 
Fig. 4.7: Immunotluorescence staining (hl i C, green) against NR2A (AB I5551)) in UK(i sections 
(T9) isolated from a young adult rat (A) and identification of visceral afferents by using 
retrograde staining (Fast DiI Oil) on the same section (B). White arrows indicate double 
stained cells. Scale bar = 25 µm. 
Immuno- / retrograde staining of DRG sections against NR2B 
Fig. 4.8: As for figure 4.7 but against NR 2B (AB 1557P) in 110 I)R(i sectiun. s. 
In contrast to the cytoplasm-related staining in the cryosections, membrane-associated 
expression of all tested NMDA receptor subunits was indicated by the more intense 
fluorescence at the cell membrane and the staining of the neurites in cultured DRG neurons (as 
examples see figure 4.6 B for NRl and figure 4.9 for NR? B). Much higher magnification 
combined with transsections through the cells would be necessary to prove this hypothesis, but 
such technology was not available at the date of analysis. 
It would also have been sensible to provide a direct comparison for all NMDA receptor 
subunits for DRG sections and DRG cultures isolated from the same spinal regions, but 
unfortunately not enough samples were processed for such an analysis. 
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The selectivity of the Santa Cruz antibodies could be demonstrated by preincubation with 
control peptides. In this case, immunostaining was mostly abolished (small boxes in figure 4.6 
B and figure 4.9). 
Fig. 4.9: Immunofluorescence staining 
against NR2B (sc-1469) in DRG 
cultures (2 days in vitro, L6-S1) 
isolated from young adult rats. The 
image in the right corner represents 
the corresponding immunostaining 
after pre-incubation with blocking 
peptide. Scale bar = 50 pm. 
A membrane-associated staining was also observed with the NR3A antibody (figure 
4.10), which was provided by Dr. Sundström from the Karolinska Institute (Sweden), with 
proven specificity in Western blots performed with protein samples isolated from NR3A 
transfected HEK293 cells and the spinal cord of young rats. Possible cross reactions with other 
NMDAR subunits have not been discussed (co-operation report). The presence of NR3A is of 
particular importance as this might indicate a functional expression of NR3A containing 
receptors in the DRG neurons, which has not been reported in the literature so far. 
1: 1g. 4.10: lmmunofluorescence staining 
against NR3A (C-terminal AB, 
generated at the Karolinska 
Institute, Sweden) in DRG cultures 
(2 days in vitro, T9-L6) isolated 
from young adult rats. Scale bar = 
50 Fun. 
Hippocampal cultures were used as positive controls, and revealed membrane associated 
staining (data not shown), with one exception. In contrast to the positive staining in the dentate 
gyrus region of hippocampus published by Marvizon et al. (2002), it was not possible to show 
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Immunostaining of DRG cultures 
against NR2B 
Immunostaining of DRG cultures 
against NR3A 
staining with a NR2A selective antibody from Santa Cruz, either in the hippocampal cultures or 
in the DRG samples. However, the positive staining with the NR2A antibody from Chemicon 
was consistent with another NR2A specific antibody from ABR (data not shown), even though 
the selectivity of the ABR antibody is not known. 
Table 4.6: Summary of immunofluorescence staining performed against various NMDA receptor 
subunits in DRG sections and cultured DRG neurons isolated from young adult rats, as well 
as hippocampal (HIC) cultures isolated from rat embryos (E20). 















DRG sections + n. t. + - + + + n. t. 
DRG cultures n. t. + n. t. n. t. n. t. + + 
HIC cultures + n. t. + - n. t. + n. t. n. t. 
n. t.: not tested, +: positive staining (cytoplasmic for DRG sections and mainly membrane associate for 
DRG and HIC cultures), -: negative staining 
Double immunostaining with mouse NR1 (MAB 363) and rabbit anti NR2 subunits was 
also planned, to investigate subunit co-expression, but the secondary anti mouse FITC 
conjugated antibody that was used gave a background staining level that was too high (even 
though it was absorbed with rat serum) and could therefore not be used. 
4.4 Discussion 
One of the first indications for the presence of NMDA receptors in rat DRG neurons was 
presented by Sato et al. (1993) at the mRNA level. This added further insights into the presence 
of ionotropic glutamatergic receptors in primary sensory afferents, already accepted for AMPA 
and kainate receptors. The possible involvement of NMDA receptors in nociceptive processes 
was then inferred by the discovery of their localization at the central as well as at the peripheral 
terminals of primary afferent neurons and their influence on the release of substance P (SP) and 
Calcitonin-gene-related peptide (CGRP) at both terminals (Liu et al., 1997a; McRoberts et al., 
2001). But the exact subunit composition and the resulting pharmacology of these NMDA 
receptors is still under debate (e. g. Li et al., 2006). Molecular biological characterization ought 
therefore to help clarify the proposed different pharmacology of NMDA receptors expressed by 
DRG neurons. 
The most straightforward approach, from a practical point of view, was to perform RT- 
PCR experiments. From these experiments, which were restricted to NRI splice variants, the 
presence of the NI cassette (NRI1, ) seems to be more prominent than NRa, in DRG tissue. 
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This conclusion is based on the results from experiments investigating the presence/absence of 
the N-terminal cassette by two possible amplification products within one PCR run (inclusion of 
N1= larger PCR product, excision of Ni = smaller PCR product). DRG tRNA samples showed 
a higher band intensity for the larger amplification product, although such products are usually 
weaker due to inferior efficiency compared to competitive smaller amplification products. This 
observation fits nicely with the results from Li et al, (2006) using the same approach in DRGs. 
It is also worth mentioning that in tRNA samples of the small intestine, the band representing 
NR10, x was more intense (see figure 4.2). This tissue contains - beside the NMDA receptors of 
the extrinsic primary afferents - NMDA receptors in the enteric nervous system (Burns et al., 
1994), which might allow one to hypothesise that the NMDA receptors of the intrinsic primary 
afferents mostly contain NR1 splice variants lacking exon 5, despite the limitations discussed 
above. It was previously reported that the predominant splice variants in cortex and 
hippocampus were those without the Ni insert, whereas in the cerebellum the major variant was 
NR1100, i. e. containing Ni (Laurie et al., 1995; Prybylowski & Wolfe, 2000). This difference in 
expression was also found in the present RT-PCR experiments, further supporting the 
validity/interpretation of the present data. Additionally, the detection of mRNA forming all 
possible C-terminals of the NR1 subunit also parallels the results of Li et al. (2006). 
Due to the fact that the presence of mRNA for NMDA subunits is not strong evidence for 
the presence of the receptor subunit proteins, Western blotting experiments were performed to 
investigate the expression of NMDA receptor subunits at the protein level in DRGs isolated 
from various spinal levels appropriate to the splanchnic, sciatic and pelvic nerves, in 
comparison to cortex and cerebellum. 
It has to be noted that most of the experiments regarding the molecular biological 
characterization of DRG neurons were already planned before publication of the frequently 
cited paper from Marvizon et al. (2002). This was the reason for starting with the Chemicon 
antibodies as they seemed (from preliminary experiments) to be the most suitable ones, despite 
the fact that no control peptides were commercially available. The antibodies from Santa Cruz 
were only used for evaluation of the results published by Marvizon et al. (2002), mainly by 
immunostaining. 
The validity of the Western blots could be confirmed by the expression levels in the 
positive controls (cortex and cerebellum protein samples) and were consistent with results from 
the literature, i. e. high levels of NR2A and NR2B and to a lesser extend NR2C in the cortex, 
whereas in cerebellum NR2C is the dominant subunit, followed by NR2A and only little NR2B 
(Monyer et al., 1992; Laurie et al., 1997; Wenzel et al., 1997). 
But in general a much higher expression level of all investigated NMDA receptor 
subunits was found in CNS tissue samples compared to the protein samples isolated from 
DRGs. The lower receptor amounts in the DRG samples, reflected by the weaker bands in the 
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blot, might be explained by the fact that only the cell bodies of primary afferent neurons were 
isolated, lacking their central and peripheral terminals which may contain most of the NMDA 
receptor protein. 
The lower receptor levels found in the DRG samples are in line with real-time RT-PCR 
experiments shown by Marvizon et at (2002). Although the same tRNA amounts (checked by 
reference genes) were used, two order of magnitude less mRNA was amplified from the DRGs 
compared to various CNS tissues. 
Unfortunately the immunoblots using the Nlcassette specific antibody did not correspond 
to the RT-PCR experiments and literature data, where a higher expression level in the 
cerebellum samples would have been expected in contrast to cortex protein. Retrospectively, it 
is clear that the use of a house-keeping gene to control the amount of protein applied to the gel 
would have been very helpful here. 
One relevant finding within the Western blots that were performed was the presence of a 
second (specific) band, detected in all experiments, directed against the C-terminal cassettes of 
NR1. Beside the expected band at around 110 kDa, a higher migrating band could be detected 
with a different expression pattern between the CNS and PNS protein samples. According to the 
antibody datasheet this band is a post-translationally modified form of NR1. 
Prybylowski & Wolfe (2000) verified the specificity of the various C-terminal cassette 
antibodies from Chemicon, using Western blots against NR1 splice variants expressed in 
transfected HEK293 cells. Interestingly, in their experiments using anti-NR1 C2', two separate 
bands appeared in brain tissue, one of approximately 115 kDa and another of circa 150 kDa. But 
the higher migrating band was disregarded for further analyses because it was missing in the 
NR1ooo transfected HEK-293 cells. 
The differences in the molecular weight of the NR1 splice variants are too small to 
explain this phenomenon, since differences in molecular weight could not be detected in normal 
sodium dodecyl sulfate (SDS) polyacrylaminde gel electrophoresis using different splice variant 
DNA clones (Holmes et al., 2002). 
Beside serine phosphorylation in the Cl cassette of the NR1 subunit, which might also 
alter the protein mobility during SDS-polyacrylamide gel electrophoresis (Leveque et al., 2000), 
there is considerable evidence that the major differences in the molecular weight is due to a 
higher glycosylation status. Glycosylation contributes considerably to the molecular weight of 
NMDA receptors. Between 1.0 and 2.9 kDa extra molecular weight is possible per consensus 
glycosylation site, and the NRI subunit contains 10 potential N-glycosylation sites 
(UniProtKB/Swiss-Prot entry P35439; http: //www. expasy. org/uniprot/P35439), resulting in an 
approximately 20 kDa increase of the NR1 protein by the sugar moieties. 
The various higher molecular weight bands found in all experiments targeting the C- 
terminal exon cassettes of the NR1 splice variants could therefore represent a heterogenous 
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degree of glycosylation (approx. additional 7-20 kDa). This deduction is supported by 
Marvizon et al. (2002) detecting a 140 kDa band for the NR1 subunit in the DRG extracts, in 
contrast to the 120 kDa band found in brain membrane extracts; here too it was explained by a 
highly glycosylated form of NR1 in the DRGs. The same is true for the NR2B subunit where 
several more-or-less distinct higher molecular weight bands (> 200 kDa) could be detected in 
the own experiments, which parallels with the published work of Marvizon et al. (2002) 
showing a smear of higher molecular weight protein bands. 
It is well known that glycosylation patterns can be tissue- or cell-specific. For instance, 
findings from Hinoi et al. (2002) led them to the assumption that the NR1 subunit is more 
glycosylated in rat adrenal medulla than in hippocampus. 
As stated in the introduction, the hypothesised difference in NMDA receptor 
pharmacology in the periphery might occur due to a variation in the level of glycosylation of the 
NMDA receptor subunits. Glycosylation influences several properties of glutamate receptors. It 
was shown for example that glycosylation is necessary for the binding of the NMDA receptor 
antagonist 5,7-DCKA (Kawamoto et al., 1995). 
Deglycosylation experiments using N-glycosidase F (cleaves glycosylated asparagines), 
which was shown to reduce the molecular mass of NR1 protein considerably to normal levels 
(Clark et al., 1998), should clarify the validity of this assumption. But preliminary experiments 
undertaken here to investigate the glycosylation status of the NR1 splice variants did not work, 
probably due to degradation of the enzyme during storage/transport. 
According to the Western blots performed by Marvizon et al. (2002), rat DRG contain 
NR1, NR2B, NR2C, and NR2D but not NR2A subunits. Despite the fact that the NR2A specific 
antibody from Santa Cruz worked in their positive controls using brain extracts for Western 
blots and brain sections for immunohistochemistry, the NR2A subunit was not detected in DRG 
samples. These data are not in line with the present findings using the Chemicon antibody 
which revealed weak but positive bands in Western blots as well as a clear immunostaining in 
cryosections. The positive immunostaining revealed with the Chemicon NR2A antibody could 
be further confirmed by another NR2A specific antibody supplied by ABR in the same tissue / 
cell cultures, however this is by no means any guarantee of specificity. In the present 
experiments, the Santa Cruz NR2A antibody worked neither in the DRG cryosections nor in 
hippocampal cultures. Based on these results, it might therefore be concluded that the quality of 
this antibody is suspect. In more sensitive real-time RT-PCR experiments (published in the 
same paper), although higher levels of NR2B and NR2D were again inferred, NR2A and NR2C 
could also be clearly detected. As such, even Marvizon et al. (2002) did not rule out that the 
NR2A subunit might be functionally important. 
In addition to the fact that the cell culture conditions might affect the NMDAR subunit 
expression pattern - in this case particularly the presence and absence of NGF - the different 
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age of the animals tested might also be an explanation for the different findings - especially 
with respect to NR2A expression level. In the present experiments only samples from young 
and young adult (maximum 7 week old) rats were used to enable a comparison with the DRG 
cultures. This compromise age was, on the basis of evaluation of the CNS literature, deemed to 
be old enough to address the adult receptor expression profile but young enough to facilitate the 
preparation of cell cultures. However, Marvizon et al. (2002) used 2-4 month old animals. 
Aside from the classical NMDA receptors also found in the adult CNS, an additional 
NMDA receptor may be expressed in the DRGs containing the more recently cloned NR3A 
subunit. The detection of the NR3A and not of the NR3B subunit in the DRG neurons of young 
adult rats is very interesting because the NR3A subunit is generally only expected during 
development (until second postnatal week) in the CNS (spinal cord, brainstem, hypothalamus, 
thalamus, hippocampus, and amygdala) and was not detected in peripheral tissues (Ciabarra et 
al., 1995). On the other hand NR3B expression is known to be restricted to somatic 
motoneurons of the brainstem and spinal cord and the expression is constant from postnatal 
development into adulthood (Nishi et al., 2001; Matsuda et al., 2002). The presence of NR3A 
containing receptors in adult peripheral nervous tissue would therefore represent a crucial 
difference to the CNS. 
The observed immunoreactive bands in the DRG protein samples at approx. 135 kDa 
represent NR3A (Fig. 4.6 D). For the rat NR3A subunit a long and a short splice variant are 
known (Sun et al., 1998), but as for the NR1 splice variants, the difference in the amino acid 
length is too small (18 amino acids) to be discriminated in the Western blots (UniProtKB/Swiss- 
Prot entry P35439; http: //www. expasy. org/uniprot/Q9R1M7). The many unspecific bands of 
lower molecular weight are difficult to explain, beside possible protein degradation, they are in 
line with the cross-reacting bands found by Ciabarra & Sevarino (1997) in P7 rat body and brain 
protein samples with a self made antibody. The presence of the NR3A subunit was also 
ascertained in the current study by positive membrane-associated immunostaining using a 
specific antibody from the Karolinska Institute (co-operation report assured specificity in 
Western blots). Even though no experimental studies investigating the role of NR3 in pain 
mechanisms have been published so far, this might indicate that the postulated different NMDA 
receptor pharmacology in primary visceral afferents is influenced by NMDA receptors 
containing the NR3 subunit. This subunit has been reported to act in dominant-negative manner 
by reducing NMDA-evoked currents, channel conductance, and Cat+-permeability in 
NR1/NR2/NR3A assemblies (Sucher et al., 1995; Perez-Otano et al., 2001; Nishi et al., 2001). 
Electrophysiological characterization of NR1/NR2/NR3 receptors in mammalian cells also 
showed higher potency for glycineB antagonists vs. memantine (Pina-Crespo & Heinemann, 
2004). 
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Postulating the presence of NR1/NR2A/NR3A receptors in adult primary afferent fibres, 
on the basis of the novel finding of NR3A subunits in adult, peripheral sensory neurons, it might 
also be sensible to investigate whether such receptors are still present in models of 
inflammatory and chronic pain. A downregulation of the NR3 subunit under such conditions 
might implicate a hypersensitisation by abolishing the dominant-negative effect of NR3. If 
triheteromeric NMDA receptors containing NR3A subunit were affected in this manner, this 
would further strengthen the idea that treatment of inflammatory / chronic pain could be 
mediated via peripherally restricted glycineB antagonists, and that this mechanism would be 
very selective, with a low risk of side effects. 
NR1/NR3 containing "excitatory glycine receptors", which are activated by glycine alone 
and form relatively Cat-impermeable cation channels resistant to Mgt+, MK-801, memantine 
and competitive antagonists, as reported by Chatterton et al. (2002), might be of less importance 
as they have not yet been detected in vivo. 
Immunostaining experiments should provide information about NMDA receptor 
expression at the cellular level. In general the results were consistent with the immunoblotting 
results. Control peptides were available for the Santa Cruz antibodies to evaluate their 
specificity to the target epitope. The antibody that is bound to the excess of control peptide 
could not bind to protein in the cell and therefore the immunostaining is knocked out. Non- 
specific binding to proteins other than the antigen would not be blocked by the peptide resulting 
in residual staining. Beside the possible unspecific binding to proteins with similar amino acid 
sequence the lack of complete inhibition of the immunostaining by the control peptide in these 
experiments was probably due to an inadequate pre-incubation period and too low a 
concentration of the immunizing peptide. The pre-absorption method was performed according 
to the manufacturer's protocol (5-fold excess of control peptide), however 5- 50-fold excess of 
control peptide is common. In their Western blotting experiments Marvizon et al. (2002) used 
undiluted control peptides (resulting in an at least 100-fold excess compared to the antibody) 
overnight at 4°C. 
The supposed cytosolic immunostaining of the NMDA receptor subunits in the DRG 
cryosections, in contrast to the membrane associated staining in the cultured neurons, agrees 
with the literature (Ma & Hargreaves, 2000; McRoberts et al., 2001; Marvizon et al., 2002) and 
suggests that these receptors are transported to the peripheral and central terminals of primary 
afferents, where a membrane associated localization would be necessary for functional 
receptors. 
As far as it is possible to infer from the experiments performed here (including the 
retrograde staining), there seems to be no difference in the NMDAR subunit composition in the 
DRGs along the length of the spinal column, nor between neurons innervating different organs 
(especially visceral vs. somatic). This statement is supported by the molecular biological and 
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electrophysiological characterization published by the group of Mayer (McRoberts et al, 2001; 
Marvizon et al., 2002; Li et al., 2004). Later electrophysiological studies (see chapter 5.4) also 
showed that there is no functional difference between somatic and visceral primary afferent 
neurons. 
Further molecular biological and retrograde staining experiments were, at this stage of the 
project, deemed to have lower priority, due to the extensive molecular biological 
characterization of DRG neurons by the above mentioned group. Marvizon et al. (2002) 
investigated the NMDA receptor expression composition in different types of DRG neurons. 
NR2B was found to be localized in A- and C-fibres, whereas NR2D (and perhaps NR2C) was 
restricted to C-fibres. Co-localization of NR2B and NR2D was not detected. Despite the limited 
selectivity of the NR2C and NR2D antibodies from Santa Cruz (due to their cross reaction) used 
in their study, a dominant expression of the NR2D subunit vs. the NR2C subunit was postulated 
on the basis of real-time RT-PCR studies. 
It was consequently concluded that two distinct NMDARs exist, a conclusion that was 
further supported by their finding that NR2C/D staining is co-localized with the C-fibre markers 
CGRP (mostly in C-fibres), neurokinins (e. g. SP), and isolectin B4 (1B4) binding protein. 
Nevertheless, especially with respect to the NR2A expression, it might have been sensible 
to test duplicate antibodies from different commercial sources (e. g. Chemicon or ABR vs. Santa 
Cruz) on adjacent sections of the same tissue to examine whether the staining pattern was 
similar, since it is not possible to make a substantiated conclusion based on the present 
heterogeneous dataset (i. e. using one antibody on cryosections and one on cultured neurons). 
The involvement of NMDA receptors under physiological conditions (McRoberts et al., 
2001) as well as in the presence of inflammation (see Appendix 1) in visceral nociceptive 
processing, is now well accepted. But with the exception of the microdialysis studies that 
strongly support a peripheral site of action for the NMDA receptor glycine site antagonists - 
even under inflammatory conditions (chapter 3.4) - the effect of inflammation directly on 
NMDA receptor expression was not investigated so far in this project. However, there is 
growing evidence for NMDA receptor changes that might influence nociceptive processing in 
primary afferents during inflammation (e. g. Zhou et al., 2006b). 
For example, an increase of NMDA receptors in primary afferent nerve fibres could be 
observed by immunohistochemical staining 48 h after complete Freund's adjuvant (CFA) 
induced inflammation of the hindpaw (Carlton & Coggeshall, 1999). Interestingly, when 
analysing the changes of the NR1 subunit directly on DRGs under similar inflammatory 
conditions, immunostaining was decreased, with a maximum effect 3 days after CFA (Wang et 
al., 1999). This apparently contradictory finding might be explained by a massive transport of 
NMDA receptors out of the cell body to the peripheral terminals. On the other hand it was also 
shown by immunofluorescence double staining, that the number of IB4 and NR1 double- 
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labelled neurons increased significantly on days 3 and 7 after CFA injection, due to increased 
NMDAR expression (Wang et al., 2006). In consideration of the data presented by Wang et al. 
(1999) it might be hypothesised that whilst the total number of NR1 positive cells might 
decrease, the proportion of small NRI positive neurons might increase. 
Additionally, in a model of experimental colitis, an increase of NR2B expression 
accompanied with a persistent tyrosine phosphorylation, was observed in DRG neurons at the 
beginning of the chronic phase of inflammation (5 days after intracolonic TNBS). Because only 
NR1011 was decreased and the other NR1 splice variants/NR2 subunits were unchanged, NR2B 
phosphorylation was held responsible for the pharmacological changes of the NMDA receptor 
after experimental colitis (Li et al., 2006). 
These papers illustrate that the influence of inflammatory conditions on NMDA receptor 
expression and pharmacology is not yet clear. Nevertheless NMDA receptor phosphorylation 
seems to be important, in conjunction with the inflammatory nociceptive response. Ito et al. 
(2003) showed that kinins and prostanoids produce post-translational changes in pain 
transducers. (e. g. transient receptor potential vanilloid 1 receptor, TRPV1) and sensitization of 
NMDA and AMPA receptors by phosphorylation. It could be shown that NMDA 
phosphorylation increased NMDA receptor activity leading to central sensitization with 
allodynia and hyperalgesia (Caudle et al., 2003). This might indicate that post-translational 
modification of NMDA receptors following peripheral insult could lead to enhanced NMDA 
receptor function, which may enhance excitability and/or excitotoxicity. 
4.5 Conclusion 
There is considerable published evidence from discoveries over the last few years that the 
NR2B subunit is particularly important in nociceptive pathways, especially with respect to 
reports that this is the most prominent NR2 subunit in DRGs. However, the present findings 
also indicate a possible role of NR2A and possibly also NR3A in peripheral nociceptive 
processing. Additionally, the present results indicate that it might also be sensible to address 
further possible post-translational modifications of NR1 (i. e. of the C2' cassette) and NR2B 
(glycosylation as well as phosphorylation) subunits, especially regarding possible changes under 
inflammatory conditions. 
Overall, evaluation of the results of the present molecular biological characterization of 
NMDA receptors in DRG neurons, indicate that it might be more sensible to further characterize 
NMDA receptors in DRGs electrophysiologically in order to gain a better understanding of 
potential differences in DRG vs. CNS NMDA receptor pharmacology. With respect to the 
higher potency of the glycineB site antagonists in the visceral pain models, such differences 
might also be investigated with respective cell cultures in vitro. The following chapter describes 
experiments conducted to address this issue. 
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CHAPTER V 
5 PHARMACOLOGICAL CHARACTERIZATION OF DRG 
NEURONS IN COMPARISON TO CNS NEURONS AND 
STABLY TRANSFECTED NR1o11/2A HEK CELLS 
5.1 Introduction 
Following on from the introduction of chapter 4, where the possible influence of receptor 
subtype composition and post-translational modifications on receptor pharmacology were 
discussed, the following electrophysiological experiments were mainly performed to 
characterize the functional pharmacology of NMDA receptors in primary sensory DRG neurons. 
As the preparation and cultivation of the DRG neurons was first established in this 
laboratory during this PhD project, it was very important to start by ensuring a characteristic 
and consistent receptor profile in vitro (also serving as a cell viability check). This was done by 
confirming the presence of functional GABAA and kainate activated currents in patch-clamp 
experiments before characterizing the pharmacology of the NMDA receptors. 
The molecular biological evaluation of the NMDA receptor subunits expressed in primary 
afferent neurons only suggests that there are variations in the glycosylation status of subunits 
and the involvement of the NR3A subunit. It does not, however, provide definitive evidence for 
differences between these NMDA receptors and those present in the CNS that could explain the 
differential NMDA receptor pharmacology postulated on the basis of the results of the visceral 
pain experiments. 
For the functional characterization of DRG neurons, these cells were compared 
electrophysiologically with neuronal cells of central origin (hippocampal neurons) to facilitate a 
direct pharmacological differentiation from the central NMDA receptors classically targeted for 
CNS diseases. 
It is already known that glycine shows different affinities at various NMDA receptor 
subtypes via allosteric interactions between NR2 subunits and the glycine recognition site on the 
NRl subunit (e. g. Monyer et al., 1992) and therefore an evaluation of the pharmacology of 
transfected cells heterologously expressing defined NMDA receptor subunit combinations was 
postulated to help deduce the NMDA receptor composition in the cultured DRG neurons. 
Accordingly, in addition to the primary cultures of DRG and hippocampal cells, NMDA 
receptor properties were analysed in stably transfected HEK 293 cells. Due to the positive 
detection of the NR2A subunit in the immunoblotting and -staining experiments (chapter 4) - 
which contrasts with the findings of Marvizon et al. (2002) - human NRloll and NR2A 
expressing HEK293 cells were generated first and used for patch-clamp experiments to compare 
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the pharmacology of these NMDA receptors with those of the DRG neurons. Subsequently, the 
generation of NR1/NR2B HEK293 cells was also planned. 
Possible differences in the potencies of various glycineB site antagonists were the major 
focus of this study, as these compounds were sometimes more potent than was expected in the 
in vivo models of visceral pain. However, potent, high affinity glycineB site antagonists (e. g. 
MDL-105,519, L-689,560, or L-701,324) were not used here in the patch-clamp experiments, as 
they display very slow kinetics so that steady-state conditions are very difficult to achieve in 
such experiments. Interestingly, no information is available at time of writing concerning the 
potency of glycineB site NMDA receptor antagonists upon NMDA-induced currents recorded 
from DRG neurons. 
In addition, various agonists as well as partial agonists were used in anticipation that any 
potency differences could also be used to identify different NMDA receptor subtypes. In 
particular, different potencies and intrinsic activities of partial agonists would be expected to 
help to characterize the NMDA receptor pharmacology of DRG neurons (Sheinin et al., 2001 
and 2002). 
To assess the affinity of the glycineB site modulators on the binding pocket per se, [3H]- 
MDL-105,519 displacement studies with rat cortical membranes were also performed, using a 
96-well plate robotic platform. 
In addition to the application of various glycineB site agonists and antagonists to clarify 
the NMDA receptor subtypes expressed in DRG neurons, the most intuitive way to prove the 
presence of NR2A subunits in DRG neurons would have been to use NR2A subtype-selective 
antagonists. Unfortunately no truly NR2A subtype-selective organic antagonists are available. 
NVP-AAM077 ([(R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydro- 
quinoxalin-5-yl)-methyl]-phosphonic acid) has been claimed to be a NR2A subtype-selective 
antagonist with 130 fold selectivity over NR2B (Liu et al., 2004; Zhou & Baudry, 2006). 
However, data published by Neyton & Paoletti (2006) revealed this substance to have much 
lower subunit selectivity than was claimed (213 nM for NR1/NR2B receptors vs. 23 nM for 
NRl/NR2A receptors). These authors showed that the apparent greater selectivity of NVP- 
AAM077 was due to the lower potency of glutamate at NR2A subtype-containing receptors and 
the use of the same concentration of agonist for different receptor subtype combinations 
therefore marred results (Liu et al., 2004; Zhou & Baudry, 2006). Aside from these caveats, 
NVP-AAM077 is not commercially available. 
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Zn2+ is known to be a highly selective, very potent antagonist for NR2A subunit- 
containing NMDA receptors by binding to a modulatory N-terminal domain (with an IC5o of 
approximately 20 nM, e. g. Paoletti et al., 1997; Traynelis et al., 1998). Higher concentrations 
also block other NMDA receptor subtypes. However, due to the fact that > 50 nM Zn 21 
contaminations have been reported to be present even in standard buffers (Fayyazuddin et al., 
2000) identification of NR2A subunit-containing receptors using Zn2+ would also have been 
problematic. The only way to circumvent such contamination by Zn2+ would be to use special 
assay protocols (e. g. to buffer contaminating Zn2+ by metal chelators; Paoletti et al., 1997; 
Traynelis et al., 1998). Such measures would, however, restrict the usefulness of Zn2+ as a 
pharmacological tool to identify different NMDA receptor subtypes, since such metal chelators 
could have a severe impact on cellular physiology. Therefore, no experiments with Zn2+ were 
performed. 
However, NR2B subtype-selective antagonists have not only already been used to 
identify NR2B subunit-containing NMDA receptors in DRG neurons, but also have very low 
potency for NR1/NR2A receptors. Such agents were therefore hypothesised to offer an 
alternative approach to support the functional expression of NRI/NR2A NMDA receptors in 
DRG neurons. NR2B-subtype-selective antagonists such as ifenprodil, eliprodil, or Ro25-6981 
are well-characterized. Although they act in a noncompetitive and voltage-independent manner, 
it has to be considered that high agonist concentrations might be needed for effective inhibition, 
as these compounds show a use-dependent blockade with increasing agonist concentrations 
(Kew et al., 1996). The use of NR2 subtype selective antagonists to elucidate the NMDA 
receptors composition becomes even more complicated when triheteromeric NMDARs (e. g. 
NR1/NR2A/NR2B) are expressed in the tissue of interest (Neyton & Paoletti, 2006). 
Finally, due to the identification of the NR3A subunit at the protein level, it was 
important to test for the presence of excitatory glycine receptors, which are assembled from 
NRI and NR3 without NR2 subunits and are activated by glycine alone (Chatterton et al., 
2002). This is despite the fact that such receptors have not yet been shown to be functionally 
present in native tissue, whereas triheteromeric NMDA receptors consisting of NR1/NR2/NR3 
are more likely to exist (Neyton & Paoletti, 2006). 
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5.2 Experimental Protocols 
5.2.1 Whole cell patch-clamp recordings 
Stock solutions of GABA, kainate, and NMDA receptor antagonists/partial agonists were 
always prepared freshly on the day of the experiment. But for NMDA and glycine, stock 
solutions of 200 mM and 10 mM, respectively, were frozen in aliquots at 20°C after 
preparation, as they were required for most recordings of NMDA receptor currents. Test 
solutions were diluted from stock solutions to the desired final concentrations in extracellular 
solution (ECS, for the composition, see Chapter 2.13.1). 
The cell cultures used for the patch-clamp experiments were prepared as described in 
Chapters 2.7 - 2.9. In order to focus on myelinated AS- and unmyelinated C-fibres carrying 
nociceptive information from the periphery to the spinal cord, only small to medium size DRG 
neurons (20 - 40 µm) were used for recordings. In general, recordings were performed from 
neurons originating from T9-T12 of the spinal cord to ensure the presence of at least a 
proportion of cells with visceral inputs. For some experiments, due to the fact that only 
approximately 10-15 % of the respective DRG neurons are connected to the viscera (Perry & 
Lawson, 1998), visceral DRG neurons were specifically identified by retrograde labelling with 
Fast DiI Oil injected into the muscle wall of the small intestine 10 - 14 days before cell culture. 
When starting with the electrophysiological recordings from DRG cultures, within the 
first 10 DRG preparations, the neurons were tested for the presence of GABAA- and kainate- 
activated currents as a positive control for a viable cell culture expressing two characteristic 
ligand-gated ionotropic receptors normally found on DRG neurons. In addition, (-)-bicuculline 
methiodide (which is more water soluble and stable than the bicuculline base) was used as a 
competitive GABA antagonist, but due to the fact that it has been reported not to be selective 
(Seutin & Johnson, 1999), the non-competitive antagonist picrotoxin was also used to ensure 
selective receptor-mediated effects. UBP 301 served as a potent, kainate receptor-preferring 
antagonist that has been reported to have a 30-fold selectivity for kainate over AMPA receptors 
(More et al., 2003). The concentrations of agonist and antagonist tested were based on 
previously reported values, see table 5.1. 
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Table 5.1: Summary of GABAA and kainate receptor agonists and antagonists tested in patch-clamp 

















GAGA 10 H2O 10 (-)-Bicuculline 10 H2O 10 
GABA 10 H2O 10 Picrotoxin 25 EtOH 10 
Kainate 50 H2O 30 UPB 301 5 DMSO 3 
For the electrophysiological comparison of the NMDA receptor characteristics expressed 
in DRG neurons with those expressed in hippocampal neurons and human NRloll/NR2A 
overexpressing HEK293 cells, currents were activated by 200 µM NMDA. During experiments 
testing the potency of the antagonists, glycine was present as a co-agonist in all solutions, at a 
concentration of 10 µM, regardless of the glycine affinity in the respective cultures. IC50-values 
were subsequently normalized by calculating the equilibrium dissociation constant (Kb; Cheng 
& Prusoff, 1973). This procedure was necessary because glycinea antagonists compete with 
agonist for the same binding site and their IC50 potency therefore depends on the affinity of 
agonist for this binding site as well as the concentration used. 
Since microbial organisms also metabolize glycine, microbial contamination in the 
perfusion system could lead to dramatic alterations of the glycine concentration in the 
extracellular solutions. D-serine is not metabolized so easily and therefore might be preferred as 
co-agonist. For the evaluation of postulated excitatory glycine receptors in the DRGs, however, 
glycine must be used, as D-serine was shown to inhibit glycine-activated currents (Chatterton et 
al., 2002). This functional antagonistic effect of D-serine was very recently explained to be due 
to rapid desensitization (Yao & Mayer, 2006; Awobuluyi et al., 2007). Additionally, there is 
little data available on the levels of D-serine that might be present at such peripheral NMDA 
receptors. 
Glycine was chosen as the standard ligand for most experiments. The possible influence 
of microbial organisms on glycine levels was minimized by using a very clean perfusion 
system. The system was rinsed thoroughly with 0.1 M HCI, followed by H2O, after each 
compound test and tubing systems were often completely exchanged, especially when different 
glycine concentrations where tested. 
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In general agonists/antagonists were applied cumulatively with both decreasing and 
increasing concentrations but in case of high affinity antagonists, only increasing concentrations 
were used (described in Chapter 2.13.1). The cumulative stimulation protocol was chosen to 
ensure a fast determination of concentration dependencies of the test compounds. This was 
especially important for the DRG neurons - due to their less robust properties there was 
substantial risk of the cells not surviving longer perfusion protocols. The use of this cumulative 
stimulation protocol did not allow the evaluation of blocking and unblocking kinetics of 
antagonists, but this aspect was not of interest here. However, preliminary experiments with the 
hippocampal neurons and transfected HEK cells showed very similar EC5o/IC50 determinations 
independent of the kind of stimulation protocol (cumulative vs. kinetic) used. For such kinetic 
protocols, single concentrations of antagonist are applied in the continuing presence of agonist, 
and the control current is taken as the mean of the steady-state current before and after 
antagonist application (Parsons et al., 1999). 
With respect to glycine-sensitive receptor desensitization (the degree of NMDA-receptor 
desensitization is inversely related to the glycine concentration, Parsons et al., 1993a) only the 
plateau (steady state) and not the peak NMDA current responses can be reliably compared 
between cell types, since the degree of glycine-sensitive desensitization induced by the 
antagonists seems to be dependent on their potency (Parsons et al., 1997). Moreover, 
NRloll/NR2A receptors expressed in BEK293 cells did not show glycine-sensitive 
desensitization, an observation confirmed by other groups. As such, extremely lengthy 
antagonist preincubation protocols as described by Parsons et al (1993a) were not used. 
The range of antagonist and partial agonist concentrations tested was selected both on the 
basis of the glycine potencies in the corresponding cultures and in consideration of former data 
generated in superior colliculus or hippocampal neurons (e. g. Parsons et al., 1997). When 
agonist tests were performed with the partial agonists, glycine only served for determination of 
the magnitude of control and recovery currents (table 5.2). 
100 
Table 5.2: Summary of glycineB site NMDA receptor agonists, partial agonists, and antagonists tested in 
patch-clamp experiments in the presence of 200 µM NMDA 
Stock 
Test Cell type in 
sol. Solvent Test solution [µM] Tested as Glycine* [gM] 
compound culture 
IMMI 
DRG 10 H2O 10,3,1,0.3,0.1 Agonist 30 (control) 
Glycine hNRI/NR2A 10 H2O 3,1,0.3,0.1,0.03 Agonist 10 (control) 
HIC 10 H2O 1,0.3,0.1,0.03,0.01 Agonist 3 (control) 
DRG 10 H2O 30 (control), 10,3,1,0.3,0.1 Agonist 0 
D-serene 
hNRI/NR2A 10 H2O 30 (control), 10,3,1,0.3,0.1 Agonist 0 
DRG 10 H2O 30,10,3,1,0.3 Agonist 10 (control) 
hNRI/NR2A 10 H2O 30,10,3,1,0.3 Agonist 10 (control) 
ACPC 
HIC 10 H2O 30,10,3,1,0.3 Agonist 10 (control) 
hNR1/NR2A 10 H2O 1,3,10,30,100 Antagonist 10 
DRG 100 H2O 1000,300,100,30,10 Agonist 10 (control) 
3,10,30,100,300; 
DRG 100 H2O Antagonist 10 
30,100,300,1000,3000 
hNR1/NR2A 100 H2O 1000,300,100,30,10 Agonist 10 (control) 
D-cycloserine 
10,30,100,300,1000; 
hNRI/NR2A 100 H2O Antagonist 10 
30,100,300,1000,3000 
HIC 100 H2O 300,100,30,10,3 Agonist 10 (control) 
HIC 100 H2O 30,100,300,1000,3000 Antagonist 10 
s, 3,10,30,100,300; 
DRG H2O Antagonist 10 
100 30,100,300,1000,3000 
(+R)-HA-966 
hNR1/NR2A 100 H2O 30,100,300,1000,3000 Antagonist 10 
HIC 100 H2O 30,100,300,1000,3000 Antagonist 10 
5ý DMSO 0.01,0.03,0.1,0.3,1; 
DRG Antagonist 10 
10 DMSO 0.03,0.1,0.3,1,3; 
5 7-DCKA , hNR1/NR2A 20 DMSO 0.01,0.03,0.1,0.3,1 Antagonist 10 
HIC 20 DMSO 0.3,1,3,10,30 Antagonist 10 
DRG 4 H2O 0.1,0.3,1,3,10 Antagonist 10 
DRG 4 H2O 0.03,0.1,0.3,1,3 Antagonist 3 
DRG 4 H2O 0.03,0.1,0.3,1,3 Antagonist 1 
MRZ 2/576 
0.1,0.3,1,3,10; 
hNRI/NR2A 4 H2O Antagonist 10 
0.3,1,3,10,30 
HIC 4 H2O 0.3,1,3,10,30 Antagonist 10 
DRG 4 H2O 0.1,0.3,1,3,10 Antagonist 10 




HIC 4 H2O 0.3,1,3,10,30 Antagonist 10 
hNR1/NR2A 4 H2O 0.1,0.3,1,3,10 Antagonist 3 
* glycine as co-agonist was present during the whole cell perfusion, with the exception of the agonist 
test of partial agonists, where glycine was only used for control and recovery currents. The maximal 
concentration of D-serine (30 µM) served as its own control. 
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Previous experiments investigating the solvent effect of DMSO on NMDA activated 
currents clearly demonstrated that the end concentration should not exceed 0.5 % to ensure that 
responses were not affected by DMSO. Due to the fact that most of the glycineB site modulators 
are water soluble, DMSO was only used for UPB 301,5,7-DCKA, and eliprodil. DMSO 
concentrations did not exceed 0.15 %. 
For the single point studies with the NR2B selective antagonists eliprodil and Ro25-6981 
(which have been reported to be about 5000-fold more selective for NR2B subunit-containing 
receptors over those containing NR2A subunits) a concentration of 10 µM was selected, which 
would maximally inhibit currents elicited in purely NR2B subunit-containing NMDA receptors, 
but only have a small, albeit detectable, effect on NR2A subunit-receptors. Studies on cloned 
receptors expressed in Xenopus oocytes generated the following potencies: for Ro25-6981; IC50 
in NR1OO1/NR2B = 0.009 µM, and IC50 in NR1oo1/NR2A = 52 µM (Fischer et al., 1997); and for 
eliprodil; IC50 in NR1021/2B = 3.02 µM, and IC50 in NRI011/2A > 100 µM (Avenet et al., 1997). 
As the effect of NR2B subtype-selective antagonists on NMDA receptors is known to be 
highly dependent on the relative level of NMDA receptor activation (e. g. Kew et al., 1996) it 
was essential to use near saturating agonist concentrations to ensure sufficient receptor 
activation. The standard concentrations of NMDA (200 µM) and glycine (10 µM) were 
sufficient (data not shown, Li et al., 2004). 
Table 5.3: Summary of NMDA receptor agonists, NR2B selective antagonists, and channel blockers 
tested in patch-clamp experiments 
Stock 
Cell type in Glycine 




NMDA DRG 200 ECS agonist 10 
control) 
3,10,30,100,300, (1000 
NMDA hNRI/NR2A 200 ECS agonist 10 
control) 
DRG 10 H2O 10 antagonist 10 
Ro25-6981 
hNRI/NR2A 10 H2O 1,3,10,100 antagonist 10 
Eliprodil DRG 10 DMSO 10 antagonist 10 
HIC 10 H2O 0.3,1,3,10,30 antagonist 10 
Memantine hNRI/NR2A 10 H2O 0.1,0.3,1,3,10 antagonist 10 
DRG 5 H2O 0.1,0.3,1,3,10 antagonist 10 
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For the evaluation of possible `exitatory glycine receptors', DRG neurons were cultured 
in the additional presence of 5,7-DCKA (1 µM, resulting in 95% block of classical NMDA 
receptors in DRG neurons; see figure 5.6) to protect them from possible excitotoxic effects from 
glutamate/glycine in the culture medium. The glycineB antagonist 5,7-DCKA was used in 
addition to the competitive glutamate site antagonist DL-APS (2-Amino-5-phosphonovaleric 
acid) as the latter would have had no effect on `excitatory glycine receptors' that have been 
reported to be activated by glycine alone (Chatterton et al., 2002) and expression of which 
might be influenced by continuous activation by glycine during the culture period. 
5.2.2 Patch-Clamp data analysis 
Despite the relatively long time between control and recovery currents in the case of the 
cumulative NMDA stimulation protocol, current rundown was usually not problematic for 
NMDA receptor patch-clamp recordings from all three cell types (normally less than 10% over 
a 1.5 minute period in the continuous presence of agonist). However, in order to produce the 
most accurate assessment of potency, the analysis of the patch-clamp data was always corrected 
for extrapolated linear current rundown. Antagonism of NMDA receptor-mediated currents was 
measured as the magnitude of the steady-state blocked current as a percentage of the mean of 
the control and recovery current. In antagonist protocols with 5 cumulatively-increasing 
concentrations of antagonist, current rundown was calculated individually for each antagonist 
concentration by a linear projection from the steady-state control and recovery current before 
and after the end of the application of the 5 antagonist concentrations. As a result of this linear 
projection, the rundown correction for the first antagonist concentration was influenced by 85 % 
of the control current (before the first antagonist concentration was applied) and by 15 % of 
recovery current (after application of the last antagonist concentration). For the second 
antagonist concentration, these same currents were then multiplied by 0.7 and 0.3 respectively, 
and so on for all concentrations. The same was true for protocols with decreasing concentrations 
of co-agonist. 
The potency of compounds was in general assessed by plotting the mean percentage 
current magnitude (± SEM) against antagonist concentration, and then a curve was fitted using 
the logistic equation for which the variable parameters IC50 and Hill coefficient were free and 
the range and background values were normally set to 100 and 0 respectively. For partial 
agonists (due to their intrinsic activity) the curve fitting by means of the four-parameter logistic 
equation used open range and background levels (equation 4). For agonists, an open range was 









For normalization of the calculated IC5o values of the tested glycineB antagonists, 
depending on the agonist affinity (EC50) in the test system, the equilibrium dissociation constant 
(Kb) was determined according to the Cheng & Prusofff (1973) equation (5): 
K6 = 
IC50, 
antagonist [5] I+ [agonist] / EC50, 
agonist 
Resulting EC50 values of agonists and Kb values for antagonists (given as mean ± SEM) 
were further analysed statistically to evaluate significant differences between the compound 
potencies in the various cell cultures, either by using a One Way ANOVA corrected by the 
Tukey Test for pairwise multiple comparisons, or were graphically correlated comparing agonist 
and antagonists in the different cell cultures. 
5.2.3 [3HJ-MDL-105,519 binding assay and data analysis 
The binding/displacement assays on the 96-well plate robotic format were performed with 
[3H]-MDL-105,519, a selective and high affinity antagonist for the glycineB site (e. g. Baron et 
at, 1996), as described in chapter 2.14. After determination of the optimal radioligand 
concentrations in saturation experiments, displacement studies were performed with the same 
compounds used for the patch-clamp studies. Stock solutions were prepared likewise, where 20- 
fold concentrated working solutions were prepared in 50 mM Tris-HC1(pH 8.0) containing 10 
% DMSO, resulting a 0.5 % DMSO end concentration in the assay buffer. 
IC5o values, representing the potency of the test compounds to inhibit 50 % of the MDL- 
105,519 binding, were also corrected in accordance to the Cheng & Prusoff (1973) equation (6). 
K_ 
IC50 
[6] '1+ [radiol igand ]/ Kd, radioligand 
The equilibrium dissociation constant K; of an unlabeled competitive inhibitor 
characterizes its affinity to the binding site independent of the radioligand concentration. Kd is 
the equilibrium dissociation constant of the radioligand. 
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5.3 Results 
GABA- and kainate-activated currents were recorded, and acted as positive controls for 
characteristic receptor expression in DRG neurons in vitro. GABA (10 µM)-induced steady 
state currents were antagonized by 10 µM (-)bicuculline down to 5% of the control values and 
to 11 % of control currents by 10 pM of the non-competitive GABAA receptor blocker 
picrotoxin. UBP 301 (3 µM) reduced kainate (30 µM)-activated currents to 48 % of control 
values (data not shown). These data were generally in line with the antagonistic potencies 
published in the literature; see Fabbro & Nistri (2004) for bicuculline and picrotoxin and More 
et al. (2003) for UBP 301. As these recordings only served as positive controls in the first 10 
DRG culture preparations, further experiments targeting GABA or kainate receptors were not 
performed. 
5.3.1 Patch-clamp recordings from NMDA receptors 
DRG neurons connected to the viscera could be identified by retrograde staining with 
Fast DiI Oil. DRG preparations from unstained animals showed no fluorescence. Staining 
selectivity was not quantified, but examination of DRG cultures isolated from T5-T8, T9-12, 
T 13-L2, and L3-L6 clearly showed that the largest proportion of stained cells was present in T9- 
12 (figure 5.1), followed by T13-L2, whereas the number of stained neurons was low in T5-8 
and L3-L6. Time constraints precluded performing further control experiments such as on 
cervical DRGs that are anatomically entirely isolated from connections from the dye injection 
site. 
Retrograde staining of cultured DRG neurons 
Fig. 5.1: Identification of visceral dorsal root ganglia (DRG) neurons after retrograde labelling (red) of' 
the small intestine with Fast Dil Oil (Molecular Probes) 10-14 days before the actual cell 
preparation. The white arrows identify visceral neurons (isolated from T9-T12 DRGs) in the 
phase contrast (A) and fluorescence micrographs (B). Scale bar = 50 µm. 
105 
Differences in NMDA receptor characteristics were not observed between DRG neurons 
innervating the small intestine vs. randomly selected (visceral and somatic) neurons with respect 
to the average currents and potency of glycineB site agonists/antagonists, respectively, although 
the data set was limited. Due to the fact that the majority of retrogradely labelled neurons did 
not seal properly, only -10 visceral neurons were patched successfully in the overall staining 
experiments compared to -80 randomly selected unstained neurons. Further evaluation of 
possible differences between NMDA receptors functionally expressed in visceral vs. somatic 
neurons was not pursued because Li et al. (2004) have clearly demonstrated that NMDA 
receptor characteristics (NMDA and glycine stimulated average currents, current density, 
capacitance, current kinetics, and sensitivity to ifenprodil) of colon-specific neurons 
(retrogradely labelled by fluorescently tagged cholera toxin B) were not significantly different 
from neurons randomly selected from unstained cell cultures. All the following results are 
therefore based on randomly selected/unstained DRG neurons. 
NMDA receptors require both glutamate/NMDA and glycine for channel opening. 
Concentration-dependent receptor activation by NMDA was first tested in the presence of 10 
pM glycine under the standard conditions (- 70 mV, Mg2+-free) resulting in an EC5o for NMDA 
of 40.9 ± 5.4 µM with a maximal activation at approximately 1000 µM (data not shown). All 
patch-clamp results targeting the NMDA receptor are summarized in table 5.3 at the end of the 
results section of this chapter. 
Based on these results, 200 pM NMDA (around EC30, Parsons et al. 1993b) was used for 
further experiments investigating the potencies of glycineB site modulators. Ascending glycine 
concentrations ranging from 0.1 - 10 gM in DRG neurons revealed an approximately 
10-fold 
lower affinity in this type of cell culture (EC5o = 3.96 ± 0.93 µM) in comparison to the 
hippocampal neurons (HIC, EC50 = 0.34 ± 0.10 µM). The glycine affinity to its NMDA receptor 
binding site in hNR1/2A BEK293 cells was more similar to that in DRG neurons (ECS0 = 2.37 ± 
0.22 µM); see figure 5.2. The same range and relative values of agonist affinity was seen for D- 
serine, giving EC50s of 4.43 ± 0.35 pM for DRG neurons, 0.48 ± 0.06 µM for hippocampal 
neurons, and 2.32 ± 0,24 µM for the transfected HEK293 cells (data not shown). 
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Potency of co-agonist glycine on NMDA activated currents 
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Fig. 5.2: Concentration-dependence of the (steady-state) NMDA receptor activation (200 pM NMDA, 
-70 mV) by glycine using DRG neurons (open circles) in comparison to hippocampal 
neurons (HIC, open diamonds) and human NRloll/NR2A stably expressing HEK293 cells 
(open squares). Merged traces of several recordings are shown for each cell type. Within this 
`cumulative' compound application protocol, the agonist NMDA (200 µM) and co-agonist 
glycine, at the highest concentration tested, are applied first, followed by 5 sequentially 
decreasing concentrations of glycine (illustrated by the decreasing bar thickness given below 
the test concentrations) during constant application of NMDA, resulting in stepwise reduced 
currents. For recovery glycine is again switched to the highest concentration. Note that the 
current scale bars are different for each cell culture. Mean rundown-corrected percentage of 
current activation (± SEM) was plotted against agonist concentration on a logarithmic scale. 
Estimation of EC50 values and curve fitting were made according to the four-parameter 
logistic equation. Where SEM error bars are not visible they are smaller than the symbols. 
Note that these conditions apply to subsequent figures unless stated otherwise. 
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As a consequence of the different agonist affinities, the potencies of the Merz pyrido- 
phthalazine-diones MRZ 2/576 and MRZ 2/596 to antagonize steady-state inward current 
responses to NMDA (200 µM) and 10 gM glycine were respectively ten times higher in DRG 
neurons and hNR1/NR2A expressing cells than in cultured rat hippocampal neurons. IC50 values 
for MRZ 2/576 were 0.41 ± 0.03 µM, 0.57 ± 0.05 µM, and 3.02 ± 0.43 µM for DRG neurons, 
hNRlOOl/NR2A HEK cells and hippocapmpal neurons, respectively, and for MRZ 2/596 were 
1.08 ± 0.10 µM, 1.06 ± 0.13 µM, and 9.82 ± 1.06 µM, respectively (see figures 5.3 and 5.4). 
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Fig. 5.3: Concentration-dependence of the (steady-state) NMDA receptor blockade (200 µM NMDA, 
10 µM glycine, -70 mV) by MRZ 2/576 on the 3 cell types tested. The layout is as for Fig 
5.2, but antagonists are being tested here. The agonist NMDA (200 µM) and glycine (10 µM) 
are applied, then 5 concentrations of antagonist are sequentially coapplied (here in increasing 
concentrations, resulting in stepwise decreasing currents) before the antagonist is removed 
and current is allowed to recover. Mean rundown-corrected percentage blockade of NMDA 
induced currents (± SEM) was plotted against antagonist concentration on a logarithmic 
scale. 
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Antagonistic potency of MRZ 2/596 on NMDA activated currents 
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Fig. 5.4: As for figure 5.3 but with MRZ 2/596. 
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The glycine dependency of the glycineB site antagonists became even more obvious when 
dose response curves (DRC) of MRZ 2/576 were performed with different glycine 
concentrations, showing a clear parallel rightward shift of the DRC with increasing glycine 
concentration (figure 5.5). The MRZ 2/576 ICso values were correspondingly increased (1 pM 
glycine: 0.084 ± 0.004 µM; 3 µM glycine: 0.180 ± 0.011 µM; 10 µM glycine: 0.412 ± 0.031 
µM) whereas the Kb values (0.067 ± 0.003 µM, 0.102 ± 0.006 µM, and 0.117 ± 0.009 µM, 
respectively) remained more or less constant. One way ANOVA revealed a significant 
difference between these values (p < 0.01). However, post-hoc pairwise comparisons with the 
Tukey Test revealed no difference between 3 and 10 µM (p = 0.455). This apparent discrepancy 
might be explained by errors in the analysis due to the small currents induced by I µM glycine 
(figure 5.5). Additionally, the glycine dependency of MRZ 2/576 found in the DRG neurons is 
perfectly in line (considering the I 0-fold difference in agonist affinity) with results published by 
Parsons et al. (1997) using hippocampal neurons and MRZ 2/502 (the free base form of MRZ 
2/576) in the presence of 1,3 and 10 µM glycine (IC50: 0.28 ± 0.03,1.06 ± 0.09 and 3.08 ± 0.14 
µM, respectively corresponding to Kb values of 0.080 ± 0.018,0.124 ± 0.029 and 0.118 ± 0.248 
µM, respectively). 
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Glycine dependency of MRZ 2/576 antagonistic potency 
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Fig. 5.5: Increasing glycine concentrations (upward triangle: 1 µM, downward triangle: 3 µM, and 
circle: 10 µM) reduce the antagonistic potency of MRZ 2/576 on steady-state NMDA (200 
µM, - 70 mV)-induced currents in DRG neurons. Estimation of IC50 values and curve fitting 
were made according to the four-parameter logistic equation (range and background values 
were set to 100 and 0 respectively). 
When normalizing the antagonistic potencies of MRZ 2/576 and MRZ 2/596 according to 
the Cheng-Prussoff relationship, the resulting Kb values were similar for all tested cultures. The 
mean Kb values of MRZ 2/576 among the three different cultures were not statistically 
significant different (p = 0.508, One way ANOVA). In the case of MRZ 2/596 the One way 
ANOVA identified a just significant difference in the Kb values (p = 0.049), but the Tukey Test 
(a more conservative pairwise multiple comparison procedure) resulted in p>0.05 for all 
comparisons. 
Despite the fact that 5,7-DCKA works as a full antagonist at the glycine binding site, the 
difference in the antagonistic potency was even higher (at least 20-fold) than for the MRZ 
compounds when comparing DRG neurons (IC50 = 0.080 ± 0.006 PM) and recombinant 
hNRI/NR2A receptors (ICso = 0.094 ± 0.008 µM) vs. hippocampal neurons (IC50 = 2.137 ± 
0.180 µM), see figure 5.6. This difference is higher than would have been predicted based on 
the difference in agonist affinity but is supported by the significantly different Kb values (p < 
0.001) of the DRG neurons (0.023 ± 0.002 µM) and transfected HEK cells (0.018 ± 0.002 µM) 
compared to those calculated for hippocampal neurons (0.070 ± 0.006 µM). 
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Antagonistic potency of 5,7DCKA on NMDA activated currents 
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Fig. 5.6: As for figure 5.3 but with 5,7-DCKA. 
hNRI/2A HEK: 5,7DCKA 
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Partial agonists were tested as agonists and antagonists, depending on their intrinsic 
activity. In the nominal absence of glycine, D-cycloserine potentiated NMDA responses. 
Similarly to glycine, it showed a relatively high (although not 10-fold) difference between DRG 
neurons (EC5o = 19.8 ± 1.3 µM) and hNR1/NR2A recombinant HEK293 cells (EC5o = 32.5 ± 
5.7 µM) vs. hippocampal neurones (EC50 = 4.48 ± 0.42 µM). The maximum degree of 
activation by D-cycloserine (compared to glycine which was used as a control) was 30.8,42.4 
and 39.2 %, respectively. The antagonistic effect of D-cycloserine in reducing responses down 
to these levels of intrinsic activity revealed rather similar ICso values for DRG, HEK293 and 
hippocampal cells, namely 136 ± 14,128 ± 17, and 178 ± 12 µM, respectively (figure 5.7). 
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Fig. 5.7: Concentration-dependent effects of the partial glycineB site agonist D-cycloserine on steady- 
state NMDA-induced inward current responses (200 1. M NMDA, -70 mV) of DRG neurons 
(circles) in comparison to hippocampal neurons (HIC, diamonds) and human NRloll/NR2A 
stably-expressing HEK293 cells (squares), tested as an agonist (open symbols) in the nominal 
absence of glycine, and as an antagonist in the continuous presence of 10 gM glycine (filled 
symbols). On the left side, merged traces for all three cell types are shown, when the partial 
agonist D-cycloserine was tested as an antagonist (see figure 5.3). Since D-cycloserine shows 
a low affinity, either increasing or decreasing concentrations could be used. The traces on the 
right are representative for the evaluation of the intrinsic activity of D-cycloserine in 
comparison to glycine. The agonist NMDA (200 µM) and co-agonist glycine (10 µM) are 
applied, but then 5 decreasing concentrations of partial agonist D-cycloserine are sequentially 
co-applied in the absence of glycine before D-cycloserine is removed for current recovery in 
the presence of glycine. The maximal antagonistic effect of D-cycloserine is therefore limited 
by its intrinsic activity. Estimation of ECso/IC50 values and curve fitting were made according 
to the four-parameter logistic equation (range and background values were based on the 
intrinsic activity). 
1-Aminocyclopropanecaboxylic acid (ACPC) showed a very high agonistic potential in 
all three cell cultures, with intrinsic activities of 77.3,72.7, and 76.4 % in DRGs, HEKs, and 
HIC, respectively; EC5o values were 2.56 ± 0.17,1.55 ± 0.12, and 1.23 ± 0.20 µM, respectively. 
As a result of this, there was only a relatively small range on which to test potential antagonist 
effects, which were therefore only tested in the hNR1/NR2A expressing HEKs (in the presence 
of 10 pM glycine) because these cells generally showed the largest NMDA-induced currents. 
The IC50 value obtained was 8.73 ± 1.64 µM. 
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Effect of partial agonist ACPC on NMDA activated currents 
DRG: ACPC 
30 10 310.3 pM 
0 
Gycine 10 pM 





(merge of 3 traces) 
HIC: ACPC 
30 10 310.3 pM 
Gycine 10 pM 
NMDA 200 uM 
80 On = 5, EC5o = 1.52 NM 0 
Intrinsic activity: 72.7% 
 n 3, ICso   8.73 NM 
60 
Z 40 O DRG; 
n 6, ECso = 2.56 NM 
C 20 Intrinsic activity: 77.3% 
C OHIC: 
n 5, ECso   1.23 uM 
p Intrinsic activity: 76.4% 
0.1 1 10 100 
ACPC concentration [pM] 
hNR9/2A HEK: ACPC 
0.3 13 10 30 iM 
0 
_ 
Gycine 10 IN 
NMDA 200 uM 
500 pA 
25 sec 
(merge of 5 traces) 
Fig. 5.8: As for figure 5.7 but with ACPC. 
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In contrast to the expected partial agonist properties (e. g. shown by Karcz-Kubicha et al., 
1997) (+R)-HA966 acted as a full antagonist in DRG neurons and hNR1/NR2A cells, with IC5o 
values of 128 ±9 and 219 ± 13 µM. In hippocampal neurons (+R)-HA966 showed a low 
intrinsic activity of 7.0% and IC50 of 218 ± 17 µM (figure 5.9). 
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Effect of partial agonist (+R)-HA966 on NMDA activated currents 
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Fig. 5.9: As for figure 5.8 but with (+R)-HA966 (only tested as antagonist). 
In summary, the measured EC50s of agonists and partial agonists, as well as the Kb values 
of the tested glycineB site antagonists in the DRG neurons, correlated very well with those of the 
stably hNRloll/NR2A transfected HEK293 cells. This is not only particularly apparent from the 
excellent correlation coefficient of 0.99 but also the slope of one and an intercept of very near 
zero, when the respective pEC5o/pKb-values (p = log10 in molar) were compared (figure 5.10). 
Comparing the antagonist/partial agonist pKb results from the DRG neurons with those from 
hippocampal neurons (using data with 5 compounds), a good correlation coefficient of 0.99 was 
also obtained. 
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Fig. 5.10: 
Correlation diagram, comparing the pECso 
and pKb values of glycine8 site agonists, 
partial agonists, and antagonists found in 
DRG neurons with those measured in human 
NR1011/NR2A expressing HEK293 cells 
(linear regression equation: intercept 0.03 ± 
0.31, gradient 1.03 ± 0.05, correlation 0.99). 
D-cycloserine was tested as an agonist and an 
antagonist. 
Despite the clear differences in the potency of these compounds between DRG neurons 
and hNRI/NR2A HEK293 cells vs. hippocampal neurons, no differences in potency of the 
channel blocker memantine were observed between the various tested cell tines. 
NMDA/glycine-activated currents were inhibited by memantine with a similar, statistically non- 
significant different IC50s (p = 0.597) in DRG neurons (0.78 ± 0.06 µM), hNR1/NR2A 
expressing HEK293 cells (0.76 ± 0.08 µM) and hippocampal neurons (0.85 ± 0.06 µM). See 
figure 5.11. 
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Fig. 5.11: Data for the uncompetitive NMDA channel blocker memantine. Layout as for figure 5.3 
In pilot experiments, the NR2B selective antagonists Ro25-6981 and eliprodil were in 
effect not active in DRGs and hNR1/NR2A HEK293 cells. Nanomolar potencies are to be 
expected for NR2B containing NMDA receptors (Fischer et al., 1997), but reduction of NMDA- 
induced currents in DRG cells only occurred with 10 pM Ro25-6981 and then only to 91.5 ± 1.4 
% of control currents (n=3). For recombinant receptors, a similar low level of block, to 87.7 ± 
2.4 % (n=3), was seen with 10 µM Ro25-6981. A concentration of 100 µM was more effective 
in reducing NMDA responses (to 44.18 ± 2.14 % of control values; n=4) but this is a very high, 
non-selective concentration of the antagonist, see figure 5.12. Eliprodil (10 µM) was as weak as 
Ro25-6981 (91.5 ± 8.8 % of control currents, n= 2) in DRG neurons (data not shown). 
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Fig. 5.12: The minimal antagonist effects of the NR2B-selective antagonist Ro25-6981 in DRG neurons 
(left; 10 µM) and human NR1o11/NR2A HEK293 cells (right; 10 and 100 µM) in the 
continuous presence of 200 pM NMDA and 10 pM glycine. 
Beside the functional assessment of the potency of the glycineB site modulators on the 
three different cell types in culture, the affinity of these compounds to the binding pocket per se 
were also investigated. In Scatchard analysis [3H]-MDL-105,519 had a Kd of 7.32 ± 1.16 nM 
and a B,, of 1.95 ± 0.12 pmol/mg protein (n = 4, figure 5.13). 
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In the subsequent displacement studies, 2 nM [3H]-MDL-105,519 was used so as to save 
on radioligand, even though 5 nM might have been better considering the Scatchard analysis, to 
gain a better readout and a better bound/non specific binding ratio. In these studies, non-specific 
binding (determined with 1 mM glycine) was in general only 15-20 %, and standard compounds 
displaced binding to non-specific levels with potencies similar to the literature, and with Hill 
coefficients close to unity. ICso values were corrected according to the Cheng-Prussoff 
relationship for 2nM [3H]-MDL-105,519 (see figure 5.14 for representative dose response 
curves and table 5.4 for summary). 
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Fig. 5.14: Representative binding experiments showing the concentration-dependent displacement of 
[3H]-MDL-105,519 binding to rat cortical membranes by (left graph) glycineB agonists 
(white symbols), partial agonists (grey symbols) and (right graph) antagonists (black 
symbols). Displacement experiments were performed as described in Chapter 2.14. 
Nonspecific binding (15-20 %) was detected by the addition of unlabeled glycine (1 mM). 
The displacement efficiency was assessed in quadruplicates per assay and plotted as the 
percentage of specific binding against the compound concentration. Estimation of IC50 values 
and curve fitting were performed according to the four-parameter logistic equation. 
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Table 5.4: Summary of patch-clamp and binding results targeting the NMDA receptor in DRG neurons 
(DRG), stably hNRloll/NR2A expressing HEK 293 cells (hNRI/NR2A), hippocampal 
neurons (HIC) and cortical membranes (Cort. mem. ). 










mean SEM mean SEM mean SEM 
NMDA 
PC / agonist DRG 40.9 5.3 1.22 0.13 
PC / agonist hNR1/NR2A 23.5 1.9 1.45 0.11 
PC / agonist DRG 3.96 0.93 1.26 0.18 
Glycine PC / agonist hNR1/NR2A 2.37 0.22 1.08 
0.05 
PC / agonist HIC 0.34 0.10 0.78 0.08 
Binding Cort. mem. 0.39 0.02 0.67 0.08 0.31 0.01 
PC / agonist DRG 4.43 0.35 0.98 0.03 
D-serine PC / agonist hNR1/ NR2A 2.32 0.24 1.32 
0.11 
PC / agonist HIC 0.48 0.06 0.86 0.09 
Binding Cort. mem. 0.34 0.09 0.70 0.03 0.27 0.07 
PC / antagonist DRG 0.080 0.006 0.94 0.06 0.023 0.002 
5 7DCKA PC 
/ antagonist hNRI/NR2A 0.094 0.008 0.88 0.05 0.018 0.002 
, PC / antagonist HIC 2.14 0.18 1.02 0.05 0.070 0.006 
Binding Cort. mem. 0.087 0.015 0.67 0.07 0.068 0.011 
PC / antagonist DRG 0.41 0.03 1.06 0.06 0.12 0.01 
MRZ2/576 PC / antagonist hNR1/NR2A 0.57 
0.05 1.16 0.11 0.11 0.01 
PC / antagonist HIC 3.02 0.43 1.00 0.13 0.10 0.01 
Binding Cort. mem. 0.32 0.00 0.84 0.08 0.25 0.00 
PC / antagonist DRG 1.08 0.10 0.93 0.08 0.31 0.03 
MRZ2/596 PC / antagonist hNRI/NR2A 1.06 
0.13 1.21 0.13 0.20 0.03 
PC / antagonist HIC 9.82 1.06 0.90 0.08 0.32 0.04 
Binding Cort. mem. 0.39 0.08 0.86 0.12 0.31 0.06 
PC / agonist DRG 2.56 0.17 1.38 0.06 77.3 
PC / agonist hNR1/NR2A 1.55 0.12 1.72 0.18 72.7 
ACPC PC / antagonist hNR1/NR2A 8.73 1.64 0.93 0.20 1.67 0.31 72.7 
PC / agonist HIC 1.23 0.20 1.03 0.14 76.4 
Binding Cort. mem. 0.23 0.08 0.89 0.30 0.18 0.07 
PC / antagonist DRG 128 8 1.08 0.08 36.3 2.47 0.00 
+R)- PC / antagonist hNR1/NR2A 218 13 0.94 0.04 41.9 2.50 0.00 
966 PC / antagonist HIC 218 17 0.91 0.05 7.10 0.54 6.95 
Binding Cort. mem. 6.01 1.07 0.71 0.10 4.72 0.84 
PC / agonist DRG 19.8 1.4 1.48 0.14 30.8 
PC / antagonist DRG 136 14 1.28 0.15 38.53 4.09 30.8 
D- PC / agonist hNR1/NR2A 32.5 5.7 1.03 0.10 
42.4 
cycloserine 
PC / antagonist hNR1/NR2A 128 17 1.20 0.23 24.42 3.34 42.4 
PC / agonist HIC 4.48 0.42 1.10 0.14 39.2 
PC /antagonist HIC 178 12 0.93 0.05 5.81 0.4 39.2 
Binding Cort. mem. 3.85 1.76 0.59 0.03 3.02 1.38 
PC / antagonist DRG 0.78 0.06 0.84 0.05 
Memantine FE-/ antagonist hNRI/NR2A 0.76 0.08 0.91 0.06 
PC / antagonist HIC 0.85 0.06 0.81 0.05 
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Comparing the binding affinities of the glycineB modulators found in the [3H]-MDL- 
105,519 displacement studies (pK; ) with their functional potency on NMDA receptors of 
hippocampal neurons (pKb) showed a very good correlation coefficient of 0.98 (see figure 5.15). 











-+- Log potency Correlation diagram, comparing the 
(+R)-HA-966 
pEC50 and pK, /pK; values, respectively, 
D-cycloserine 
of glycine3 site agonists, partial agonists, 
and antagonists. EC50 values were 
determined in patch-clamp experiments 





Correlation coefficient: 0.975 
-7 -6 -5 
Patch-clamp pEC5o/pKb [M] in HIC 
using hippocampal neurons; binding 
affinity was measured by [3H]-MDL- 
105,519 displacement studies in rat 
cortical neurons. Linear regression 
equation: intercept -1.07 ± 0.49, gradient 
0.84 ± 0.08, correlation 0.98. 
`Excitatory glycine receptors' could not be identified electrophysiologically under 
standard patch-clamp conditions using application of glycine (30 µM) alone for 5s every 30 s 
(data not shown). This glycine concentration was shown to induce maximal currents in 
NR1/NR3A and NR1/NR3B expressing Xenopus oocytes (Chatterton et al., 2002). Another set 
of experiments, in the absence of (-)bicuculline methiodide (which was generally present during 
all recordings from NMDA receptors of DRG neurons), was performed due to the possibility 
that this GABAA antagonist might have also blocked excitatory glycine receptors - this 
compound is known to affect several receptors (Seutin & Johnson, 1999). These experiments 
also could not detect excitatory glycine receptors. 
5.4 Discussion 
Taken together, the data presented in this chapter have led to the hypothesis that the 
higher potency of glycineB antagonists found in in vivo models of visceral pain can be 
accounted for by a lower glycineB site agonist affinity due to a predominant functional 
expression of NR2A containing NMDA receptors in DRG neurons. Agonistic and antagonistic 
potencies of the glycineB site modulators in recordings from hNRI/NR2A transfected HEK293 
cells support this hypothesis, with very similar potencies for all compounds tested on these two 
cell types. 
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When comparing the patch-clamp data generated with cultured hippocampal neurons and 
the binding results from adult cortical membranes, it is important to mention that, despite the 
fact that the level of NR2A expression increases in these brain regions during development, 
NR2B levels are comparable in the two regions in adult animals (e. g. Wenzel et al., 1997; Kew 
et al., 1998; Di Luca et al., 1999). These developmental changes in expression levels are also 
seen in in vitro cultures. In primary neuronal cultures of day 17 embryonic rat forebrains, NR2B 
mRNA levels were found to increase dramatically during the first 10 days and then plateaued 
out over subsequent days in culture, whereas NR2A levels increased progressively with time (at 
least up to 21 days in culture), but never reached the mRNA level of NR2B (Cheng et al., 
1999). The increase of NR2A with time and the constant NR2B plateau levels after an initial 
increase are reported consistently throughout the literature, but the ratio of NR2A and NR2B 
after approximately 2 weeks in vitro (and later) is controversial. For instance, recent findings on 
the protein level of hippocampal neurons suggested that NR2A is the dominant NR2 subunit 
after 2 weeks in culture (Brewer et al., 2007). Different neuronal cell types, preparation, and 
culture conditions might explain the discrepancies between studies, but in summary, it can be 
concluded that the hippocampal neurons used in the PhD project contained a sufficient 
population of NR2B subunits to explain the higher glycine affinity. Data published by Sinor et 
al. (2000) with cortical neurons support the hypothesis that NRI/NR2B receptors remain 
important in mature cultures of cortical neurons. Unfortunately, no molecular biological 
characterization data of these cell lines was available or evaluated during the PhD project. 
The hypothesis of the 10-fold difference in agonist affinity being dependent on the NR2A 
vs. NR2B subunit expression is perfectly in line with the results of Kutsuwada et al. (1992). 
They demonstrated NR2 subunit-dependent glycine EC50-values, as expressed in Xenopus 
oocytes (NR1/NR2A = 2.1 µM, NR1/NR2B = 0.3 µM). This approximately 10-fold difference 
in affinity parallels data in the same expression system showing the dependence of glycine 
EC50-values on subunit composition: NR1011/NR2A = 2.24, NR1o11/NR2B = 0.43, 
NRloll/NR2C = 0.11, and NRloll/NR2D = 0.05 pM (unpublished internal Merz 
Pharmaceuticals report from P. Spielmanns). Additionally, Priestley et al. (1995) evaluated the 
pharmacological properties of human NRloll/NR2A stably expressing mouse fibroblast cells in 
comparison to those expressing NRloll/NR2B NMDA receptors. Here, glycine also had a 10- 
fold higher affinity for the NR2B subunit-containing receptors than in the cells expressing 
NR1/NR2A NMDA receptors. Furthermore Kew et al. (1998) clearly showed the connection 
between reduced glycine affinity and increase of NR2A expression during ontogeny in cortical 
neurons. 
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As a consequence of the 10-fold lower glycine affinity at NMDA receptors containing the 
NR2A but not the NR2B subunits, the glycine site antagonists (e. g. MRZ 2/576 and MRZ 
2/596) are respectively more potent, which parallels nicely with antagonistic potencies reported 
for the glycine site antagonists 7-Cl-kynurenate and L-689,560 (both of which are highly 
potent) in NR1 ol1/NR2A vs. NR10l l/NR2B recombinant receptors in Xenopus oocytes (Avenet 
et al., 1997). The slightly lower potency of MRZ 2/596 vs. MRZ 2/576 in antagonising 
NMDA/glycine induced currents is in line with the differences in their anti-allodynic effect in 
LPS-induced visceral pain (see Appendix I). 
5,7-DCKA also showed a similar potency between DRG neurons and hNRI/NR2A 
HEK293 cells, but compared to MRZ 2/576 and MRZ 2/596, the difference in potency at 
hippocampal neurons was even greater. This increased selectivity of 5,7-DCKA in DRG 
neurons and transfected HEK293 cells might be explained by the reported dependency of 5,7- 
DCKA binding on the glycosylation status of NR1 subunits (Kawamoto et at, 1995), since a 
higher glycosylation rate was postulated for DRG neurons, based on the findings discussed in 
chapter 4. 
The NR1 subunit contains 10 potential N-glycosylation sites, whereas only three of the 
asparagin (Asn) glycosylation sites are situated at the ligand binding domain (Asn 440, Asn 
471, and Asn 491). With the help of the NR1 crystal structure, it might therefore be postulated 
that Asn 491 can directly interact with the agonist/antagonist binding and might be especially 
beneficial for the small molecules like 5,7-DCKA (MW 258.06 g/mol) in contrast the other, 
normally larger, glycineB site antagonists. 
For the uncompetitive NMDA receptor antagonist memantine, which functions as an 
open channel blocker, the potency was (relatively) independent of the cell type used and the 
IC5o values were very similar (p = 0.597). These results are perfectly in line with previous 
studies in which memantine showed the same potency at NRloll/NR2A and NR1011/NR2B 
recombinant rat NMDA receptors in HEK293 cells (ICso = 0.93 ± 0.15 and 0.82 ± 0.12 µM; 
Bresink et at, 1996) as well as in Xenopus oocytes (Avenet et al., 1997). Memantine is more 
potent at NR2C or 2D containing receptors (Bresink et al., 1996; Parsons et at, 1999), but these 
do not seem to be relevant for the present studies, since NR1/N2C and NR1/N2D NMDA 
receptors are expected to show even higher affinity for glycine. 
Apart from the conclusive results for the glycine site full agonists and antagonists (as well 
as for the channel blockers) the observations regarding the partial agonists suggest a more 
complex structure-activity relationship in addition to the influence of the NR2 subunit on the 
affinity of the co-agonist glycine to the binding site. 
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The data found with the partial agonists are more challenging to interpret since the 
differences in potencies between the cell types were not as large as for the agonists and 
antagonists. Additionally, possible differences in their intrinsic activities have to be considered. 
The ECso values for D-cycloserine measured in the present patch-clamp experiments (DRG: 
19.8 µM, hippocampal neurons: 4.5 µM, and hNRloll/NR2A HEK293 cells: 32.5 µM) gave a 
potency ratio of 4-8 between HIC and DRG or HEK cells. Recordings from recombinant 
NMDA receptors expressed in oocytes (Dravid & Traynelis, 2005) produced NR2 subunit 
dependent EC50 values of D-cycloserine. NR1011/NR2A containing receptors were activated by 
D-cycloserine with an EC50 of 17.0 µM whereas for NRloll/NR2B a lower EC50 of 6.6 pM was 
detected, a 3-fold difference. Previously reported values from this laboratory, using superior 
colliculus neurons, yielded an EC50 of 9.8 µM (Karcz-Kubicha et al., 1997), slightly greater 
than the current HIC value of 4.5 M. These results with D-cycloserine on different cell types 
therefore provide further support for the hypothesis that it is the predominance of NR2A 
subunits that defines the NMDA receptor pharmacology of DRG neurons, whereas more 
predominant expression of NR2B subunits defines the pharmacology of CNS neurons. 
Different values of intrinsic activities have been reported in the literature for D- 
cycloserine. These might also be NR2 subunit or alternatively NR1 splice variant, or even pH- 
dependent (Sheinin et al., 2001). For instance, Karcz-Kubicha et al. (1997) found an intrinsic 
activity of 57 % in superior colliculus neurons, whereas Priestley & Kemp (1994) reported a 
maximal activation of 86 % in cortical neurons. At a neutral pH (7.2), the efficiency of 1 mM 
D-cycloserine (relative to 10 pM glycine) was similar (approx. 30%) in recombinant 
NRloil/NR2A and NR1o11/NR2B containing NMDA receptors expressed in Xenopus oocytes 
(Sheinin et al., 2001). The latter data are in line with the present results which showed only very 
minor differences in the intrinsic activities between the cell types, albeit that the absolute 
potencies found here did not closely match those reported in the literature. 
Interestingly, ACPC also showed no significant differences in intrinsic activity (p = 
0.340) between the tested cell types, although according to previously published data, a lower 
efficiency would have been expected with NR1/NR2A; for instance Sheinin et al., 2002 found a 
maximal efficacy of 56.6 % for the NRloll/NR2A subunit combinations which was lower 
compared to the intrinsic activities reported for NRloll/NR2B and NRlol1/NR2C receptors (84.7 
and 79.8 %). This could be explained by additional effects of higher concentrations of ACPC at 
the glutamate binding site (Karcz-Kubicha et al., 1997; Nahum-Levy et al., 1999). In the current 
experiments, the competitive antagonist site of ACPC at the glutamate binding site was not 
observed, perhaps because the maximal ACPC concentration (100 PM) was too low to compete 
with 200 pM NMDA, this is in line with the data of Inanobe et al. (2005). The calculated EC5o 
of 1.52 ± 0.12 µM for ACPC in hNR1/NR2A expressing HEK cells is perfectly in line with the 
results published by Awobuluyi et al. (2007) obtained from oocytes expressing NR1/NR2A 
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(EC50 = 1.30 ± 0.07 µM), but also parallel the hippocampal data (EC50 = 1.23 ± 0.20 µM) 
suggesting that the ACPC potency is independent of which NR2 subunit is present in the 
NMDA receptor. 
Concerning (+R)-HA966, the antagonist potency seen here (IC50 = 217.7 ± 16.6 µM, 
intrinsic activity = 7.0 %) agrees very well with previous data on superior colliculus neurons 
(IC50 = 276 ± 24 AM; intrinsic activity = 13.3%; Karcz-Kubicha et al. (1997)). Interestingly 
(+R)-HA-966 worked as a full antagonist in the DRG neurons (IC50 = 128.0 ± 8.7 AM). This 
parallels the complete block of glutamate-evoked contractions (ICso = 165 AM) of guinea pig 
ileum longitudinal muscle myenteric plexus (LMMP) preparations (Campbell et al., 1991). 
Similarly, (+R)HA-966 worked as a full antagonist in the hNRl/NR2A expressing HEK cells 
used here. All these data support a special pharmacology of peripheral NMDA receptors related 
to the expression of NR2A subunits. 
However, the hypothesis of predominant functional expression of NR2A subunits in DRG 
neurons is in clear contrast to the results reported by McRoberts, Mayer and colleagues (e. g. 
Marvizon et al., 2002) who postulated that NR2B was the major NR2 subtype. In addition to the 
discussion in chapter 4.4, the electrophysiological results published by this group (Li et al., 
2004) might also be interpreted differently. 
On the basis of the glycine affinities found in the present experiments, the published 
glycine EC50 of 1.86 µM (95% CI: 1.40-2.46 µM) in the presence of 250 gM NMDA (Li et al., 
2004) are more in line with the EC50 values found in the hNR1/NR2A HEK293 (EC50 = 2.37 ± 
0.22 µM) and the DRG neurons (EC50 = 3.96 ± 0.93 µM) than NR2B subunit-containing 
NMDA receptors. Additionally, the ICS0 of the NR2B selective antagonist ifenprodil (2.57 µM, 
Cl: 2.04-3.24 µM) suggests that the DRG neurons tested by Li et al (2004) did not express a 
large population of NR1/NR2B containing receptors, as nanomolar potency would have been 
expected for NR2B containing receptors (Kew et al., 1998; Kiss et al., 2005). This lower 
potency was explained by the authors by a higher glycosylation status of the NMDA subunits, 
as reported previously by the same research group (Marvizon et al., 2002). Due to the fact that 
higher apparent molecular weight bands were also found in the present experiments in tests of 
the NMDA receptor expression levels in DRG (chapter 4.3.2) this does not explain the 
discrepancy. 
Comparing the present DRG preparation and cultivation protocols with the methods 
described by the research group of McRoberts and Mayer, differences were identified which 
might explain the differing results and NMDA receptor properties (subunit compositions), 
respectively. Within this PhD project, DRG neurons were maintained under serum free 
conditions using Neurobasal A medium (In Vitrogen) supplemented with B27 (In Vitrogen), 
since B27 supplementation is generally known to reduce glial growth (Brewer et al., 1993). In 
contrast, the corresponding DRG in vitro cultures described in the cited literature (Ennes et al., 
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1997; McRoberts et al., 2001; Li et al., 2004 and 2006) were cultivated in DMEM 
supplemented with 10 % foetal bovine serum, 10 % horse serum, and 5 ng/ml nerve growth 
factor (NGF). 
The presence of NGF in particular might influence NMDA receptor composition I 
function. For example, NGF, which itself induces peripheral inflammatory states, was shown to 
lead to an up-regulation of BDNF (Kerr et al., 1999), which might then influence NMDA 
receptor expression (Small et al., 1998). NGF might also control NMDA expression itself by 
up-regulating the NMDARI promotor (Bai & Kusiak, 1997). Additionally, NGF and BDNF 
phosphorylate NR2A and 2B subunits (Di Luca et al., 2001), and BDNF was also shown to 
induce phosphorylation of NR1 (Suen et al., 1997). 
However, the NGF concentration used in the McRoberts studies might have been too low 
to induce such a signalling cascade. If BDNF expression were induced by NGF, BDNF would 
rather have increased the NR2A subunit expression (Small et al., 1998) and this cannot 
therefore be taken to explain differences in the present results and those reported by Li et al. 
(2004). 
As already mentioned in the previous chapter (4.4), the age of the animals might also be 
crucial. The present results are based on DRG neurons isolated from young rats (5 weeks old), 
whereas the data from the above mentioned groups were generally derived from older (adult) 
animals, the age of which varied between the publications (200-3 50 g, McRoberts et al., 2001; 
150-200 g, Li et al., 2004 and 250-350 g, Li et al., 2006). This would imply that peripheral 
NR2B levels might increase during development, in contrast to the CNS (e. g. cortex and 
hippocampus) where NR2A expression increases during ontogenesis (Wenzel et al., 1997) 
Despite the limited experiments undertaken here on Ro25-6981 and eliprodil, the low 
level of inhibition of NMDA responses of DRG neurons and hNRl/NR2A HEK cells clearly 
support the hypothesis of NR2A rather than NR2B being the prominent NR2 subunit subtype. 
These results parallel the IC5o values published by Fischer et al. (1997) for NRlool/NR2A 
cloned receptors in oocytes (52 µM) in contrast to those found in NRlool/NR2B (0.009 µM) 
receptors and cortical neurons (0.015 µM, after 5-8 day in vitro (and therefore expressing 
mainly NR1/NR2B receptors, ) and are also in line with the minimal effect of ifenprodil (3 µM) 
in NRIoll/NR. 2A expressing HEK cells reported by Weitlauf et al. (2005). These compounds are 
also very weak at NR2C and NR2D subunit-containing receptors. 
Triheteromeric NRl/NR2AJNR2B receptors can also be tentatively excluded, since a high 
(nanomolar) potency would still be expected within these cells, just with a limited degree of 
inhibition (Hatton & Paoletti, 2005). Since the experiments by Li et al. (2004) revealed a 
complete block with ifenprodil in DRG neurons, this might argue for pure diheteromeric 
receptors NR1/NR2B (and NR1/NR2A). For further comparison and proof of the assumptions, 
experiments with stably expressing hNRI/NR2B cells, especially with respect of the NR2B 
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subtype-selective compounds, would be very sensible, but this cell line had not become 
available before the end of the PhD Project. 
Although the present experiments generally implied NR2A expression in the tested DRG 
neurons, the in vivo relevance of this data for chronic pain is uncertain. Electrophysiological 
characterization of DRG neurons after induction of chronic pain states (e. g. chronic constriction 
injury model) or experimental colitis (TNBS) would be very useful to investigate possible 
changes of NMDA receptor pharmacology under such conditions, akin to the experiments of Li 
et al. (2006). 
Despite the fact that NR3A expression was shown at the protein level in DRG neurons, 
`excitatory glycine receptors' (Chatterton et al., 2002) could not be identified in these cells 
electrophysiologically. This is consistent with the failure in the published literature to 
demonstrate in any native cells the existence of functional excitatory glycine receptors. This 
may be especially difficult when NR2 subunits are present since triheteromeric NR1/NR2A- 
B/NR3A(B) receptors have been proposed to dominate under such conditions (Smothers & 
Woodward, 2007). Although not analysed quantitatively in this study, the receptor currents 
induced by NMDA and glycine in DRG neurons were relatively small compared to those in 
hippocampal neurons and transfected cells. This difference could be explained by a dominant- 
negative effect of NR3 containing triheteromeric receptors, since the presence of NR3 subunits 
has been shown to reduce agonist-induced current amplitudes in oocytes and transfected 
HEK293 cells by reduced Ca2-permeability and single-channel conductance (Ciabarra et al., 
1995; Das et al., 1998; Nishi et al., 2001; Perez-Otano et al., 2001; Yamakura et al., 2005). 
Importantly, the co-expression of the NR3 NMDA receptor subunit is claimed not to alter the 
potency of glycine and glutamate. Recordings from NR1/NR2A and NR1/NR2B co-expressed 
with or without NR3B in Xenopus oocytes clearly showed similar potencies for both agonists - 
glycine showed a 10-fold lower affinity at NR2A containing receptors in both the presence and 
absence of NR3 (Yamakura et al., 2005). Furthermore, current inhibition by the NR2B subtype- 
selective antagonist ifenprodil was also similar for di- and triheteromeric assemblies (Smothers 
& Woodward, 2003). The concluded presence of triheteromeric NMDAR containing NR3A 
further support their postulated role in pain pathways and hypersensitivity (on the basis of the 
reduced agonist-induced currents - see discussion in chapter 4). 
For further clarification of the DRG neurons' pharmacology, we are planning to 
undertake single channel recordings from NR1/NR2A/NR3A co-assemblies, especially with 
respect to glycineB site antagonists. 
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5.5 Conclusion 
Taken together, the positive detection of NR2A expression in the immunoblotting and 
staining (see sections 4.3.2 and 4.3.3), the clear correlation of the potencies of the glycineB site 
NMDA receptor agonists and antagonists found in the DRG neurons and human NR1o11/NR2A 
expressing HEK293, and the -10 fold greater potency of glycine in CNS neurones that would be 
expected to contain NR2B subunits, all provide substantial evidence for the functional 
expression of NR2A subunits in the NMDA receptors tested in DRG neurons. We conclude that 
this is most likely and perhaps the dominant reason for the higher potency of peripherally- 
restricted glycine$ site antagonists in models of visceral pain, when compared with the potency 
of the same agents in in vivo models targeting NMDA receptors in the CNS. However, glycineB 
site antagonists were not more potent in models of somatic pain (e. g. after acute somatic 
nociceptive input; Olivar & Laird, 1999) although greater potency would have been expected 
since the NMDA receptor pharmacology was similar in somatic and visceral DRG neurons (Li 
et al., 2004). This discrepancy remains unresolved. 
Nevertheless further experiments with stably transfected NR1011/NR2B cells would be 
very sensible, since these experiments would provide further evidence for or against the 
hypothesis of the predominant role of NR2A subunits in DRG cells, and are especially 
important because subtype-selective NR2A antagonists are not yet available (see introduction, 
5.1). 
Besides the influence of the NR2 subunit subtype on the affinity of the glycineB site 
modulators, the various results generated with the partial agonists suggest a more complex 
structure-activity relationship that has not been clarified so far. 
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CHAPTER VI 
6 GENERAL DISCUSSION AND CONCLUSIONS 
As a consequence of the identification of NMDA receptors expressed in the enteric 
nervous system (ENS) and in extrinsic primary afferents (both spinal and vagal), the evidence 
for the involvement of peripheral NMDA receptors in visceral (as well as somatic) nociception 
and pain pathologies has increased considerably over the last few years. The presence of 
NMDA receptors in peripheral (visceral and somatic), as well as central terminals, of primary 
afferent neurons clearly indicated that NMDA receptors could participate in peripheral 
nociceptive transmission that would then contribute to central sensitization in dorsal horn 
neurons. 
At the beginning of the PhD project there were insufficient data to clearly support the 
hypothesis for a peripheral site of action of NMDA receptor antagonists in various pain models. 
This was especially true for the apparent anti-allodynic effect of systemically- 
administered, non-brain permeable glycineB antagonists (MRZ 2/596; Sladek et al., 2002; see 
Appendix I) in an inflammatory in vivo model of Irritable Bowl Syndrome (IBS). However, the 
systemic lipopolysaccharide (LPS) induced inflammatory conditions used could conceivably 
have altered the permeability of the blood-brain barrier (BBB) and thereby have facilitated 
access of MRZ 2/596 into the CNS (e. g. Huber et al., 2001 and 2002). 
The established in vitro blood-brain barrier (BBB) model is a very useful tool for the 
evaluation of the brain permeability of compounds at early stages of drug development. 
Additionally, such in vitro models can be used to investigate the direct influence of pro- 
inflammatory mediators on functional BBB characteristics. However, with respect to the time 
frame of the inflammatory effects (longer in vivo than could be mimicked in vitro) and the 
actual concentrations of the pro-inflammatory mediators affecting endothelial cells, the in vitro 
situation could not reliably be used to predict the situation in vivo. 
The microdialysis experiments in vivo, performed under the same inflammatory 
conditions as used in the mentioned IBS model, indicated that there was no significant change 
to the brain permeability of MRZ 2/596 (figure 3.5) and so generated very clear supportive 
evidence for a peripheral site of action of the NMDA receptor antagonists, even in such 
inflammatory states. 
Functionally significant peripheral NMDA receptor-mediated mechanisms were further 
supported by the antinociceptive effect of the peripherally restricted glycinea antagonist 5,7- 
DCKA in two different models of somatic neuropathic pain (chronic constriction injury and 
spinal nerve ligation), without showing any ataxic side effects that are normally seen for 
centrally active antagonists and without blocking responses of central neurons to NMDA 
applied locally via microiontophoresis (Christoph et al., 2005). 
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The low brain permeability of 5,7-DCKA was confirmed with studies that showed both a 
low permeability coefficient determined in the in vitro BBB model (see figure 3.2) and its 
inefficacy on maximal electroshock (MES) induced convulsions at the maximal test dose of 108 
mg/kg i. p. (unpublished internal research report). 
Additionally, partial restraint stress (PRS), a relatively mild stress induced by a restriction 
of body movements, was used as an additional IBS model (Appendix I). This model is 
characterized by clear hyperalgesia and produces fewer potential problems related to BBB 
disruption than the LPS model. Using this stress model, Bueno et al. showed that glycineB site 
antagonists such as MRZ 2/596 and 5,7-DCKA, significantly reduced abdominal contractions in 
response to colorectal distension at doses of 1.0 mg/kg i. p. (p < 0.05) and 0.1 mg/kg i. p. (p < 
0.01), respectively (see Appendix I). With respect to CNS-mediated side effects, even 68.1 
mg/kg of 5,7-DCKA (i. p) showed no significant inhibition of spontaneous locomotion in 
contrast to the brain penetrant glycineB antagonist L-701,324 (Christoph et al., 2005). 
Considering these promising preclinical data, peripheral NMDA receptors seem to offer a 
very attractive target for non-brain permeable NMDA receptor antagonists for the treatment of 
various pain indications because such agents are believed to bear a very low risk of producing 
classical CNS-mediated side effects (Parsons, 2001; Christoph et al., 2005). Peripheral side 
effects are conceivable, but are likely to be of limited significance. For example, experiments 
assessing the effect of MRZ 2/596 on postprandial colonic transit showed the compound to have 
no influence on the colonic mean retention times at the lowest anti-allodynic doses (0.1 and 1 
mg/kg, i. v. ), therefore unwanted constipation or diarrhoea, as is known for alosetron and 
tegaserod, respectively, seem less likely to be peripheral side effects of glycineB antagonists 
(Sladek et al., 2002; Appendix I). 
Furthermore, these peripheral NMDA receptors were suggested (Parsons, 2001) to have 
different pharmacological properties in comparison to central NMDA receptors due to the 
apparent relatively greater potency of brain penetrant glycineB site antagonists such as MRZ 
2/576 in visceral pain models vs. those targeting the CNS (e. g. MES studies). 
Due to the fact that these variations might arise from a diversity of NMDA receptor 
subtype expression, relevant tissues (mainly DRGs) were investigated regarding their NMDA 
subunit profile using different molecular biological methods such as reverse transcriptase - 
polymerase chain reaction (RT-PCR), Western blots, and immunostaining. 
There is considerable published evidence from investigations over the last few years that 
the NR2B subunit is particularly important in nociception - although studies to date have 
focussed only on central nociceptive pathways. The development of NR2B subtype-selective 
antagonists was therefore evaluated as one of the most attractive strategies to gain good 
analgesic effects with reduced risks of side effects (Chizh & Headley, 2005). Published data, 
postulating that NR2B (beside NR2D) is also the most prominent NR2 subunit in DRGs 
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(Marvizon et al., 2002) and that the expression is even increased after experimental colitis (Li et 
al., 2006) seemed to strengthen this idea of NR2B association with nociceptive processing. 
However, despite the fact that the molecular biological characterization of the NMDA 
receptors expressed in the DRG neurons of the rat performed by the research group of E. A. 
Mayer (e. g. publications by Li, Marvizon, and McRoberts) was far more extensive than my own 
characterization, especially with respect to the sample numbers, some doubts arose regarding 
their negative NR2A and positive NR2B results. Despite possible differences of NMDA 
receptor subunit expressions in DRG neurons depending on the cell preparation and cultivation 
conditions (e. g. age of the animals or cultivation with or without NGF) it might have been 
sensible to use other NR2A specific antibodies, since the quality of the antibody supplied by 
Santa Cruz is questionable (see discussions in chapters 4.4 and 5.4 for further details). 
The present findings provide substantial evidence for the functional expression of NR2A 
subunits in DRG neurons, which was previously reported to be negligible (e. g. Marvizon et al., 
2002) in these primary afferent cells. Western blots and immunostainings in DRG 
sections/cultures directed against the NR2A subunit were clearly positive (figures 4.5 and 4.7). 
The quality and specificity of the antibodies used is always an issue in such studies. However, 
considering the fact that the positive controls from the CNS tissues used provided the expected 
results, the subunit expression results for peripheral tissues that are presented in this thesis 
appear reliable, even if the number of replications should be increased. 
The presence of the NR2A receptor subunit in DRG cells was supported by the functional 
characterization of DRG neurons. Patch-clamp experiments revealed the potencies of glycineB 
site agonists and antagonists upon DRG cells to be comparable to those found in the human 
NR1o11/NR2A expressing HEK293 cell line that was used as a comparator. In contrast, cultured 
hippocampal neurons showed a ~10 fold greater potency of glycine, and a -10 
fold lower 
potency of glycineB antagonists, potencies that are in line with cells known to express high 
levels of NR2B subunits. 
On the basis of the high correlation between NMDA receptor function in the tested DRG 
neurons and the hNRl0ll/NR2A cloned receptors (pECso/pKb correlation coefficient between 
DRG and NR1/NR2A HEK293 = 0.99, figure 5.10), a nearly pure functional expression of 
NR1/2A NMDA receptors in DRG neurons (i. e. without NR2B) might be postulated. As a 
consequence of this, the results of the molecular biological experiments targeting the NR2B 
subunit might be interpreted differently to the way originally done in chapter 4.4. Since no band 
was detected in the DRG protein samples that directly corresponded to the NR2B band found in 
the protein samples isolated from cortex and cerebellum, this might indicate a lack of normal 
NR2B expression in DRGs. The higher molecular weight bands that appeared in the respective 
Western blots therefore might not represent glycosylated NR2B, as suggested in chapter 4.4, but 
rather unspecific binding of the antibody used. If functional NR1/NR2B subunit-containing 
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receptors are really expressed at such high levels as denoted from the glycosylated NR2B band 
thicknesses in the Western blots, one would not anticipate the similar potencies that were 
observed in the functional tests of glycineB agonists and antagonists in DRG neurons and human 
NR1/NR2A cloned receptors. 
The -10-fold greater potency of glycineB antagonists at peripheral vs. central NMDA 
receptors is probably too small, on its own, to provide a definite therapeutic advantage (100-fold 
selectivity being a useful rule of thumb for clinically useful selectivity). However, in 
combination with the restricted access of glycineB antagonists to the CNS due to their polar 
nature, peripherally restricted glycineB antagonists could represent an interesting therapeutic 
approach to a variety of peripherally-located pathologies that generate debilitating clinical states 
of visceral pain. 
However, a major drawback of the NR2A hypothesis postulated in the current study was 
published by Petrenko et al. (2003a). In their study, NR2A knock-out mice showed no 
difference in pain-related behaviours in inflammatory (formalin and complete Freund's 
adjuvant) and neuropathic (spared nerve injury) pain models in comparison to wild type 
animals. This unchanged nociceptive behaviour was argued to be due to the unaltered 
expression level of NR2B leading to the hypothesis that NR2B is the main NR2 subunit 
involved in nociceptive transmission. As with all (except conditional) knock-out studies, the 
conclusion from this observation is weakened because it is not justified to assume that the 
knock-out animals make no compensatory change of either NR2B or a different receptor 
population such as mGluRl/5. Additionally, the expression levels of NR2A under inflammatory 
and neurophatic pain conditions is not yet known. 
These conflicting results highlight the need for further validation of the 
electrophysiological properties of DRG neurons presented here (in comparison to CNS neurons) 
and those data published in the literature (e. g. Li et al., 2004). In this regard, similar 
experiments with stably transfected NRloll/NR2B HEK293 cells might seem to be sensible. 
Primarily, the potencies of the glycineB agonists and antagonists should be investigated, but also 
NR2B selective antagonists should be tested. Despite the fact that the NR2B selective 
compounds Ro25-6981 and eliprodil were clearly ineffective in DRG neurons as well as 
NRloll/NR2A HEK293 cells (figure 5.12), a positive control showing the NR2B selectivity is 
lacking in the present results and this would be needed to add further evidence that the tested 
compounds are really not active in DRG neurons - such NR2B selective antagonists are 
technically difficult to test due to a particular kind of use dependency (Kew et al., 1996). The 
hNR1o11/NR2B HEK293 are in preparation but unfortunately are not yet available. 
Beside the possibility of somewhat questionable NR2B glycosylation, the molecular 
biological experiments also provided evidence for a post-translational modification of NR1 
(mainly glycosylation of C2' containing splice variants) in the DRG samples. The detection of 
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the higher molecular weight bands in the respective Western blots needs further investigation, 
for example with deglycosylation experiments using N-glycosidase F. In this regard the 
previously used method needs to be optimized since preliminary experiments did not work. 
NR1 glycosylation is particularly interesting, since glycosylation of the NR1 subunit was 
reported to increase the affinity of 5,7-DCKA (Kawamoto et al., 1995). If this were true, this 
might explain the greater difference of the 5,7-DCKA antagonistic potency in DRG neurons and 
hNRloli/NR2A HEK293 cells vs. hippocampal neurons compared to the Merz glycineB 
antagonists (-8 vs 25-fold difference respectively, see table 5.4). Interestingly, a higher potency 
of 5,7-DCKA was also observed in the stress-induced hyperalgesia in vivo model, which might 
further support such a glycosylation theory. 
The posttranslational modifications might also account for the more variable results 
generated with the glycineB partial agonists, suggesting a more complex structure-activity 
relationship in addition to the influence of NR2 subunits as already discussed. 
Additionally, further attention should be paid to NR3A subunit expression in DRG 
neurons, since NR3A was previously reported to be present in the CNS only during early 
development (Ciabarra et at, 1995). Despite the fact that co-expression of the NR3 subunit is 
expected to have no influence on the glycine and glutamate affinity in triheteromeric NMDA 
receptors (Yamakura et al., 2005), such receptors do show a different pharmacology (a 
dominant-negative effect of NR3, e. g. Nishi et al., 2001). As a consequence of this, 
electrophysiological experiments with NR1/NR2A/NR3A and NR1/NR2B/NR3A expressing 
HEK293 cells, respectively (e. g. by analysing differences in Mg2+ affinity), might be sensible 
for further correlation analysis between different tissues and heterologously expressed receptors. 
However, for this approach to be successful, single channel recordings would be essential, due 
to the fact that one would expect expression of classical heteromeric as well as such 
triheteromeric NMDA receptors within one cell. 
An investigation into the developmental changes in the NMDA receptor subunit 
composition in DRG neurons (especially with regard to the NR2A and NR2B subtypes) might 
also be sensible since it is possible that it may be different from that known to apply in the CNS 
(i. e. increase of NR2A expression during ontogeny; see discussions in chapters 4.4 and 4.5; 
Wenzel et al., 1997). A different developmental profile in vivo and/or ex vivo could perhaps 
explain the disparities between the present study and those published previously. It is notable 
that in the current study the DRG neurons were prepared from 5 week old rats whereas those 
used by the group of Mayer (e. g. Marvizon et al., 2002) were adults (200-350 g). 
Apart from the clear anti-allodynic effect of glycineB site antagonists in LPS-induced 
visceral pain (see Appendix 1), possible alterations in the expression pattern or post- 
translational modifications of the NMDA receptor due to the inflammatory challenge have not 
yet been investigated. 
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This might be of particular interest for the evaluation of the present results with respect to 
the previously cited in vivo experiments. For example, an increased NR2B expression in DRG 
neurons accompanied by persistent tyrosine phosphorylation and changes in NMDA receptor 
pharmacology was shown after experimental colitis induced by intracolonic application of 
2,4,6-trinitrobenzenesulfonic acid (TNBS; Li et al., 2006). In general, published data addressing 
such adaptive changes are quite controversial. In the spinal cord, for example, formalin 
treatment was shown to increase NR2A and decrease NR2C expression levels, although levels 
of NR1 splice variants and NR2B were unaltered (Gaunitz et al., 2002). Caudle et al. (2005), 
however, evidenced unchanged levels of NR1 and NR2A but a depression of NR2B after 
carrageenan-induced inflammation. 
Beside the involvement of central NMDA receptors in processing nociceptive 
information, especially those receptors expressed by spinal cord dorsal horn neurons, this thesis 
addressed the potential role of NMDA receptors expressed by spinal primary afferents. There 
has, however, been an accumulation of evidence over recent years that, beside the spinal 
primary afferents, NMDA receptors are also expressed in vagal afferents (Sengupta et al., 2004) 
as well as within the enteric nervous system (Patierno et al., 2005; Zhou et al., 2006). These too 
may play an important role in nociception, especially under pathophysiological conditions such 
as bowel disorders/visceral pain. The hypothesis of the involvement of vagal afferents in 
nociceptive processing may be supported by the fact that these nerves - at least in part - 
mediate the release of the proinflammatory mediators that were shown to directly control rectal 
allodynia (Coelho et al., 2000b). 
The presence of NMDA receptors at each level of the neural axis therefore offers the 
possibility of targeting each level individually with specific NMDA receptor antagonists 
(Petrenko et al., 2003b). This abundant NMDA receptor expression with possible variations in 
the subunit compositions might explain the altered antinociceptive effects of NMDA receptor 
antagonists in visceral vs. somatic pain models (Olivar & Laird, 1999), despite the fact that in 
previous studies, no differences in NMDA receptor expression / pharmacology were observed 
between different types of DRG neurons (e. g. Li et al., 2004). 
In conclusion, molecular biological and electrophysiological characterization of the DRG 
neurons emphasises the higher efficiency of glycineB antagonists in models of visceral pain due 
to their higher potency at NR1/2A containing receptors, found to be expressed in primary 
afferents. However, a better knowledge of the protein expression, pathophysiological roles and 
pharmacological properties of the NMDA receptors present in intrinsic neurones and extrinsic 
primary afferents is needed for a proper understanding of their role in visceral nociceptive 
processing and in clinical pain states involving visceral pain. 
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APPENDIX I 
1. LPS- and stress-induced visceral hypersensitivity 
NMDA receptors are present not only in the CNS, but also in the periphery, and there is 
growing evidence for their involvement in nociceptive processing. 
Systemically administered NMDA receptor glycineH site antagonists (e. g. MRZ 2/576) 
were shown to attenuate behavioural responses to distension of the non-inflamed rat ureter, but 
not have an effect on somatic pain stimuli, in contrast to the NMDA receptor antagonist 
memantine, which inhibited both visceral and somatic noxious stimuli. This suggests that 
NMDA receptors are involved in the processing of acute nociceptive inputs from viscera (Olivar 
& Laird, 1999). Moreover, the effective dose of MRZ 2/576 was at least 10-fold lower than that 
known to antagonise NMDA receptors in the CNS (Parsons et al., 1997), indicating either a 
different pharmacology and/or a peripheral locus for this effect (Parsons, 2001). 
On the basis of these findings, the anti-nociceptive potency of various glycinea site 
selective NMDA receptor antagonists in the periphery was further addressed by the group of L. 
Bueno (Neurogastroenterology and Nutrition Unit, Ecole Superieure d'Agronomie de Purpan, 
Toulouse, France) targeting visceral hypersensitivity. LPS and stress-induced visceral allodynia 
and hyperalgesia, respectively, were used as in vivo models for irritable Bowel Syndrome (IBS). 
They are summarised in brief here (although not performed by myself) because the work is 
unpublished, yet it has been integral to the development of the concepts within, and the 
experimental development of, the work presented in this thesis. 
The effects of MRZ 2/576 and MRZ 2/596 were first evaluated on rectal sensitivity using 
LPS-induced (1 mg/kg i. p. ) delayed (10 hours) rectal allodynia in awake rats. 
Later, a variety of glycineB antagonists (here: MRZ 2/576 and 5,7-DCKA) were also 
tested for their potency to attenuate stress induced visceral hyperalgesic responses (a more 
pathophysiologically relevant in vivo model for IBS). 
Additionally, with respect to possible peripheral side effects, MRZ 2/596 was examined 
for its effect on postprandial colonic transit by measuring the mean retention time of 




Experiments were performed with female Wistar rats for the stress induced, and male 
Wistar rats for LPS induced models of visceral hypersensitivity and evaluation of possible 
effects on postprandial colonic transit. All animals were individually housed and kept under 
constant temperature (21 ± 2°C), light-dark cycle (12/12 h) and food / water were available ad 
libitum. All protocols were approved by the Local Animal Care and Use Committee of Institut 
National de la Recherche Agronomique. 
1.1.2 Surgical procedures for electromyographic recordings 
Male (250-300 g) and female Wistar rats (200-225 g) were surgically prepared for 
electromyography according to a previously described technique (Morteau et al., 1994) for 
evaluation of LPS-induced and stress-induced visceral pain, respectively. They were 
premedicated with 0.3 ml of acepromazine (0.6 mg/kg, i. p. ) and anaesthetized by i. p. 
administration of ketamine (120 mg/kg). 
After laparotomy, three groups of nichrome wire were implanted in the striated muscles of 
the abdomen 2 cm from the site of laparotomy for evaluation of colorectal sensitivity. Electrodes 
were exteriorized on the back of the neck and protected by a glass tube attached to the skin. 
1.1.3 Electromyographic (EMG) recordings 
EMG recordings began 5 days after surgery. Electrical activity was recorded with an 
electroencephalograph machine using a short time constant (0.03 s) to remove low-frequency 
signals (<3 Hz). 
1.1.4 Distension procedure 
Rats were accustomed to being held in polypropylene tunnels (diameter: 7 cm ; length: 20 
cm) where they could not move or escape, over several days before colorectal distension (CRD), 
in order to minimize recording artefacts. The balloon used for distension was 4 cm long and was 
made from a latex condom. It was sutured with silk to an arterial embolectomy catheter. CRD 
was performed by insertion of the balloon into the rectum to 1 cm from the anus. The tube was 
fixed to the base of the tail. It was inflated progressively, either in steps of 0.4 ml, from 0 to 1.2 
m1, or by isobaric steps of 15 mmHg, from 0 to 60 mmHg, each distension step lasting 5 
minutes. In order to detect a possible leakage, a syringe filled with water was used to inflate and 
deflate the balloon. 
Isobaric distensions of the colon were performed by connecting the balloon to a 
computerized barostat. Colonic pressure and balloon volume were continuously monitored 
using a potentiometric recorder. 
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1.1.5 LPS-induced delayed visceral allodynia 
EMG recordings began 5-8 days after surgery. Rats (n = 6-7) received LPS at dose of 1 
mg/kg i. p., 10 hours before i. v. administrations of test compounds (e. g. MRZ 2/576; 0.01,0.1, 
and 1 mg/kg, or MRZ 2/596; 0.1 and 1 mg/kg, i. v. ) or vehicle (saline, 0.1 ml/rat). CRD was 
performed 30 minutes after drug (n = 5-6 in a randomised order). A control CRD was performed 
1 hour before LPS administration. 
1.1.6 Stress-induced visceral hypersensitivity 
Partial restraint stress (PRS), a relatively mild stress, was performed as previously 
described (Williams et at, 1988). Female rats were lightly anaesthetised with diethylether and 
their foreshoulders, upper forelimbs and thoracic trunk were wrapped in a confining harness of 
paper tape to restrict, but not prevent body movements. The animals were then placed in their 
home cage for 2 hours. Control (sham stress) animals were lightly anaesthetized but not 
wrapped. 
Animals (n = 10) were submitted to control distension and then to 2 hour PRS session or 
sham stress. Test compounds (e. g. MRZ 2/596; 0.1,1,5 mg/kg, i. p) or vehicle (0.3 ml, i. p. ) were 
given directly after the PRS session, 30 minutes before a second distension. 
1.1.7 Postprandial colonic transit 
After an overnight fast, surgery was performed in rats premedicated with 0.2 ml 
acepromazine (0.5 mg/kg) injected i. p. and anaesthetized as described above. Each animal was 
then fitted with a small catheter (PE 10) inserted into the lumen of the proximal colon 0.5 cm 
from the cecocolonic junction and exteriorized on the back of the neck. 
For one week before and one week after surgery, animals were conditioned to eat their 
daily food ration for 4 hours from 10: 00 a. m. to 2: 00 p. m. Colonic transit was measured by 
injecting radiolabelled sodium chromate (1 microcurie 5'Cr dissolved in 0.1 ml of saline) into 
the proximal colon by the catheter at the end of this period of food access. Colonic mean 
retention time (MRT) was calculated from the radioactivity of faecal samples collected each 
hour, until no radioactivity was detectable (Theodorou et al., 1989). MRZ 2/596 (0.1,1 and 5 
mg/kg) or vehicle (NaCl 0.9 %, 0.1 ml) were administered, i. v. just before the injection of "Cr. 
1.1.8 Data analysis 
The number of spike bursts that correspond to abdominal contractions was determined in 
5 minutes periods corresponding to each step of distension. Colorectal balloon volumes were 
determined on the potentiometric recorder as the maximal volume obtained for each stage of 
distension. 
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Values were expressed as means f SEM. Statistical analysis of the results were 
performed by an one-way analysis of variance (ANOVA), followed by a Dunnett's multiple 
comparison test. P value < 0.05 was considered significantly different. 
1.2 RESULTS 
1.2.1 LPS-induced delayed rectal allodynia 
Progressive rectal distension increased the number of abdominal contractions, with the 
first significant increase corresponding to a volume of distension of 0.8 ml and being considered 
as the pain threshold in the basal situation (= control rectal distension). LPS, at the dose of I 
mg/kg i. p., significantly (p < 0.05) increased the number of abdominal contractions to the lowest 
volume of distension (i. e. 0.4 ml) 10 hours after its injection, whereas LPS had no effect on the 
response to higher volumes (0.8 and 1.2 ml). This lowering of the first volume producing 
abdominal cramps is considered as a rectal allodynia (figures 7.1 and 7.2). 
The effects of different glycineB antagonists with different brain penetration 
characteristics on such LPS-induced delayed (10 hours) rectal allodynia were compared. 
MRZ 2/576 significantly reduced (p < 0.05) the number of abdominal contractions 
observed for the lowest volume of distension at doses of 0.1 and 1 mg/kg, i. v. compared to the 
"LPS + vehicle" value (13.0 ± 5.3 vs. 35.3 ± 3.4 and 7.7 ± 2.2 vs. 37.8 ± 8.4 contractions /5 
minutes, respectively, figure 7.1). Results are given as mean ± SEM, n=5-7. This represents a 63 
% and 80 % reduction of the allodynic effect, respectively (figure 7.3). MRZ 2/576, at the dose 
of 0.01 mg/kg i. v., had no significant effect (p>0.05) on the number of abdominal contractions 
induced by LPS at the lowest volume of distension (23.2 1 5.0 for drug vs. 37.8 ± 8.4 
contractions /5 minutes for "LPS + vehicle"; data not illustrated). 
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Fig. 7.1: Effect of MRZ 2/576 at 0.1 mg/kg (open squares, n= 5-6) and 1 mg/kg (filled squares, n- 6- 
7) (i. v. ) on delayed (10 hours) rectal allodynia induced by peripheral administration of LPS 
(1 mg/kg, i. p. ) in awake rats (mean ± SEM) when CRI) was performed 30 minutes after 
substance injection in comparison to untreated control animals (open circles) and LPS + 
vehicle treated rats (full circles). *p<0.05, ** p<0.01: significantly different from 
corresponding control value (-Ih). +p<0.05: significantly different from corresponding 
"LPS + vehicle" value. 
MRZ 2/596 (which shows restricted access to the brain, due to a nitrogen in the tricyclic 
ring instead of a nitric oxide group as in MRZ 2/576) administered at doses of 0.1 and 1 mg/kg 
i. v., also significantly reduced (p < 0.05) the number of abdominal contractions observed for the 
lowest volume of distension, 10 hours after LPS (19.0 ± 6.8 vs. 37.4 t 7.1 and 16.7 t 3.3 vs. 
35.2 ± 4.1 contractions /5 minutes as the "LPS/Vehicle" value, figure 7.2), reflecting a 49 % and 
53 % reduction of the LPS induced allodynia, respectively. Figure 7.3 compares the two 
compounds. 
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Fig. 7.2: As for figure 7.1 but with 0.1 mg/kg (open di amonds) and 1 mg/kg (filled diamonds) MRZ 
2/596 (i. v. ). 
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Fig. 7.3: Comparative effects of MRZ 2/576 (left graph) and MRZ 2/596 (right graph), at doses of 0.1 
mg/kg i. v. and 1 mg/kg i. v. (hatched bars) on delayed (10 hours) rectal allodynia (distension 
volume 0.4 ml) induced by LPS (1 mg/kg, i. p. ) in awake rats (mean f SEM, n-5-7) in 
comparison to untreated control animals (white bars) and LPS + vehicle treated rats (black 
bars). ** p<0.0 1, *p<0.05 significantly different from corresponding control value (-I h). + 
p<0.05: significantly different from corresponding "LPS + vehicle" value. 
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1.2.2 Stress-induced delayed rectal hyperalgesia 
Under basal conditions, colorectal distension was associated with an increase of 
abdominal contractions proportional to the level of pressure applied (from 15 to 60 mmllg). 
Thirty minutes after the end of a restraint stress session, the number of abdominal contractions 
in response to colorectal distension were significantly increased at distending pressures from 30 
to 60 mmHg (figure 7.4). 
After the stress session, MRZ 2/596 (i. p. ) significantly (p < 0.05) reduced the number of 
abdominal contractions, 'in comparison with vehicle values, when administered at the doses of 1 
mg/kg (figure 7.4) and 5 mg/kg (data not shown) at the distending pressure of 45 to 60 mmllg. 
At the lowest dose of 0.1 mg/kg, MRZ 2/596 had no significant effect on stress-induced 
hypersensitivity to rectal distension (data not shown). 
5,7-DCKA significantly (p < 0.01 and p<0.05 at distending pressures 15 - 45 mmHg 
and 60 mmHg, respectively) reduced stress-induced hyperalgesia at the tested dose of 0.1 mg/1: g 
(i. p. ). 
Effect of glycine6 site NMDAR antagonists in stress-induced hyperalgesia 
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Fig. 7.4: Effect of MRZ 2/596 (1.0 mg/kg, i. p., full diamonds, left graph) and 5,7-DCKA (0.1 mg/kg. 
i. p., open triangle, right graph) on stress-induced hyperalgesia to colorectal distension (CRD) 
in female rats (n = 10, mean ± SEM) when CRD was performed 30 minutes after substance 
injection in comparison to untreated control animals (open circles) and stressed rats (full 
circles). ** p<0.01, *** p<0.001: significantly different from corresponding control value. 
+p<0.05, ++ p<0.01: significantly different from corresponding "stress + vehicle" value. 
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1.2.3 Effect of MRZ 2/596 on postprandial colonic transit 
In rats receiving vehicle alone (NaCl 0.9%, 0.1 ml), the colonic mean retention time 
(MRT) was 6.1 ± 0.5 hours. This postprandial colonic transit was not affected by the lowest 
anti-allodynic doses (0.1 and 1 mg/kg, i. v. ) of MRZ 2/596 (MRT: 7.1 ± 0.9 and 5.8 f 0.4 hours, 
respectively). Only at the relatively high dose 5 mg/kg, which is irrelevant for the anti-allodynic 
effect, did MRZ 2/596 significantly increase colonic MRT (9.0 ± 1.3 hours, figure 7.5). 
Influence of MRZ 2/596 on 















1.3 Summary and conclusions 
Fig. 7.5: 
Influence of intravenous (i. v. ) administration 
of MRZ 2/596 (0.1,1, and 5 mg/kg, white 
bars) on colonic transit in awake rats. Data 
are expressed in mean retention time (hours). 
*p < 0.05: significantly different from 
corresponding vehicle (NaCI) values (black 
bar). Mean f SEM, n= 8-11. 
In summary glycineB antagonists were effective to abrogate LPS and stress-induced 
colorectal allodynia and hyperalgesia, respectively. 
MRZ 2/576 and MRZ 2/596 both reduced LPS-induced delayed (10 hours) rectal 
allodynia. However, MRZ 2/576 had a greater potency compared to MRZ 2/596, for both 0.1 
and 1 mg/kg doses. 
In the stress-induced IBS model, MRZ 2/596 and 5,7-DCKA were also effective in 
reducing hyperalgesia to distension at doses of 1 and 5 mg/kg, and at 0.1 mg/kg, respectively. 
MRZ 2/596 did not work at lower doses. Although 5,7-DCKA has not yet been tested at lower 
doses, one would predict a greater potency for 5,7-DCKA. 
The lack of effect of MRZ 2/596 on colonic transit at an antinociceptive dosage, may 
suggest a lack of the constipation side effects observed with 5-HT3 antagonists (Wolfe et at, 
2001). The finding also suggests the hypothesis of a direct action of MRZ 2/596 on the 
nociception pathway rather than an indirect action resulting from a change in colonic tone. 
MControl Q MRZ 2/596 
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APPENDIX II 
Full papers (thesis related) 
Danysz W, Kozela E, Parsons CG, Sladek M, Bauer T& Popik P (2005). Peripherally 
acting NMDA receptor/glycine(B) site receptor antagonists inhibit morphine tolerance. 
Ne uropharmacol ogy 48: 360-71. 
Abstract: The present study focused on the role of peripheral ionotropic N-methyl-d- 
aspartate (NMDA) receptors in the development of tolerance to morphine-induced 
antinociception. An initial experiment revealed that NMDA channel blocker memantine, and 
NMDA receptor/glycine(B) site antagonist MRZ 2/576 inhibited maximal electroshock-induced 
convulsions (MES) in female NMR mice with respective potency of 5.93 and 20.8mg/kg, while 
other NMDA receptor/glycine(B) site antagonists MRZ 2/596 and MDL 105,519 were 
ineffective, supporting lack of CNS activity of the latter two agents. This observation was also 
supported by blood-brain barrier experiments in vitro. In male Swiss mice, morphine (10mg/kg) 
given for 6 days twice a day (b. i. d. ) produced tolerance to its antinociceptive effects in the tail- 
flick test. The NMDA receptor/glycine(B) site antagonists, MRZ 2/576 at 0.03,0.1,0.3mg/kg 
and MRZ 2/596 at 0.1,0.3,3 and 10mg/kg attenuated the development of morphine tolerance. 
Similarly, in male C57/BI mice, morphine (10mg/kg) given for 6 days b. i. d. produced tolerance 
to its antinociceptive effects in the tail-flick test. Like in Swiss mice, in C57/BI mice morphine 
tolerance was attenuated by both MRZ 2/576 and MRZ 2/596. Another NMDA 
receptor/glycine(B) site receptor antagonist, MDL 105,519 (that very weakly penetrates to the 
central nervous system) also inhibited morphine tolerance at the dose of 1 but not 0.1 mg/kg. 
Moreover, both naloxone hydrochloride (5 and 50mg/kg) and centrally inactive naloxone 
methiodide (50mg/kg) inhibited morphine tolerance suggesting the involvement of peripheral 
opioid receptors in this phenomenon. The present data suggest that blockade of NMDA 
receptor/glycine(B) sites in the periphery may attenuate tolerance to the antinociceptive effects 
of morphine. 
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Sladek M, Bauer T, & Parsons CG (submitted). Prediction of CNS permeability of 
various NMDA receptor antagonists in vitro: Further refinement of an established Blood-Brain 
Barrier (BBB) model. JNeurosci Methods 
Abstract: The purpose of the present study was to optimize a well established blood- 
brain barrier (BBB) model in order to examine in vitro brain penetration on the level of medium 
throughput drug screening. Sub-cultured bovine brain capillary endothelial cells were co- 
cultured with cryo-preserved rat cortical astrocytes under refined culture conditions to ensure 
maximal efficiency without losing BBB characteristics. The formation of the BBB phenotype 
was confirmed on the protein level using immunohistochemistry and Western blotting, showing 
all relevant endothelial cell markers, including tight junctions as well as influx and efflux 
transport mechanisms. Drug transport was examined with different NMDA receptor antagonists, 
in comparison to sucrose. The penetration rates of the standard glycineB site NMDA receptor 
antagonists 5,7-DCKA and MDL105,519 were similar to that of sucrose, in contrast to the 
NMDA receptor channel blockers (+)-MK-801, memantine, and neramexane, which showed 
very good BBB penetration. Most importantly, structurally similar glycinea antagonists known 
to have different in vivo CNS-mediated efficacies could clearly be separated with respect to 
their ability to penetrate the BBB. Additionally, an efflux assay was established to investigate 
possible drug interactions with the multi-drug resistance efflux system, P-glycoprotein (P-gp). 
Merz glycineB antagonists proved to be poor substrates for the P-gp transporter. 
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Posters (thesis related) 
Sopala M, Sladek M, Schimpf T, Lorenz B, Eilbacher B, Danysz W& Bartmann A 
(2000). Comparison of blood-brain barrier penetration of NMDA receptor antagonists in vitro 
with CNS action in vivo. Soc. Neurosci. Abst. 26: 126.10 
Abstract: Drug transport into the brain is often limited by the Blood-Brain Barrier (BBB) 
and needs to be optimized. However, assessing BBB penetration in vivo is very time consuming 
and costly precluding bigger scale screening. To resolve this obstacle, we have established a 
coculture system that closely mimics the in vivo situation by culturing brain capillary 
endothelial cells on one side of a filter and astrocytes on the other side in a well. Under these 
conditions, endothelial cells retain all the endothelial cell markers and characteristics of the 
blood-brain barrier, including tight junctions. The transport of different glutamate receptor 
antagonists through BBB in vitro was compared with their anticonvulsive activity against MES 
(maximal electroschock) seizures in mice (indicative of their penetration to the brain in vivo). 
The penetration rate in vitro of 5,7-DCKA and MDL 105,519 was very low (Pe values of 
0.44* 104 cm/sec and 0.2* 104 cm/sec), corresponding with the in vivo ED50 against MES of 
higher than 50mg/kg. Other NMDA receptor antagonist tested in the in vitro BBB as 
Memantine (Pe value 6.83 * 104 cm/sec), MK-801 (3.99*104 cm/sec) and the new Merz 
compounds 2/579 (5.42* 10-4 cm/sec) and 2/576 (2.43 * 10"4 cm/sec) showed really good 
bioavailability in the brain as well as potent activity in vivo (ED50 values against NIES 6.9 
mg/kg for Memantine resp. 0.22 for MK-801,3.6 for 2/579,7.7 for 2/576). There is a good 
correspondence between penetration through BBB in vitro and in vivo activity for the tested 
substances, indicating good predictive validity of the in vitro BBB model. 
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Sladek M. Bradesi S, Parsons CG, Fioramonti J& Bueno L (2002). Blockade of 
peripheral NMDA receptors in rats affects rectal hypersensitivity and postprandial colonic 
motility but not colonic transit. Soc. Neurosci. Abst. 28: 451.3 
Abstract: In addition to the CNS, NMDA receptors are present in the periphery, 
particularly in the myenteric plexus of the gut and these receptors are sensitive to positive 
modulation by glycine. We compared the effects of two selective NMDA glycineB antagonists 
which cross the blood brain barrier easily (MRZ 2/576) or poorly (MRZ 2/596) on allodynia to 
rectal distension induced by LPS (lmg/kg i. p. ) 10 hr. before i. v. administration of glycineB 
antagonist. Rectal distension (volume from 0 to 1.2 ml in 0.4 ml steps) was performed 30 
minutes after test compounds or vehicle injections and colonic contractions were recorded from 
electrodes inserted into the proximal colon. LPS significantly increased the number of 
abdominal contractions for the volume of distension of 0.4 ml, 10 hours after its injection, but 
had no effect on higher volumes. MRZ 2/576 abrogated the rectal allodynia induced by LPS at 
both 0.1 and 1 mg/kg by 79.7 and 63.2% respectively. Similarly, MRZ 2/596 at doses of 0.1 and 
1 mg/kg inhibited LPS-induced delayed rectal allodynia (52.6 and 49.2% inhibition 
respectively). These doses of MRZ 2/596 significantly reduced colonic motility induced by 
feeding (70±5 vs 59±3 and 53.8±3 spike burst/30 minutes, respectively). However, colonic 
mean retention time assessed with radiolabelled sodium chromate was not affected by MRZ 
2/596 at either dose (6.1±0.5 vs 7±0.9 and 5.8±0.4 hours, respectively. These results confirm 
that this peripheral NMDA glycineB antagonist possesses visceral antinociceptive properties 
and at similar doses, reduces colonic motor responses to meal, but does not affect colonic 
transit. 
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Sladek M, Parsons CG & Headley PM (2005). Peripheral vs. central efficacy of NMDA 
receptor / glycineB site receptor antagonists. J. Physiol. (Lond. ) 567P: PC79 
Abstract: NMDA receptors are present not only in the CNS but also in the periphery, and 
there is growing evidence for their involvement in visceral nociceptive processing. For example, 
the glycineB selective antagonists MRZ 2/576 (brain permeant) and MRZ 2/596 (brain 
impermeant (Danysz & Parsons, 1998) were both anti-allodynic in a rat model of Irritable 
Bowel Syndrome (IBS); the delayed rectal allodynia (10 h, 0.4 ml distension) induced by LPS 
(1 mg/kg i. p. ) was abrogated by MRZ 2/576 and MRZ 2/596 at 0.1 mg/kg by 79.7 and 52.6%, 
respectively (Sladek et al. 2002). In the current work, any preparative surgery was done under 
sodium pentobarbitone anaesthesia (60 mg/kg i. p); at the end of the experiments animals were 
humanely killed, as were all donor animals. Brain penetration was examined in an in vitro 
model of the blood-brain barrier (BBB) using bovine brain capillary endothelial cells co- 
cultured with rat cortical astrocytes (Danysz et al. 2005). MRZ 2/596 showed a permeability 
coefficient similar to that of the BBB-impermeant marker sucrose, 1.11 f 0.05 (SD) x 10-5 cm/s 
and 0.77 ± 0.02 x 10-5 cm/s, respectively. On the other hand, MRZ 2/576 showed a medium 
BBB permeability in vitro (pe-coefficient 34.56 ± 4.42 x 10-5 cm/s). These in vitro data are 
consistent with brain microdialysis studies in awake rats (5 days after probe implantation), 
where MRZ 2/596 and MRZ 2/576 at the very high dose of 30 mg/kg i. p. generated maximal 
concentrations in brain of 0.11 t 0.05 µM (S. E. M. ) (n=3) and 1.34 ± 0.43 µM (n=5), 
respectively. Central and peripheral NMDA receptor properties have also been compared in 
patch-clamp experiments. The IC50 rank order of steady-state inward current responses of 
cultured rat hippocampal neurons (Danysz et al. 2005) to NMDA (200 µM with glycine 10 µM) 
were memantine (NMDA receptor channel blocker) > MRZ 2/576 > MRZ 2/596 (n = 4-8). In 
contrast, in cultures of dorsal root ganglia (DRG) from adult rats, NMDA activated currents 
were antagonized by memantine, MRZ 2/576 and MRZ 2/596 with similar IC50s of 1 pM (n=7- 
11). Visceral DRG neurons were identified by retrograde labelling with Fast DiI-oil (Molecular 
Probes) injected into the muscle wall of the small intestine 10-14 days before cell preparation. 
The NRI and all NR2 subunits were expressed as shown by Western blotting, immunostaining, 
and RT-PCR of both DRG cultures and cryosections (cf. Marvizon et al. 2002). However, for all 
NR1/NR2 subunits examined, no difference in the expression pattern was detected that might 
explain the different glycine-related pharmacology in DRG cells in comparison to the CNS. 
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role of glycineB site antagonists in visceral pain. Soc. Neurosci. Abst. 31: 52.15 
Abstract: Peripheral NMDA receptors may be involved in visceral nociceptive 
processing. As shown at SFN 2002 (#451.3), the brain impermeant, selective glycineB 
antagonist MRZ 2/596 was anti-allodynic in a rat model of irritable bowel syndrome (IBS) at 
0.1 mg/kg i. p. Low brain penetration was confirmed in an in vitro model of the blood-brain 
barrier (BBB). MRZ 2/596 showed a permeability coefficient similar to the BBB-impermeant 
marker sucrose, 1.11 ± 0.05 x 10-5 (SD) cm/s and 0.77 ± 0.02 x 10-5 cm/s respectively. The in 
vitro data were consistent with brain microdialysis studies in awake rats, where MRZ 2/596 at 
the very high dose of 30 mg/kg i. p. generated maximal brain concentrations of only 0.11 uM. 
This compound at 25 mg/kg i. p was also completely inactive against maximal electroshock- 
induced convulsions (NIES) in mice. The related moderately brain permeant compound MRZ 
2/576 was also far more active in the IBS model than following systemic administration against 
MES or micro-iontophoretic excitation of single spinal neurones in rats. These findings suggest 
that peripheral NMDA receptors might have a different pharmacology to those in the CNS. The 
pharmacology of NMDA receptor in cultures of adult rat DRG neurons was therefore analysed 
using patch clamp experiments. Visceral DRG neurons were identified by retrograde staining 
with Fast DiI-oil. Steady-state inward current responses to NMDA (200 uM with glycine 10 
uM) were antagonized by MRZ 2/576 and 2/596 with similar IC50s of 0.87 f 0.14 uM (n=7) 
and 0.85 ± 0.11 uM (n=11). In cultured rat hippocampal neurons, MRZ 2/576 was weaker (IC50 
of 3.08 ± 0.14 uM, n=8) under similar conditions, but was three fold more potent than MRZ 
2/596. The expression of NRI and all NR2 subunits was shown by Western blotting, 
immunostaining, and RT-PCR of DRG cultures and cryosections. For all NR1/NR2 subunits 
examined, no difference in the expression pattern was detected that might explain the different 
pharmacology in DRG cells in comparison to the CNS. 
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Sladek M. Hechenberger M, Gilling K, Jatzke C, Parsons CG, Headley PM (2007). 
Electrophysiological comparison of the NMDA glycineB receptor pharmacology of cultured 
DRG neurons, hippocampal neurons and NRl-la/2A transfected HEK-293 cells. Soc. Neurosci. 
Abst. 33: (submitted) 
Abstract: NMDA receptors are present not only in the mammalian CNS but also in the 
enteric nervous system and in extrinsic primary afferents, including the peripheral and central 
terminals of DRG neurons. There is growing evidence for the involvement of peripheral NMDA 
receptors in visceral and neuropathic pain. GlycineB antagonists are particularly potent in in vivo 
models of visceral pain, suggesting a different NMDA receptor pharmacology to that found in 
the CNS. In extension to our experiments presented at SFN in 2005, the properties of NMDA 
receptors of DRG cultures from young adult rats were analysed electrophysiologically using 
steady-state inward current responses to NMDA (200 µM) and various glycineB site agonists 
(glycine, D-serine), partial agonists (ACPC, (+R)-HA-966, D-cycloserine) and full antagonists 
(e. g. 5,7-DCKA, MRZ 2/576, MRZ 2/596) with differing affinities. The same compounds were 
also tested on cultured hippocampal neurons. Because the affinity for the glycine binding site is 
strongly dependent upon the NR2 subunit subtype expressed, HEK293 cells expressing NR1- 
la/2A receptors were also tested in both patch-clamp and FLIPR experiments. Additionally, 
[3H]-MDL 105,519 displacement studies with rat cortical membranes were performed using a 
96-well plate robotic format to assess their affinity for the glycine binding pocket per se. All 
results showed a good correlation between the different assay types. Interestingly, the 
pharmacology of the DRG neurons was similar to that of the NR1-la/2A-expressing HEK293 
cells (similarly high EC50 values of glycine / D-serine, and low ICsos of glycineB antagonists), 
whereas in cultured rat hippocampal neurons the agonists were tenfold more potent and the 
antagonists tenfold less potent. Assuming that the tested hippocampal neurons express a mixture 
of NRI/2A and NRI/2B containing NMDA receptors under these conditions (Cheng et al., 
1999), these results might suggest that the NMDA receptors functionally expressed in the DRG 
neurons tested here mostly contained the NR2A subunit, and that the observed central- 
peripheral differences in potency in these and in vivo experiments are due mainly to the reduced 
affinity of glycine / D-serine for NR2A subunit-containing peripheral NMDA receptors. These 
findings are in clear contrast to previously published data which claim that NR2B is the major 
NR2 subunit in DRG cells so further experiments are needed using NR2B selective antagonists 
and NRl/2B expressing cells. 
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